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ABSTRACT 
 
 
MicroRNAs (miRNAs), short non-coding RNAs, which act post-transcriptionally 
to regulate gene expression, are of widespread significance and have been implicated in 
many biological processes during development and disease, including muscle disease. In 
addition to the myomiRs, which are miRNAs highly enriched in striated muscles, recent 
advances in sequencing technology and bioinformatics led to the identification of a large 
number of miRNAs in vertebrates and other species. However, for many of these miRNAs 
specific roles, in particular during myogenesis, have not yet been determined. 
Here, I investigated the potential functions of miR-128, confirmed an interaction 
with one of its candidate targets, Eya4, and looked at the impact of its knock-down on 
skeletal myogenesis in the chicken embryo. 
 
The expression pattern of miR-128, as well as 22 other somitic miRNAs, were 
characterised by LNA in situ hybridisation (LNA ISH).  
Eya4 was identified as a candidate ‘muscle’ target of miR-128 by computational 
analysis. Its expression pattern was characterised; miR-128 and Gga-Eya4 displayed 
similar profiles in developing somites. Using the miRanda algorithm potential miRNA 
binding sites were identified in the 3’ untranslated region (UTR) of other transcription 
factors, which along with Eya4 are members of the PAX-SIX-EYA-DACH (PSED) 
network (Six1/4, Eya1/2/3, and Dach1).  
These miRNA/target interactions were examined in vitro and in vivo. Gga-Eya4 
was confirmed as a target of miR-128 as well as miR-206 by luciferase reporter assays. 
MiR-128/Gga-Eya4 interaction was validated by RNA ISH and RT-qPCR after 
antagomiR (AM)-128 injection in chicken embryos. Knock-down of miR-128 resulted in 
a significant de-repression of Gga-Eya4 expression; an increase in Gga-Six4 and Gga-
Pax3 expression was also observed, whereas Gga-MyoD1 expression was decreased. 
 
With this project, using a combination of cell-based experiments and animal 
studies, I showed that miR-128 could play an important role in the regulation of skeletal 
myogenesis in the chicken embryo by targeting Gga-Eya4, a member of the PSED 
network. 
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CHAPTER 1: INTRODUCTION 
 
 
1.1.  Skeletal muscle development 
 
1.1.1. The chicken embryo: a model system for skeletal myogenesis 
 
The chicken embryo has a long history as a major system in developmental 
biology (Stern 2005; Hirst & Marcelle 2015).  
Readily available and easy to incubate, embryo development can be directly 
observed by cutting a small window in the egg shell. The establishment of a staging atlas 
by Hamburger and Hamilton in 1951, allowed specific developmental landmarks to be 
seen and correlated with experimental manipulations of development (Hamburger & 
Hamilton 1992). The relative transparency of the embryos, and the regular formation of 
pairs of somites, transient metameric structures, along the anterior-posterior axis, allowed 
to accurately stage the embryos. 
The external development of chicken embryos allows for convenient experimental 
manipulations at specific embryonic stages, such as, for example, grafting and lineage 
tracing (Ordahl & Le Douarin 1992). In the last few years, the classical approaches have 
been enriched by major technical advances, such as the development of new methods for 
gain- and loss-of function analysis (in vivo electroporation) (Nakamura & Funahashi 
2012); and the completion of the first draft of the sequence of its genome (Hillier et al. 
2004). In December 2015, the newest chicken genome, version Gallus_gallus-5.0 
(Galgal5; GCA_000002315.3) was released; it was sequenced and assembled using 
varied sequencing technologies, including Sanger, Illumina and 454 (International 
Chicken Genome Sequencing Consortium). 
With its rapid external development, its relative transparency, and an easy access 
to its somites, as well as its genome having been sequenced, the chicken embryo 
constitutes a model of choice for studying skeletal myogenesis. 
 
 
1.1.2. Origin of skeletal muscle in vertebrates: from gastrula to somite 
 
The vertebrate skeletal musculature is a complex and heterogeneous organ system 
serving multiple functions in the organism.  
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During early embryonic development, skeletal muscles are generated by a series 
of distinct morphogenetic events extremely well regulated (reviewed in Musumeci et al. 
2015). Embryogenesis, the process by which the embryo forms and develops, is a 
succession of several phases: cleavage, gastrulation, neurulation and organogenesis.  
 
The first phase, cleavage, is characterised by a series of cell divisions (mitoses). 
The different cells derived from cleavage are called blastomeres and form the blastula. 
The single-layered blastula is then reorganised into a three-layered structure, the gastrula.  
 
Gastrulation is a very important phase which, in the chicken, starts with the 
formation of the primitive streak and the determination of the body axes (reviewed in 
Bénazéraf & Pourquié 2013). The gastrulation process results from the integration of cell 
proliferation, differentiation and migration of thousands of cells. Large-scale flows of 
cells from the epiblast – cells at the posterior edge of the upper layer of the area pellucida 
– migrate into the midline of the embryo to form the primitive streak. Then, these 
prospective mesodermal and endodermal cells undergo an epithelial-to-mesenchymal 
transition (EMT) and migrate beneath the remaining epiblast cells, the future ectoderm 
(Nakaya & Sheng 2008). At the end of the gastrulation, three germ layers are formed: the 
ectoderm, the endoderm and, localised in between them, the mesoderm (Solnica-Krezel 
& Sepich 2012).  
  
 Gastrulation is followed by organogenesis, where each layer will give rise to 
specific tissues and organs in the developing embryo.  
Ectoderm (most external layer) is composed of three parts: external ectoderm, also 
known as surface ectoderm, the neural crest and the neural tube (formed during 
neurulation). These ectodermal structures will differentiate and form the epidermis, the 
skin appendages, the lens, melanocytes and the nervous tissues.  
Endoderm (most internal layer) will form the epithelial lining of most of the 
organs related to the digestive and respiratory systems (lungs, digestive tract and annexe 
organs (liver, pancreas)).  
Mesoderm (middle layer), is composed of the lateral plate mesoderm, intermediate 
mesoderm, paraxial and axial mesoderm; it will give rise to the heart, blood cells, the 
notochord, bone and cartilage, kidney and most of the smooth, cardiac and skeletal muscle 
of the body (Solnica-Krezel 2005).  
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The paraxial mesoderm, localised on both sides of the neural tube and the 
notochord, is composed of an anterior part, the cephalic paraxial mesoderm, and a 
posterior part, the pre-somitic mesoderm (PSM). The PSM will progressively segment to 
give rise to the somites (Christ & Ordahl 1995). 
 
 
1.1.3. Somite formation and differentiation: from PSM to myotome 
 
a. Somitogenesis 
 
In vertebrates, most of the axial skeleton and all skeletal muscles of the body, with 
the exception of the craniofacial bone and head muscles, are derived from the somites 
(Christ & Ordahl 1995). Somites, transient metameric structures, are generated by 
segmentation from the PSM (Fig. 1.1).  
 
Before the somites form, the paraxial mesoderm of vertebrate is segmented into 
somitomeres. They form along the length of the embryo during gastrulation, in a strict 
anterior to posterior order, and appear in bilateral pairs (Meier 1982; Jacobson 1988). 
Unlike the somitomeres in the head which remain contiguous, the somitomeres in the 
trunk and tail, gradually condense and epithelialise to become somites.  
Each newly formed somite undergoes mesenchymal-to-epithelial transition 
(MET) and results in the formation of an epithelial ball of columnar cells enveloping 
mesenchymal cells within a central cavity, the somitocoel (Fig. 1.1b). Each somite is 
surrounded by extracellular matrix (ECM) components establishing important 
connections with adjacent structures.  
 
Somitogenesis is a sequential, bilateral, directional and a periodic process. The 
first somite pair forms directly posterior to the otic vesicle region (future ear; Fig. 1.1a) 
(Hinsch & Hamilton 1956; Huang et al. 1997). From this moment, a new pair of somites 
forms sequentially, adding new segments, on both sides of the median line of the chicken 
embryo, along the anterior-posterior axis to the caudal tip as the embryo extends.  
While the first formed (or oldest) somite is located at the anterior tip of the trunk 
paraxial mesoderm, the last produced (youngest) somite is located more posteriorly.  
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Fig. 1.1: Somitogenesis in the chicken embryo. (a) Schematic of HH15 chicken embryo 
showing the position of the 25 pairs of somites along the Anterior-Posterior axis 
(according to the Hamburger and Hamilton classification (Hamburger & Hamilton 
1992)). (b-d) Transverse sections (indicated by straight lines in (a)) at different levels 
(posterior (b), intermediate (c), and anterior (d)) in the embryo show the evolution of the 
somite. Originating from the mesoderm (b), the somite forms the dermomyotome, 
sclerotome and the myotome (c). (d) At the flank-limb junction, cells from the 
dermomyotome, and the myotome migrate to give rise to most of the muscles of the body 
(vBW) and limbs (MPCs). DM: dermomyotome (dorsomedial lip (dml), ventrolateral lip 
(vll); ventrolateral dermomyotome (vlDM)); Ec: ectoderm; En: endoderm; LPM: lateral 
plate mesoderm; MPCs: myogenic progenitor cells; My: myotome; NC: notochord; NT: 
neural tube; Otv: otic vesicle; PSM: pre-somitic mesoderm; S: somite (dorsal (dS) and 
ventral (vS) somite); Sc: sclerotome; vBW: ventral body wall. Adapted from Mok & 
Sweetman 2011.  
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In the chicken, a total of 52 pairs of somites are going to be generated, with a pair 
formed every 90 minutes at 38-39°C, during the first five days of embryonic development 
(Dale & Pourquié 2000). The total number of somites (zebrafish: 30; mouse: 65; human: 
42), as well as the time needed to form a new somite (zebrafish: 30 minutes; mouse: 2 
hours; human: 4-5 hours) are species-dependent. 
 
b. Regulation of somitogenesis 
 
Somites originate at regular and cyclic species-specific intervals. This ability of 
the paraxial mesoderm can be based on a molecular oscillator, at least theoretically. 
Existence of such an oscillator had been predicted in a model called the ‘Clock and 
wavefront’ model (Cooke & Zeeman 1976), but it was only in 1997 that components of 
this oscillator were identified and called ‘segmentation clock’ (Palmeirim et al. 1997).  
 
Temporal periodicity is regulated by expression of ‘oscillating genes’ (‘clock’) 
and by gradients of signal molecules providing a ‘wave’ motion. The number of somites 
is established during the initial stages of paraxial mesoderm production. Somites appear 
exactly at the same time bilaterally in the embryo, and the clock for production of the first 
pair of somites is defined when cells enter the PSM (Palmeirim et al. 2008). This process 
appears to be under the control of multiple signalling gradients involving the WNT, 
NOTCH, fibroblast growth factor (FGF), and retinoic acid (RA) pathways (reviewed in 
Ozbudak & Pourquié 2008; Aulehla & Pourquié 2008; Aulehla & Pourquié 2010).  
 
The PSM can be divided in two regions that differ not only in terms of gene 
expression patterns, but also in morphology of the PSM cells.  
In the caudal two-third of the PSM, high FGF activity is believed to keep cells in 
a mesenchymal, undifferentiated state and oscillatory expression of segmentation clock 
genes occurs.  
Expression of these oscillating genes appears cyclically in PSM cells, at defined 
intervals. Although the origin of this periodic ‘clock’ remains unclear and highly 
discussed (Aulehla & Pourquié 2008), several gradients seem to play a role into the 
somitic segmentation. FGF and WNT proteins are produced at regular intervals in the 
most posterior portion of the PSM, and RA is produced by the newly formed somites in 
the anterior region.  
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A gradient of RA exists going in the anterior-to-posterior direction, while the 
gradient of FGF and WNT proteins is going in the posterior-to-anterior direction (Aulehla 
& Pourquié 2010). The region where these two gradients meet is called the ‘determination 
front’, or ‘wavefront’, and corresponds to the region where expression of oscillating genes 
is temporary segregated and remains active to form a new pair of somites (Del Corral & 
Storey 2004; Dubrulle & Pourquié 2004). 
 
As PSM cells leave the posterior immature region, crossing the determination 
front, and enter the anterior third of the PSM, several changes take place. The first signs 
of morphological formation occur when the most peripheral PSM cells undergo an MET 
(Nakaya et al. 2004). At this point, the somite boundaries are specified and formed 
through the activation by the NOTCH pathway of Hairy and Lunatic Fringe (Lfng). Hairy, 
via the activation of Eph/ephrin proteins and their receptors (Palmeirim et al. 1997; Jouve 
et al. 2000), and Lfng (Dale et al. 2003) facilitate the somite boundary formation, the 
detachment of a new somite from the others, and contribute to the establishment of the 
somite anterior-posterior polarisation. 
 
Recent studies questioned the role of this ‘clock and wavefront’ mechanism in 
somite formation, and suggested that somites are self-organising structures. Palmeirim et 
al. demonstrated that the molecular segmentation of the anterior part of the PSM is an 
intrinsic property and that no signal coming from neighbouring tissues is required 
(Palmeirim et al. 1997). In addition, Dias et al. showed, in ectopic somite experiments, 
that cyclic expression of clock genes, as well as waves and gradients, are not necessary 
for somite formation (Dias et al. 2014); however ‘the clock’ appears to be required for 
normal subdivision of the somites into anterior and posterior halves (Stern & Piatkowska 
2015).  
 
c. Somite differentiation 
 
Once formed, somites rapidly differentiate and develop into three distinct cellular 
compartments: sclerotome, dermomyotome, and myotome (Fig. 1.1) (Christ & Ordahl 
1995; Christ et al. 2007).  
 
During early maturation, the ventral portion of the somite undergoes an EMT 
resulting in the formation of the sclerotome (Fig. 1.1b-c).  
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The sclerotome, along with mesenchymal cells from the somitocoel, will 
contribute to the formation of most of the axial skeleton, ribs, cartilage and connective 
tissues (syndetome), and bones (vertebrae) (Scaal & Christ 2004; Brent et al. 2003; 
Baykal & Korkusuz 2016). 
 
The most dorsal part of the somite remains epithelial and is referred to as the 
dermomyotome (Fig. 1.1b-c). The dermomyotome then further sub-divides into a medial 
portion, the epaxial domain, and a lateral portion, the hypaxial domain. The epaxial 
domain will give rise to the axial musculature and skeleton, while the hypaxial domain 
will contribute to the muscles of the limbs and body walls (Fig. 1.1d). The central part of 
the dorsal layer of the dermomyotome (also called dermatome) will give rise to the 
muscles and dermis of the back (Ordahl & Le Douarin 1992; Baykal & Korkusuz 2016). 
The formation of the sclerotome and the dermomyotome define the dorsoventral axis of 
the somite. 
 
The myotome forms in between the dermomyotome and the sclerotome (Fig. 1.1b-
c), and involves two sequential steps (Fig. 1.2) (Gros et al. 2004). In a first step, myotome 
expands only from the translocation of dermomyotomal cells through the dorsomedial lip 
(dml). Through this process, older myocytes are displaced laterally by newer ones arising 
at the dml, resulting in an incremental myotome growth; cells elongate bidirectionally in 
the anterior-posterior axis of the embryo to form full-sized myocytes. In a second step, 
myocytes produced from the posterior, the anterior, and the ventrolateral (vll) borders 
enter the myotome, in a phase that combines incremental growth at the dml and vll and 
coherent growth at the posterior and anterior borders. In the process of coherent growth, 
myocytes elongate unidirectionally and the relative position of the progenitors within the 
dermomyotome is maintained with their progeny in the myotome (Denetclaw et al. 1997; 
Ordahl et al. 2001).  
The cells originating from the dorsomedial and ventrolateral lips of the 
dermomyotome contribute exclusively to the epaxial and hypaxial domain of the 
myotome, respectively, whereas the cells from the anterior and posterior borders populate 
both mediolateral domains (Gros et al. 2004; Manceau et al. 2008). 
 
At limb levels, cells from the ventrolateral edges of the dermomyotome lose their 
epithelial characteristics and migrate into the limb buds. 
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Fig. 1.2: Formation of the early myotome in the somite. Cells present at the four 
epithelial borders of the dermomyotome contribute to the myotome formation at different 
rates: Cells emanating from the dorsomedial lip (dml) translocate under the 
dermomyotome and elongate bidirectionally in the anterior-posterior axis of the embryo 
to form full-sized myocytes (1); then myocytes arise sequentially from the posterior 
border (2), from the anterior border (3), and finally from the ventrolateral lip (vll) (4). 
NC: notochord; NT: neural tube. Adapted from Gros et al. 2004. 
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The myotome is the first skeletal muscle structure to be formed during 
development. The epaxial myotome will give rise to the neck and deep back muscles, 
while the hypaxial myotome will give rise to the intercostal muscles, body wall muscles, 
trunk and limb muscles (Fig. 1.1d) (Kaehn et al. 1988; Baykal & Korkusuz 2016).  
 
d. Regulation of somite differentiation 
 
Although mesoderm is specified in a very early stage of embryogenesis along the 
anterior-posterior axis, determination of the fate of cells in each somite occurs only when 
the somite is completely formed (Brand-Saberi et al. 1996). 
The differentiation of a somite into sclerotome, dermomyotome and myotome 
depends on interactions with surrounding tissues and is regulated by extrinsic molecular 
signals from the dorsal neural tube and surface ectoderm (WNT proteins), the lateral plate 
mesoderm (bone morphogenetic proteins (BMP)), and notochord and floor plate of the 
neural tube (Sonic hedgehog homolog (SHH) and Noggin proteins (Christ et al. 2007; 
Yusuf & Brand-Saberi 2006). 
 
The ventromedial portion of the somite undergoes an EMT. The notochord and 
the floor plate of the neural tube produce and secrete SHH and Noggin proteins, which 
are able to re-programme cells; they will lose their epithelial characteristics (de-
epithelialisation) and revert to a mesenchymal-like fate (Fan & Tessier-Lavigne 1994; 
Brand-Saberi et al. 1993). These mesenchymal cells then lose the expression of N-
cadherin and become mobile (Sosic et al. 1997). They migrate ventrally to form the 
sclerotome, start to express transcription factors, such as Pax1, necessary for 
differentiation into cartilage, and form the vertebrae and a large part of each rib (Barnes 
et al. 1996). 
 
The dermomyotome cells in the dorsal part of the somite remain epithelial. This 
is mainly due to WNT signals coming from dorsal neural tube and surface ectoderm. 
Formation of the medial half (epaxial dermomyotome) is attributed to Wnt1/3a (dorsal 
neural tube) (Munsterberg et al. 1995; Ikeya & Takada 1998); and that of the lateral half 
(hypaxial dermomyotome) is influenced by Wnt6 (ectoderm) (Fan et al. 1997; Dietrich et 
al. 1997; Schubert et al. 2002). Dermomyotomal cells express Pax3 and Pax7 (Scaal & 
Christ 2004).  
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The hypaxial domain is also defined by BMP signals (Bmp4, member of the 
TGFβ-superfamily) from the lateral plate mesoderm (Cheng et al. 2004; Pourquié et al. 
1996).  
 
Soon after the establishment of the dorsal and ventral compartments of the somite, 
the myotome starts to form in between these two structures.  
The dorsal WNT signals act synergistically with the ventral SHH signal to 
promote its formation (Dietrich et al. 1997). Based on somite explant studies, it was 
proposed that Wnt1/3a, from the dorsal neural tube, in combination with low levels of 
SHH, from the notochord and ventral neural tube, could induce the myogenic 
differentiation in the epaxial and then hypaxial domain of the dermomyotome 
(Munsterberg et al. 1995).  
 
Other important players in myotome formation are BMP and Notch signallings. 
While the medial half of the myotome is under the regulation of WNT and SHH activity 
to form the epaxial domain, the lateral half receives BMP signals (Bmp4) and Notch 
signals (Delta1) from the lateral plate mesoderm (Pourquié et al. 1995; Pourquié et al. 
1996; Dietrich et al. 1998; Hirst & Marcelle 2015). Pourquié et al. showed that Bmp4 is 
responsible for maintaining the undifferentiated state of prospective hypaxial muscle and 
hence counteracts the differentiation-inducing activity of the neural tube (WNT 
signalling) (Pourquié et al. 1996). Limb muscles originate from cells that have migrated 
as undifferentiated precursors from the somites. Amthor et al. showed, by performing 
bead experiments, that a dose-dependent response of myogenic cells to BMP may 
spatially coordinate their correct positioning and growth in the limbs (Amthor et al. 1998).  
 
In addition, Marcelle et al. observed that Noggin, expressed in the dorsomedial 
somite, which antagonises BMP activity, could play a role in regulating BMP patterning 
of the somite (Marcelle et al. 1997). They showed that BMP is required for Wnt1/3a 
expression in the dorsal neural tube, which in turn can promote muscle differentiation 
(Munsterberg et al. 1995); on the other hand, they observed that ectopic expression of 
Bmp4 in the paraxial mesoderm resulted in the inhibition of myotome formation 
(Marcelle et al. 1997).  
 
WNT proteins induce the expression of myogenic regulatory factors (MRFs), such 
as MYF5 and MYOD1, indicating the beginning of the myogenesis.  
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1.1.4. Myogenesis 
 
a. Cellular heterogeneity: from myogenic progenitor cells to myotube 
 
Formation of skeletal muscle – myogenesis – is a process allowing differentiation 
of mesenchymal cells into myoblasts, which proliferate, exit from the cell cycle and fuse 
together to form multinuclear structures, called myotubes, expressing the characteristic 
proteins of muscle tissue. Myogenesis starts in the dermomyotome and requires the 
commitment of a pool of cells into the skeletal muscle lineage (Fig. 1.3). 
 
The dermomyotome is composed of a mixture of dermal and myogenic (MPCs) 
progenitor cells, which subsequently are going to give rise to the dermatome and the 
myotome. The first molecular markers characterising myogenic precursors, in the 
dermomyotome, are the paired-box transcription factors PAX3 and PAX7 (Kassar-
Duchossoy et al. 2005; Relaix et al. 2005). Their activation results from WNT signals 
(Wnt1/3a/6) from the overlying surface ectoderm (Otto et al. 2006). PAX3/7 label 
proliferating myoblasts in the dermomyotome, where they form a regulatory network with 
other factors, such as SIX, EYA and DACH proteins, to initiate the myogenesis 
programme (Heanue et al. 1999). PAX3/7 also support the proliferation and survival of 
myoblast before differentiation (Buckingham & Relaix 2007), as long as growth factors, 
especially FGFs, are available.  
As the dermomyotome matures, PAX3-expressing myoblasts migrate from the 
dorsomedial and ventrolateral lips (Galli et al. 2008). Myogenic differentiation starts 
when myoblasts delaminate from the edges of the dermomyotome and migrate ventrally 
to form the primary myotome, exclusively composed of post-mitotic myocytes. The 
myoblasts exit from the cell cycle and start to express the myogenic determination genes, 
MYF5 and MYOD1 (Ordahl et al. 2001; Gros et al. 2004). This process is associated with 
the downregulation of PAX3, in part regulated by SHH signals from the notochord and 
floor plate (Williams & Ordahl 1994; Goulding et al. 1994; Johnson et al. 1994). Once in 
the myotome, myocytes receive signals from the neural tube; Wnt11 expression in the 
dml is essential to orient myocyte elongation, all parallel and aligned along the anterior-
posterior axis of the embryo (Gros et al. 2009). 
 
The second wave of myogenesis involves fusion of myoblasts. They no longer 
proliferate and begin to secrete fibronectin in the ECM (Menko & Boettiger 1987).  
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The signal provided by this adhesion between myoblasts and fibronectin promotes the 
differentiation of the myoblasts into muscle cells. They align to form chains and fuse to 
give rise to myotubes destined to become skeletal muscle fibres. When myoblasts become 
able to fuse, myogenin, a myogenic basic helix-loop-helix (bHLH) protein, starts to be 
expressed (Bergstrom & Tapscott 2001). The latest step in myotube growth and 
differentiation involves the increased synthesis of contractile proteins, such as skeletal 
muscle actin, and myosin heavy and light chains. 
 
At limb level, a fraction of myoblasts from the hypaxial dermomyotome and 
hypaxial myotome delaminate and migrate into the forming limb buds. These migrating 
hypaxial myogenic precursor cells express Pax3 and ladybird gene, Lbx1 (Williams & 
Ordahl 1994; Pourquié et al. 1995; Dietrich et al. 1998); Lbx1 being exclusively 
expressed in this sub-population of lateral somite cells. When they reach their final 
destination, they initiate skeletal muscle differentiation programme to generate the future 
limb muscles (Cinnamon et al. 1999).  
 
b. Genetic networks regulating myogenesis 
 
i) Myogenic regulatory factors 
 
The formation of skeletal muscle is under the control of the MYOD family of 
myogenic regulatory factors (MRFs) (Fig. 1.3).  
 
The MRFs are bHLH domain-containing transcription factors. There are four 
MYOD family members. Myogenic factor 5 (MYF5) and Myogenic differentiation 
(MYOD) are primary, because they are required for determination of the myoblasts. 
Myogenin (MYOG) and MYF6 (also called MRF4) are secondary; they regulate terminal 
differentiation by activating transcription of genes encoding for specific muscle proteins 
(Bergstrom & Tapscott 2001).  
While SHH and WNT signalling pathways are necessary to form the epaxial 
myotome, they are also required to induce the activation of the primary MRFs, MYF5 
and MYOD. SHH, from the notochord and the ventral neural tube (floor plate), and 
Wnt1/3a, from the dorsal neural tube, contribute to the activation of MYF5. Wnt6, from 
the surface ectoderm, participate in the activation of MYOD (Munsterberg et al. 1995; 
Dietrich et al. 1997).  
26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3: Regulation of myogenesis during chicken development. Each step leading the 
myogenic progenitor cells to differentiate and mature myotubes are controlled by Pax3 
and the myogenic regulatory factors (MRFs). Myf5: myogenic factor 5; MyoD: myogenic 
differentiation; MRF4: myogenic regulatory factor 4 (or Myf6); MyoG: myogenin. 
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In the dermomyotome, MPCs become committed to the skeletal muscle lineage 
once they express MYF5 and MYOD. To enter the myotome, these cells need to inhibit 
the BMP signals. SHH and Wnt1/3a lead to the activation of Noggin in the dorsomedial 
lip of the dermomyotome, stimulating conversion of dermomyotomal precursor tissue 
into differentiating myotome. Then the expression of the terminal differentiation genes, 
required for the fusion of myocytes and the formation of myotubes, is performed by both 
MRF4 and MYOG (Bentzinger et al. 2012). 
 
In chicken, Myf5 is the earliest marker of determined muscle cells expressed, 
closely followed by MyoD (Mok & Sweetman 2011; Berti et al. 2015). In mice deficient 
for Myf5 and MyoD (Myf5-/-/MyoD-/-), most of the myogenic programme is severely 
affected with embryos failing to develop any skeletal muscle (Rudnicki et al. 1993). The 
MyoG knockout has an equally severe phenotype with perinatal death; the expression of 
several differentiation markers, such as myosin heavy chain and MRF4, appears to be 
reduced, whereas MyoD levels were normal (Nabeshima et al. 1993). While myoblasts 
are formed there is a complete absence of functional skeletal muscle supporting the idea 
that MyoG regulates the later stages of myogenic differentiation, whilst Myf5 and MyoD 
(and in some case MRF4) are involved in the process of determination (Moncaut et al. 
2013). 
 
ii) PAX-SIX-EYA-DACH network 
 
The PAX-SIX-EYA-DACH (PSED) network, composed of eyeless, eyes absent, 
sine oculis and dachshund genes, has been described for the first time in Drosophila 
where it plays an important role during eye development (Chen et al. 1997; Pignoni et al. 
1997).  
 
Vertebrate homologues for these genes have been described and grouped into the 
PAX (paired-homeobox; PAX1-9), SIX (sine oculis-related homeobox; SIX1-6), EYA 
(eyes absent-related homeobox; EYA1-4) and DACH (dachshund-related homeobox; 
DACH1, 2) multigene families (Hanson 2001; Relaix & Buckingham 1999).  
In vertebrates, the functions of this gene network are not restricted to eye 
formation and the PSED network plays key regulatory roles in the development of 
numerous organs and tissues such as kidney, ear and muscle (Relaix & Buckingham 
1999).  
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Notably, this network leads to the activation of the MRF genes, placing it 
upstream of the genetic regulatory cascade that directs dermomyotomal progenitors 
toward the myogenic lineage.  
 
PAX transcription factors: 
 
The balance between stem cell self-renewal and progression into a differentiation 
programme is of critical importance for tissue growth and regeneration.  
During skeletal muscle development, each muscle contains a pool of resident stem 
cells that can either differentiate into muscle fibres or remain as proliferating progenitors. 
These cells express two related paired-homeobox transcription factors, PAX3 and PAX7, 
that are essential for ensuring the myogenic potential and survival of progenitors in 
embryonic (PAX3) and adult (PAX3 and PAX7) myogenesis (Buckingham & Relaix 
2007; Buckingham & Relaix 2015).  
 
PAX3 and PAX7 are important regulators of muscle development and are 
upstream of myogenic genes in somites, limb muscles and satellite cells.  
PAX3, initially globally expressed throughout the somite, subsequently becomes 
restricted to the dermomyotome, and then to the epaxial and hypaxial dermomyotome, is 
finally downregulated as progenitor cells enter myogenesis. In Pax3 mouse mutant (Pax3-
/-), somitogenesis is affected, with abnormal myotome formation, trunk muscle defects, 
and a complete absence of limb muscles (Bober et al. 1994; Goulding et al. 1994). PAX7 
is strongly expressed in the central dermomyotome. In Pax7 mutant (Pax7-/-), skeletal 
muscle forms normally in the developing embryo (Mansouri et al. 1996). However, in 
mice lacking both Pax3 and Pax7 (Pax3-/-/Pax7-/-), major defects in myogenesis occur, 
suggesting that together these genes are required for normal muscle development (Relaix 
et al. 2005). It has been shown in studies performed on mouse mutants and overexpression 
in chicken embryos, that Pax3/7 activate and control the expression of the MRF genes, 
such as Myf5 and MyoD (Williams & Ordahl 1994; Bajard et al. 2006). 
 
 The expression of PAX3/7 is regulated by the activity of members of the SIX, 
EYA and DACH families (Heanue et al. 1999).  
 
 
 
29 
 
 SIX, EYA and DACH transcription factors: 
 
SIX homeodomain transcription factors, with EYA and DACH cofactors, have 
also been implicated in the initiation of myogenesis (Heanue et al. 1999). Similar to PAX3 
and PAX7, SIX1/4, EYA1/2/4, and DACH1/2 have been shown to synergistically 
regulate myogenesis and play a key role in the migration of myogenic precursors. The 
first indication of an upstream function in myogenesis came from experiments in the 
chicken embryo where ectopic expression of Six1 and Eya resulted in the activation of 
Pax3 and the myogenic regulatory genes (Heanue et al. 1999). Since then, analyses in 
mouse mutants have provided insight into the complex roles of Six, Eya, and Dach.  
 
SIX1 and SIX4 are currently considered to be the apex of the genetics cascade 
that directs dermomyotomal progenitors toward the myogenic lineage. SIX family 
proteins are transcription factors characterised by the presence of two conserved domains, 
a homeodomain (HD) that binds to DNA, and an amino-terminal SIX domain (SD) that 
interacts with coactivators (EYA) or corepressors (DACH, Groucho (GRO)) of 
transcription (Kumar 2009).  
 
EYA proteins are characterised by the EYA domain (ED), located in their C-
terminal region, responsible for the interaction of EYA with other proteins, including SIX 
and DACH (Li et al. 2003). Recent works have shown that EYA proteins contain both 
threonine and tyrosine phosphatase activities, placing them as unique co-transcription 
factor phosphatases (Sano & Nagata 2011; Rayapureddi et al. 2003; Tootle et al. 2003). 
It is proposed that this activity inhibits DACH corepressor function. EYA function also 
involves the recruitment of RNA polymerase II and coactivators such as CREB-binding 
protein (CBP), or corepressor such as histone deacetylase (HDAC), to the SIX complex 
(Jemc & Rebay 2007; Spitz et al. 1998; Li et al. 2003). These findings highlight a dual 
activity for EYA proteins both in the cytosol and in the nucleus. 
 
SIX proteins (SIX1 and SIX4) bind to and translocate EYA proteins (EYA1, 
EYA2), sometimes associated with DACH proteins, to the nucleus, where they act as 
cofactors to activate SIX target genes, such as PAX3, MYOD, MRF4, and MYOG 
(Grifone et al. 2005).  
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The presence of EYA proteins in theses complexes converts SIX and DACH, 
which are repressors or weak activators of transcription, into strong transcriptional 
activators.  
In mouse, Six1, Six4, Eya1, Eya2, Dach1 and Dach2, are expressed in somite, in 
the dermomyotome and subsequently in Pax3-positive myogenic progenitors.  
Unlike Pax3 and Pax7, these factors are also present in differentiated skeletal 
muscle. In the dermomyotome, Eya1 and Eya2 are mainly expressed in the epaxial and 
hypaxial domains, after the initial onset of epaxial myogenesis.  
 
The critical role of SIX/EYA in myogenesis is revealed by the phenotype of 
Six1/Six4 and Eya1/Eya2 double mutants (Grifone et al. 2005; Grifone et al. 2007), which 
are more severe than the single mutants, with loss of all muscles derived from the hypaxial 
dermomyotome, including limb and many trunk muscles. Epaxial myogenesis, leading to 
the formation of the back muscles, is not affected. In these Eya or Six double mouse 
mutants, Pax3 expression is lost in the hypaxial dermomyotome, with an absence of 
progenitor cell migration and cell death. 
A second feature of the double mutants, is a pronounced downregulation of the 
myogenic regulatory genes (Myf5, MyoD, and Mrf4, but also MyoG), observed from the 
time when Six/Eya complex would normally be active (Giordani et al. 2007; Relaix et al. 
2013). Six1/4/Myf5(Mrf4) mouse mutants do not activate MyoD and do not form skeletal 
muscle in the trunk and limbs (Relaix et al. 2013). This resembles the phenotype of 
Pax3/Myf5(Mrf4) mutants (Tajbakhsh et al. 1997).  
These observations suggest that SIX/EYA complex can act upstream of the PAX 
genes, by regulating PAX3 expression, but also downstream of the PAX genes, by 
directly targeting and regulating the expression of some of the MRFs. 
 
Similar experiments have been carried out for the DACH proteins, which are 
classified as negative SIX regulators, although they do not have any identified binding 
site. Mice with a knockout of Dach1 or Dach2 die quickly after birth, but limb 
development does not seem to be affected (Davis et al. 2001; Davis et al. 2006). This 
suggest potential overlapping function(s) of the two DACH members in this tissue; or 
that their activity as repressors of SIX, via EYA, in the SIX/EYA complex, might be only 
important in some cases. 
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 Myogenesis is a complex process with different levels of regulation. During the 
last decade, a further layer of complexity has been added with the discovery of 
microRNAs. 
 
 
1.2. MicroRNAs 
 
 MicroRNAs (miRNAs or miRs) are a class of recently identified small non-coding 
RNAs that regulate gene expression post-transcriptionally (Bartel 2004; reviewed in 
Goljanek-Whysall et al. 2012; Ha & Kim 2014). In just two decades, miRNAs have been 
shown to play important roles in many biological processes, including cell proliferation, 
apoptosis, and differentiation.  
 
 
1.2.1. Discovery of microRNAs 
 
 The first two miRNAs, lin-4 and let-7, were originally identified in the nematode 
Caenorhabditis elegans (C. elegans) as small non-coding RNAs required for the temporal 
regulation of larval development (Lee et al. 1993; Reinhart et al. 2000).  
 
lin-4 was proved not to encode for a protein but to encode for a 22-nucleotide non-
coding RNA that is partially complementary to a conserved site located in the 3’ 
untranslated region (UTR) of the lin-14 messenger RNA (mRNA) (Lee et al. 1993; 
Wightman et al. 1991). When this complex is formed, lin-14 is downregulated to allow 
the developmental transition from the first to the second larval stage (Ruvkun & Giusto 
1989).  
The discovery of lin-4 and its target-specific translational inhibition activity has 
highlighted a new mechanism of gene regulation during the development. Few years later, 
a second miRNA, let-7, was discovered (Reinhart et al. 2000).  
 
Let-7 encodes a temporally regulated 21-nucleotide small RNA that controls the 
transition from the fourth stage to the adult stage during C. elegans development 
(Reinhart et al. 2000). Similar to lin-4, let-7 performs its function by binding to the 3’UTR 
of lin-14, but also lin-28, lin-41 and lin-57, and inhibits their translation (Vella et al. 2004; 
Abrahante et al. 2003).  
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This finding suggested not only that miRNAs had the capability of controlling 
developmental timing, but also that their biological function was an efficient, fast and 
cell-economic way of post-transcriptional regulation, since one miRNA could inhibit a 
variety of independent genes (Reinhart et al. 2000). 
 
The identification of let-7 not only provided another example of developmental 
regulation by small RNAs, but also raised the possibility that such RNAs might be present 
in species other than nematode. While lin-4 appeared to be specific to worm, both let-7 
and let-41 are evolutionary conserved with homologous detected from worm to human 
(Pasquinelli et al. 2000). This extensive conservation strongly indicated a more general 
role for these small RNAs in developmental regulation (He & Hannon 2004; Lagos-
Quintana et al. 2001). 
 
 Since then, hundreds of miRNAs have been identified. Their discovery adds a new 
dimension to our understanding of large and complex gene regulatory networks. 
 
 
1.2.2. MicroRNA biogenesis 
 
a. MicroRNA genes 
 
MicroRNA genes constitute one of the most abundant gene families, and are 
widely distributed in animals, plants, protists and viruses (Griffiths-Jones et al. 2008).  
 
MiRNA genes are located within various genetic context. In animals, most of the 
known miRNAs are located in introns of protein-coding genes and long non-coding 
transcripts; a small percentage of miRNAs are encoded by exonic regions (Rodriguez 
2004). Often, several miRNA loci are in close proximity to each other, constituting a 
polycistronic transcription unit (Lee et al. 2002). The miRNAs in the same cluster are 
generally co-transcribed and have similar tissue expression profiles (coordinated cluster), 
however some clusters contain miRNAs with uncoordinated expression profiles. The 
predicted transcription start sites of such clusters being exclusively located upstream of 
the first miRNA this means that these clusters will be transcribed as single transcription 
units. The difference of tissue expression profiles of uncoordinated miRNAs suggests a 
post-transcriptional regulation of this processing.  
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Fig. 1.4: The biogenesis and function of miRNAs. MiRNA genes are transcribed by 
RNA polymerase II (Pol II) to form a capped and polyadenylated primary transcript (pri-
miRNA). Pri-miRNA is cleaved by DROSHA/DGCR8 to form a hairpin-like precursor 
miRNA (pre-miRNA). Pre-miRNA is exported to the cytoplasm by Exportin 5 where it 
is further cleaved by DICER/TRBP to form a duplex that contains guide and passenger 
strands. One of the strands is then incorporated into RNA-induced silencing complex 
(RISC). MiRNA-loaded RISC can then recognise its target mRNA leading to 
transcriptional inhibition and/or degradation of the mRNA. ORF: open reading frame. 
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In addition, the precise location of their promoters have not yet been mapped for 
most miRNA genes. For some, which reside in the introns of protein-coding genes, they 
can share the promoter of their host gene. However, it has been shown that about one-
third of intronic miRNAs are transcribed independently of their host gene (Monteys et al. 
2010). 
 
b. Production: from gene to mature microRNA 
 
The different steps involved in the biogenesis of mature miRNAs are summarised 
in Fig. 1.4 (also see Ha & Kim 2014; Gargalionis & Basdra 2013; Kim et al. 2016). 
 
In animals, miRNAs are initially transcribed in the nucleus as long, capped and 
polyadenylated primary transcripts (pri-miRNAs), by RNA polymerase II (Lee et al. 
2004; Cai et al. 2004).  
 
These long non-coding pri-miRNAs, which are composed of one or several 
hairpin stem loop structures, where the double-stranded portion is partially 
complementary, are incorporated into the microprocessor complex. This complex 
contains a nuclear RNase III enzyme, called Drosha, and its co-factor, a protein encoded 
by DiGeorge Critical Region 8 (DGCR8). After cleavage by Drosha, 60-80 nucleotide 
long imperfect stem-loop or hairpin structures with a 3’ two-nucleotide overhang, called 
precursor microRNAs (pre-miRNAs) are released (Lee et al. 2003; Gregory et al. 2004; 
Denli et al. 2004; Han et al. 2004). The basal junction, between single-stranded RNA and 
double-stranded RNA, has been shown to be a major reference point in determining the 
cleavage site (Han et al. 2006; Zeng et al. 2005); so is the apical junction, linked to the 
terminal loop of these pri-miRNAs, for optimal efficiency and accuracy of Drosha 
processing (Zeng et al. 2005; Ma et al. 2013). 
 
The efficiency of Drosha-mediated processing is crucial for determining miRNA 
abundance. Multiple mechanisms exist to control the expression level, activity and 
specificity of Drosha.  
For example, Drosha and DGCR8 auto-regulate each other; DGCR8 stabilises 
Drosha through protein-protein interactions, whereas Drosha destabilises DGCR8 mRNA 
by cleaving it at a hairpin in the second exon.  
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Post-translational modification can also regulate the protein stability, nuclear 
localisation and processing activity of the microprocessor complex (phosphorylation and 
acetylation of Drosha; phosphorylation and deacetylation of DGCR8). Also, it has been 
shown that Drosha-mediated processing can be controlled specifically by RNA-binding 
proteins that selectively interact with Drosha and/or certain pri-miRNAs (Finnegan & 
Pasquinelli 2013; Tran & Hutvagner 2013; Ha & Kim 2014). 
 
 Another source of pre-miRNAs is derived via the RNA splicing machinery of the 
cell. These pre-miRNAs are directly spliced out of small introns, bypassing the 
microprocessor complex (Drosha/DGCR8) (Berezikov et al. 2007; Westholm & Lai 
2010; Yang & Lai 2011). These Drosha-independent miRNAs, known as ‘mirtrons’, 
constitute a class of non-canonical miRNAs, as opposed to the canonical miRNA class 
(most of the miRNAs), which are Drosha and Dicer-dependent (Abdelfattah et al. 2015).  
 
The released hairpin-shaped pre-miRNAs, are being transported through the 
nuclear pore complexes and into the cytoplasm by Exportin 5 (EXP5), a Ran-guanosine-
5’-triphosphate (GTP)-dependent nuclear transport receptor (Lund et al. 2004; Yi et al. 
2003; Bohnsack et al. 2004). Hydrolysis of GTP is necessary to free the pre-miRNAs. 
 
In the cytoplasm, pre-miRNA hairpins are cleaved by the endonuclease 
cytoplasmic RNase III enzyme, Dicer, which form a complex with its co-factor, the 
transactivation response cytoplasmic RNA-binding protein (TRBP) (Bernstein et al. 
2001; Chendrimada et al. 2005; Lund & Dahlberg 2006). This endonuclease interacts 
with the two-nucleotide overhang at the 3’ end of the hairpins, generated after Drosha 
cleavage, and cuts about 22 nucleotides away the loop joining 3’ and 5’ arms (Lee et al. 
2003). 
The imperfect double-stranded RNA duplexes generated, miRNA/miRNA*, are 
20-25 nucleotides in length with 3’ two- nucleotide overhangs at both ends (Hutvagner et 
al. 2001; Zhang et al. 2002; H. Zhang et al. 2004); they are composed of a passenger 
strand/miRNA*, and a guide strand/miRNA. Although mature miRNAs can reside on 
either strand of the hairpin stem, strand selection is dictated mainly by the relative 
thermodynamic stability of the two ends of the duplex: the strand whose 5’ terminal 
nucleotides are less stable is most likely to be selected as mature miRNA (Schwarz et al. 
2003; Khvorova et al. 2003). MiRNA originating from the 5’ and 3’ strands of pre-
miRNA are referred to as 5p and 3p miRNAs, respectively. 
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Regulation of the precursor to mature step can occur in a variety of ways. Specific 
precursor miRNAs can be detained in the nucleus to prevent maturation in certain cell 
types. Precursor maturation can also be regulated by affecting Dicer levels and activity. 
For example, Ma et al. shown that human Dicer protein is able to negatively regulate its 
own catalytic activity through its helicase domain and that this auto-inhibitory effect 
could be modulated by binding of Dicer cofactors to the helicase domain (Ma et al. 2008).  
Dicer activity can also be altered through many protein interactions. One Dicer 
interactor that increases cleavage efficiency is the TRBP. Interaction with TRBP 
modulates the processing efficiency of some pre-miRNAs and tunes the length of mature 
miRNAs. TRBP can be phosphorylated by the mitogen-activated protein kinase 
extracellular signal-regulated kinase (MAPK ERK) leading to upregulation of growth-
promoting miRNAs; the reduction of the TRBP protein leads to the destabilisation of the 
Dicer protein and to the decrease of miRNA levels (Finnegan & Pasquinelli 2013; Ha & 
Kim 2014).  
 
The relative instability of the guide strand, mature miRNA, facilitates its 
preferential incorporation into the RNA-Induced Silencing Complex (RISC). In order to 
be further processed, the two stands of the duplexes will have to be unwound; however, 
it is not clear whether this unwinding is happening before or after incorporation into 
RISC. Two models have been proposed. The first one, called ‘helicase model’, suggests 
that the unwinding occurs before incorporation and implicates direct activity of a putative 
RNA helicase; however, to date, this ‘unwindase’ remains unidentified and the model has 
not been validated. The second model, called ‘duplex-loading model’, suggests the 
incorporation of miRNA duplexes, as double-stranded, into RISC. Recent works tend to 
support this latest model by having demonstrated the presence of Ago proteins into RISC 
able to separate the two strands and degrade the passenger one, before further processing 
(Diederichs & Haber 2007; Kawamata & Tomari 2010). 
 
RISC contains Argonaute (AGO), a multi-functional catalytic protein, Dicer, and 
TRBP, responsible for recruiting Dicer to AGO (Hammond 2001; Chendrimada et al. 
2005). AGO contains two conserved RNA binding domains, a PAZ domain and a PIWI 
domain that can bind the single-stranded 3’ end and 5’ end, respectively (Pratt & MacRae 
2009). AGO is needed for miRNA-induced silencing; it binds mature miRNAs and 
orients them for interaction with their target mRNAs.  
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 AGO proteins can be modulated by numerous modifications. For example, 
hydroxylation of human AGO2 increases its stability or localisation within processing 
bodies; these processing bodies are cytoplasmic loci involved in mRNA turnover and 
RNA silencing, but also thought to be sites for translational suppression and/or mRNA 
decay. Phosphorylation of AGO2 has also been reported to be mediated by MAPK-
activated protein kinase 2 (MAPKAPK2) or RACγ Serine/Threonine protein kinase 
(AKT3), resulting in its localisation to processing bodies or translational repression, 
respectively (Finnegan & Pasquinelli 2013; Ha & Kim 2014). 
 
 
1.2.3. RNA silencing 
 
 The mature miRNAs that have been loaded into RISC, target complementary 
sequences in mRNA 3’UTR using classic Watson-Crick base-pairing but also rely on the 
thermodynamic favourability of such interaction (minimal folding free energy) and the 
site accessibility (Bartel 2009; Peterson et al. 2014; Akhtar et al. 2016). The mRNA 
downregulation takes place through two main functional pathways, either mRNA 
translational repression or the mRNA cleavage (Doench & Sharp 2004; Filipowicz et al. 
2008). 
 
Mature miRNAs have a specific sequence at position 2-7 from the 5’ end, called 
‘seed’ sequence (Lewis et al. 2005; Grimson et al. 2007). When the same seed sequence 
is found in more than one miRNA they form a ‘family’. Often miRNA/target interaction 
algorithms will predict the same targets for these miRNAs, however as seed sequence 
complementarity is only one of the criteria important for miRNA targeting, being 
members of the same family does not always mean that they will have the same real 
target(s).  
 
Each miRNA can target several hundred mRNAs. In addition, because of their 
short seed sequences, multiple miRNAs can simultaneously regulate the expression of a 
specific mRNA, by targeting different sites on its 3’UTR (Selbach et al. 2008; Bartel 
2009; Friedman et al. 2009). It is estimated that miRNAs may regulate over 60% of 
transcripts in humans (Friedman et al. 2009). 
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The miRNA/RISC complex (miRISC) uses the seed sequence to find target 
sequences, called ‘miRNA response elements’ (MREs), usually localised in the 3’UTRs 
of mRNAs (Bartel 2009).  
 
The miRISC binds to mRNA(s) depending on the degree of complementarity 
between seed and target sequences. In plants, miRNAs often have targets with perfect, or 
near-perfect complementarity causing, in most of the cases, target mRNA degradation 
(Llave et al. 2002; Rhoades et al. 2002). Although perfect complementarity can happen 
in animals, it is more common to encounter miRNAs which bind to their targets with 
partial complementarity, leading to inhibition of protein synthesis by translation 
repression and/or mRNA instability (Wahid et al. 2010; Axtell et al. 2011). 
Although the pairing to the seed region is often sufficient for functional binding 
specificity, it has been suggested that some sites in the remainder of the miRNA sequence 
might also be involved, contributing to enhance binding specificity and affinity (Doench 
& Sharp 2004), however, this process is not fully understood and will need to be further 
investigated.  
 
Recent investigations have also provided evidence that miRNAs can act at 
different sites, including 5’UTRs, promoters and coding regions (Lee et al. 2009; Place 
et al. 2008; Qin et al. 2010; Tay et al. 2008; Forman et al. 2008; Lee 2014).  
For example, Place et al. found a putative miR-373 target site in the promoter of 
E-cadherin, and showed that miR-373 induces E-cadherin expression (Place et al. 2008). 
These findings reveal a new mode by which miRNAs, in some cases, can up-regulate 
gene expression. This new miRNA function, called ‘RNA activation’ (RNAa), is a 
relatively poorly characterised phenomenon, compared to RNA inhibition; however, it 
seems likely conserved across mammals including rat, mouse, and some primates (Huang 
et al. 2010; Lee 2014).  
 
 
1.2.4. MicroRNAs and myogenesis 
 
a. Dicer-dependent myogenesis 
 
Since their discovery in C. elegans, emerging evidences have highlighted key 
roles miRNAs play during development.  
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This was first demonstrated by Bernstein et al. who knocked-out Dicer in mice in 
order to prevent the processing of pre-miRNAs into functional mature miRNAs. They 
found that a complete loss of Dicer in mice results in early embryonic lethality (E7.5), 
with development likely halting in gastrulation (Bernstein et al. 2003).  
 
Furthermore, a more targeted approach has demonstrated that miRNAs are not all 
ubiquitous, like let-7; many miRNAs have been shown to be expressed in a tissue-specific 
manner (Lee & Ambros 2001; Lagos-Quintana et al. 2002). Further investigation using 
tissue-specific Dicer deletion revealed that miRNAs are required for skeletal (O’Rourke 
et al. 2007) and cardiac (Chen et al. 2006; Zhao et al. 2007) muscle development. Tissue-
specific Dicer knock-out mice were generated and showed that Dicer knock-out led to a 
significant decrease in muscle mass, a lower number of myofibres and abnormal myofibre 
morphology, as well as increased apoptosis of myogenic cells and enhanced cell death in 
myoblasts (O’Rourke et al. 2007). Similar results have been observed in zebrafish with 
loss-of-function mutation in Dicer (Mishima et al. 2009). These studies provide 
convincing genetic evidence for the essential role of miRNAs in muscle development and 
function. 
 
b. Muscle-specific microRNAs: myomiRs 
 
With respect to skeletal muscle, miRNAs can be divided into two categories: 
miRNAs that are exclusively or preferentially expressed in muscle, the myomiRs 
(McCarthy 2008); and miRNAs expressed exclusively in non-muscle tissue or broadly 
expressed across many cell types. Both categories have significant impacts on muscle 
proliferation and differentiation (Wang 2013). 
     
 The myomiR group, which initially was composed of miR-1, miR-133a and 133b, 
and miR-206, has recently expanded to include miR-208a and 208b, miR-486 and miR-
499 (Lagos-Quintana et al. 2002; McCarthy & Esser 2007; McCarthy 2008; van Rooij et 
al. 2007; van Rooij et al. 2009; Small et al. 2010). With exception of miR-206 and 208a, 
most myomiRs are expressed in both cardiac and skeletal muscles.  
MiR-206 is expressed specifically in skeletal muscle, in somites (Sempere et al. 
2004; Sweetman et al. 2008), while miR-208a is reported to be expressed predominantly 
in cardiac muscles (van Rooij et al. 2007).  
40 
 
Some studies have reported evidence that not all myomiRs are solely expressed in 
a muscle-specific manner but may be detected in low levels in other tissues; however, 
their main function is still confined to muscle. For example, miR-486 is sometimes 
considered ‘muscle-enriched’ rather than ‘muscle-specific’ as it is also expressed in other 
tissues (Small et al. 2010; Lee et al. 2008). 
 
 MiR-1, miR-133 and miR-206: 
 
 MiR-1, -133, and -206 were the first miRNAs described as myomiRs. They have 
been studied extensively and their roles in the regulation of the myogenic programme 
have been well established (reviewed in Horak et al. 2016).  
 
These miRNAs are members of the miR-1/206 and the miR-133 families. They 
are organised in bicistronic clusters on the same chromosome (miR-1-1/miR-133a-2 on 
chromosome 20 in human and chicken, miR-1-2/miR-133a-1 on chromosome 18 in 
human and 2 in chicken, and miR-206/miR-133b on chromosome 6 in human and 3 in 
chicken), and are generally transcribed together (Nohata et al. 2012). They produce very 
similar mature miRNAs.  
In chicken, the sequence of mature miR-1a-1 is identical to miR-1a-2, while the 
sequence of miR-133a-1 is identical to miR-133a-2; Gga-miR-133b differs from these by 
only a single nucleotide at the 3’ end. They share the same seed sequence, respectively. 
MiR-1b differs from miR-1a-1/1a-2 by only 1 nucleotide; miR-1a and miR-1b 
differ from miR-206 in 3 and 4 nucleotides, respectively, in the 3’ region while sharing 
the same seed sequence.  
  
In skeletal muscle, miR-1/206 and miR-133, play important roles in proliferation, 
differentiation, and cell fate specification (van Rooij et al. 2008). They are up-regulated 
during the early stages of muscle differentiation in both cell culture models (Chen et al. 
2006; Kim et al. 2006) and in developing embryos (Wienholds et al. 2005; Sweetman et 
al. 2006; Darnell et al. 2006).  
In zebrafish embryos, loss of miR-1 and miR-133 leads to the disorganisation of 
muscle segments (sarcomeres) and muscle gene expression (sarcomeric actin) (Mishima 
et al. 2009).  
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Although deletion of miR-1 in mice leads to heart defects (ventricular septal 
defects), skeletal muscles appear to form normally (Zhao et al. 2007).  
Similarly, mice lacking miR-206 do not display an overt muscle phenotype (Williams et 
al. 2009). One possible explanation could be the overlap in target genes among myomiR 
family members. This idea is supported by the double knock-out of miR-133a-1 and miR-
133a-2 in which mice showed heart defects (~50% of lethality) and skeletal muscle 
myopathy that was not present in the single miR-133a knock-out mice (Liu et al. 2008; 
Liu et al. 2011). In chicken embryos, myogenesis is delayed after inhibition of miR-206 
with absence of complete downregulation of Pax3, which is an important requirement for 
muscle differentiation (Goljanek-Whysall et al. 2011).  
 
At the onset of myogenic differentiation, muscle gene expression is regulated by 
serum response factor (SRF), myocyte enhancer factor 2 (MEF2) and the MRFs, 
including MYOD1, MYF5, MRF4 and MYOG (Chen et al. 2006; Liu et al. 2007; Ge & 
Chen 2011). In skeletal muscle, SRF and MEF2 cooperate with MYOD1 and MYOG to 
transcriptionally activate the expression of the three pairs of muscle-specific miRNAs: 
miR-1-1/miR-133a-2, miR-1-2/miR-133a-1 and miR-206/133b (Rao et al. 2006; 
Sweetman et al. 2006; Sweetman et al. 2008).  
 
As a consequence, several major changes in miRNA levels have been observed, 
especially a significant increase in miR-1 and miR-206 levels during C2C12 myoblast 
differentiation in vitro (Chen et al. 2006; Kim et al. 2006). The elevated expression of 
miR-1a and miR-206 results in promoted differentiation and in the blockade of 
proliferation due to the anti-proliferative effects of both miRNAs.  
Along with miR-1/206, the expression of miR-133a and miR-133b is massively 
induced during myogenesis (Koutsoulidou et al. 2011). Their expression levels, like the 
levels of miR-1 and miR-206, correspond to the capacity of myoblasts to form myotubes. 
Chen et al. provided the evidence that miR-133 plays an opposing role, compared to miR-
1/206, in skeletal myogenesis (Chen et al. 2006). They showed that an overexpression of 
miR-133 was able to repress the expression of MyoG and Myosin heavy chain (MHC) 
and promote myoblast proliferation; potentially by repressing SRF. However, a 
contradictory study reported on miR-133 participation in the suppression of myoblast 
proliferation and promotion of differentiation (Kim et al. 2006). These data suggest that 
miR-133 might control both cell proliferation and differentiation in a context-dependent 
manner.  
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.5: MiR-1 and miR-206 contribute to the downregulation of Pax3 during 
myoblast differentiation. Pax3 is strongly expressed in the dermomyotomal progenitors. 
As the somite develops and differentiates, Pax3 is downregulated and MRFs are 
upregulated. In committed myoblasts MRFs activate miR-1/miR-206 which are then able 
to target residual Pax3 transcripts (in grey; negative feedback). The complete silencing of 
Pax3 confers robustness to developmental timing of differentiation. Adapted from 
Goljanek-Whysall et al. 2011. 
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Recent studies provided new evidence that miR-1 and miR-206 play a major role 
in myoblast differentiation by regulation of multiple target genes.  
Notably, inhibition of endogenous miR-1 and miR-206 was shown to block the 
downregulation of most targets in differentiation cells (Gagan et al. 2012), thus indicating 
that miRNA activity and target interaction is required for muscle differentiation 
(Goljanek-Whysall et al. 2012). Goljanek-Whysall et al. showed that miR-1 and miR-206 
play a major role during myogenesis; they confer robustness to timing of myogenesis by 
regulating the transition from myogenic progenitor cells to committed myoblast. MiR-1 
and miR-206 contribute to the downregulation of Pax3 as committed myoblasts start to 
differentiate; this step being essential to initiate the myogenic programme (Fig. 1.5) 
(Goljanek-Whysall et al. 2011; Goljanek-Whysall et al. 2012).  
 
 MiR-208a/b, miR-486, and miR-499: 
 
Newly identified and recently classified as myomiRs, miR-208a/b, miR-486 and 
miR-499, are less characterised than miR-1/206 and miR-133 (reviewed in Kirby et al. 
2016; Horak et al. 2016). These new members of the myomiR family are monocistronic 
and located in protein coding genes.  
Northern blot analyses showed that they are either strictly striated muscle-specific 
(miR-208a/b, miR-499), being derived from the intron of muscle-specific myosin heavy 
chain MYH6, MYH7 and MYH7B genes, respectively; or highly enriched in muscle 
(miR-486) and encoded in the intronic region of ANK1 (ankyrin 1) gene (van Rooij et al. 
2007; van Rooij et al. 2009; Small et al. 2010). van Rooij et al. discovered that heart-
specific miR-208a, co-expressed from MYH6 gene, encoding fast myosin, is essential for 
the upregulation of slow myosin MYH7 and miR-208b in the adult heart. They also 
described that miR-208a regulates the expression of MYH7B, another slow myosin, and 
its intronic miR-499 (van Rooij et al. 2009). Although miR-486 does not have a muscle-
specific expression, it is involved in important skeletal muscle development processes. It 
has been reported that miR-486, highly upregulated during muscle differentiation, 
directly targets PAX7 and subsequently accelerate myoblast differentiation (Dey et al. 
2011). 
 
Generally, some miRNAs are seen as playing key roles during myogenesis, e.g. 
miR-1/206 or miR-133, while others are playing more subtle roles, including miR-208a/b 
which influences muscle performance by myosin switching.  
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The dysregulation of myomiRs has been reported to be associated with various 
skeletal muscle pathologies, in several types of cancers, muscle atrophy, myopathies and 
also in sarcopenia (age-related muscle wasting) (reviewed in Kirby et al. 2016).  
Rhabdomyosarcoma (RMS), a type of soft tissue sarcoma, is derived from skeletal 
muscle progenitor cells that maintain a proliferative capacity by poorly differentiate. A 
dramatic decrease in miR-1, miR-206 and miR-133a/b expression was reported in RMS 
cell line and human RMS samples, resulting in the upregulation of the oncogene c-Met, 
a validated target of miR-1/206 (Yan et al. 2009; Rao et al. 2010). Several non-myomiRs 
have also been reported to regulate tumour formation in RMS cell lines, such as miR-29, 
which promotes myogenic differentiation (H. Wang et al. 2008).  
 
 
1.2.5. Identification of novel microRNAs 
 
Although some miRNAs have been characterised in detail, in most cases there is 
only limited information about their function(s). This is in part due to the incomplete 
complementarity of miRNAs with their targets, which makes the identification of 
biologically relevant targets more challenging (Bartel 2009; Friedman et al. 2009).  
 
MiRNA identification is complicated and requires an interdisciplinary strategy 
(reviewed in Gomes et al. 2013; Akhtar et al. 2016). Different approaches have been 
adapted to identify putative miRNAs over the years. The traditional experimental method 
used to discover miRNAs consisted of cloning size-fractionated RNA followed by Next 
Generation sequencing and experimental validation, then bioinformatics tools were used 
to locate their origin in the genome and to assess structural requirements for miRNA 
biogenesis. Other experimental approaches have been used to investigate and validate 
new miRNAs, such as Northern blot and in situ hybridisation. 
 
In recent years, biological and bioinformatics approaches have enabled discovery 
of thousands of miRNAs in plant, animals, unicellular eukaryotes, and viruses. To date, 
about 30,000 mature miRNAs have been discovered and collated in miRBase, the main 
online repository of miRNA sequences and annotation (release 21 – June 2014) 
(Kozomara & Griffiths-Jones 2014); a large number of these predicted miRNAs have not 
been investigated yet and still need to be validated by experiments as real miRNAs.  
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The current release has catalogued 434 mature miRNAs in C. elegans, 466 in 
Drosophila, and 994 in chicken. These figures, significantly lower than those for mouse 
and human, 1915 and 2588, respectively, have considerably increased in just a few years, 
suggesting that more miRNAs, especially chicken miRNAs, have still to be discovered. 
 
Recent technological advances like high-throughput sequencing have made 
possible the determination of miRNA tissue distribution (Rathjen et al. 2009; Milagro et 
al. 2013).  
It is particularly of interest for the identification of new miRNAs that are enriched 
in specific tissues, like in skeletal muscle. For example, Rathjen et al. used high-
throughput Solexa sequencing of short RNA libraries generated from chicken developing 
somites and identified new variants of known miRNAs (isomiRs) (Morin et al. 2008), but 
also potential novel skeletal muscle-specific miRNAs (Rathjen et al. 2009).  
 
 
1.3. Research aims and objectives 
 
Multiple miRNAs have been identified by combining biological and 
bioinformatics approaches, with some of them shown to be involved in skeletal muscle 
development and differentiation. However, the precise roles of most of these miRNAs 
and how they act to regulate these processes remain to be identified. 
  
 This project was developed in order to get a better understanding of the 
mechanisms underlying interactions between miRNAs and their mRNA targets.  
We focused our investigation on miR-128, and looked at the interaction with one 
of its candidate targets, Eya4. We also assessed the potential impact of this interaction on 
skeletal myogenesis in the chicken embryo. 
 
The hypothesis and specific aims of the project were: 
 
Hypothesis: MiR-128 regulates the early myogenic differentiation by targeting Eya4, a 
member of the PAX-SIX-EYA-DACH (PSED) network. 
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Specific aims: 
 
1- Characterise miRNAs (specifically) expressed in skeletal muscle by LNA in 
situ hybridisation (chapter 3.1) 
 
2- Identify candidate target mRNAs by using bioinformatics tools (chapter 3.2) 
 
3- Characterise miRNA targets by molecular cloning and RNA in situ 
hybridisation (chapter 4.1) 
 
4- Investigate miR/mRNA interactions in vitro by luciferase reporter assays 
(chapter 4.2) 
 
5- Investigate miR/mRNA interactions in vivo by functional experiments 
(chapter 5) 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
2.1. Culture of chicken eggs 
 
White leghorn chicken eggs (Henry Stewart & Co Ltd, UK) were stored at 17°C 
prior to incubation at 38-39°C for the required period of time. 
 
 
2.2.  Embryo staging, harvesting and fixation 
 
Embryos were incubated in 38-39°C humidified incubator until they reached the 
desired stages, according to the Hamburger and Hamilton table (Hamburger & Hamilton 
1992).  
Embryos were harvested from eggs by cutting away connecting tissues with fine 
scissors and removing the embryos using forceps or a spoon. The embryos were placed 
in a Petri dish, containing 1X DEPC-PBS (Phosphate-buffered saline), and dissected free 
of membranes and other attached tissues.  
The embryos were then fixed overnight at 4°C in 4% (w/v) paraformaldehyde 
(PFA)/PBS. 
 
 
2.3.  Embryo dehydration 
 
Embryos were dehydrated by washing twice in 1X PBT (DEPC-PBS with 0.1% 
Tween-20), 50% (v/v) methanol, and 100% methanol, at least 5 minutes each wash. Once 
dehydrated, embryos were stored in fresh methanol at -20°C. 
 
 
2.4.  Embryo rehydration 
 
Embryos were rehydrated by washing them in 100% methanol, then 75%, 50% 
and 25% (v/v) methanol/PBT, at least 5 minutes each wash, followed by two additional 
washes in 1X PBT. 
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2.5.  Whole-mount in situ hybridisation (WMISH) 
 
2.5.1. LNA probe pre-absorption 
 
 In order to increase efficiency and reduce non-specific binding, LNA probes were 
pre-absorbed on late stage embryos (HH27-HH30). 
 
Following rehydration, embryos were treated with 30-35 µg/mL Proteinase K for 
30 minutes. Embryos were then washed twice in 1X PBT and fixed in 4% (w/v) PFA with 
0.1% (w/v) glutaraldehyde for 20 minutes and rinsed in 1X PBT for 5 minutes. 
After removing the 1X PBT, Hybridisation Buffer, pre-heated at 48°C, was mixed 
1:1 with 1X PBT and added to the embryos; they were then allowed to settle and 
transferred to fresh pre-heated Hybridisation Buffer. The Hybridisation Buffer was 
replaced and embryos were incubated for at least 2.5 hours at 48°C. Embryos were 
incubated overnight in Hybridisation Buffer with probe (Exiqon) at 48°C using a rocking 
tray; LNA probes were used at 20 nM. Next day, the probe-containing solution was 
collected and stored at -20°C for the next use.  
 
With LNA probes (miRCURY LNATM, Exiqon), the temperature of hybridisation 
is usually 20°C lower than their Melting Temperature (Tm). For all the LNA probes used 
in this project, the temperature of incubation was 48°C.  
This pre-absorption step needs to be repeated 4 to 6 times prior to first use. 
  
2.5.2. In situ hybridisation protocol 
 
To establish the pattern of expression of genes and miRNAs of interest in chicken 
embryos, RNA in situ hybridisations (ISH) and LNA ISH were performed, respectively.  
 
 Following rehydration, embryos from stage HH10 to HH22 were treated with 5-
35 µg/mL Proteinase K for 30 minutes, depending on the stage of development. Embryos 
were then washed twice in 1X PBT and fixed in 4% PFA with 0.1% (w/v) glutaraldehyde 
for 20 minutes and rinsed in 1X PBT for 5 minutes. 
 After removing the 1X PBT, Hybridisation Buffer, pre-heated at 48°C for LNA 
ISH or 65°C for RNA ISH, was mixed 1:1 with 1X PBT and added to the embryos; 
embryos were allowed to settle and transferred to fresh pre-heated Hybridisation Buffer.  
49 
 
The Hybridisation Buffer was then replaced and embryos were incubated for at least 2.5 
hours at 48°C or 65°C. After pre-hybridisation step, the buffer was removed and replaced 
with fresh Hybridisation Buffer containing either LNA probe (20 nM; Exiqon) or RNA 
probe (0.2-0.4 ng/µL), and incubated at 48°C or 65°C, respectively, overnight using a 
rocking tray.  
 
The next day, the probe-containing Hybridisation Buffer was recovered and 
stored, and any unwound probe was removed from the sample by doing two quick washes 
in Hybridisation Buffer and followed by a 10-minute wash in fresh Hybridisation Buffer. 
The embryos were washed four times in Wash Buffer for 30 minutes each wash, and then 
in Wash Buffer mixed 1:1 with 1X MABT for 10 minutes. Embryos were rinsed three 
times in 1X MABT, and then twice in 1X MABT, 30 minutes each at room temperature. 
Non-specific protein interactions were blocked by incubating embryos in Blocking 
solution (2% (w/v) BBR, 1X MABT) for 1 hour and in Blocking solution with 20% (v/v) 
goat serum for two hours at room temperature. Goat serum was previously heat 
inactivated at 55°C for 30 minutes. Antibody incubation was done overnight with anti-
Digoxigenin (DIG) (1:2000), or anti-fluorescein isothiocyanate (FITC) (1:5000), in the 
Antibody solution (2% (v/v) BBR-MABT-20% (v/v) goat serum). 
 
Excess antibody was removed by doing six washes of 1X MABT, at least 30 
minutes each wash, at room temperature. Colour reaction was performed after washing 
embryos in freshly prepared NTMT Buffer twice for 10 minutes at room temperature. 
Detection was performed by using NBT/BCIP substrates in Alkaline Phosphatase/NTMT 
Buffer for probes conjugated to DIG, or in Fast Red/0.1M Tris (pH 8.2) for probes 
conjugated to FITC. As soon as the background appeared, embryos were washed in fresh 
5X TBST (Tris-Buffered Saline, Tween-20). The colour reaction was resumed if 
necessary. Embryos were fixed in 4% (w/v) PFA. The microscopic analysis was carried 
out using an upright microscope (Zeiss) and images were captured using QCapture 
software.  
 
2.5.3. In situ hybridisation – Buffers and solutions 
 
 Hybridisation Buffer: The solution was made up with 50% (v/v) Formamide, 1.3X SSC 
(pH 5), 0.5% (w/v) CHAPS, 0.2% (v/v) Tween-20, 5 mM EDTA (pH 8) NaOH, 0.1 
mg/mL Heparin, 50 µg/mL tRNA (yeast), in H2O. 
50 
 
Wash Buffer: The solution was made up with 50% Formamide, 1X SSC (pH 5), 0.1% 
(v/v) Tween-20, and H2O. 
 
10% Boehringer Mannheim Blocking Reagent (BBR): The solution was made up with 
10 g of Blocking reagent and 1X MAB in a total volume 100 mL. The solution was 
autoclaved, aliquoted and stored at -20°C. 
 
Blocking solution: The solution was made up with 2% (w/v) BBR in 1X MAB. 
 
Antibody solution: The solution was made up with 2% (w/v) BBR, 20% (v/v) goat 
serum, anti-DIG Fab fragment (1:2000) or anti- fluorescein isothiocyanate Fab fragment 
(FITC) in 1X MAB.  
 
Alkaline phosphatase buffer (NTMT): The solution was made up with 0.1 M NaCl, 0.1 
M Tris (pH 9.5) HCl, 50 mM MgCl, and 1% (v/v) Tween-20, in H2O. 
 
Colour development substrate: 
 5-bromo-4-chloro-3-indolyl-phosphate (BCIP): 50 mg/mL, in 100% 
dimethylformamide (DMF). 
 4-Nitro-Blue Tetrazolium chloride (NBT): 75 mg/mL, in 70% (v/v) DMF. 
 
Fast Red solution: The solution was made by dissolving 1 tablet of SIGMAFASTTM Fast 
Red TR/Naphthol AS-MX in 10 mL 0.1M Tris (pH 8.2) buffer. 
 
5X TBST: The solution was made up with 80 g NaCl, 0.25M Tris (pH 7.5) HCl, 2 g KCl, 
and 10% (v/v) Tween-20, in a total volume of 1000 mL. 
 
1X PBT: Phosphate-buffered saline (PBS) with 0.1% (v/v) Tween-20. 
 
1X Maleic acid buffer (MAB): The solution was made up with 100 mM Maleic acid, 
150 mM NaCl, adjusted to pH 7.5, in DEPC H2O. 
 
1X MAB with Tween-20 (MABT): The solution was made up with 100 mM Maleic 
acid, 150 mM NaCl, and 0.1% (v/v) Tween-20, adjusted to pH 7.5, in DEPC H2O. 
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20X Saline sodium citrate buffer (SSC) (pH 5): 20X SSC buffer was made up with 
175.3 g NaCl, and 88.2 g tri-sodium citrate, adjusted with citric acid to pH 5, in a total 
volume of 1000 mL. 
 
0.5M EDTA (pH 8) NaOH: The solution was made up with 186.1 g of EDTA, adjusted 
to pH 8, in a total volume of 1000 mL. 
 
5M NaCl: The solution was made up with 282.2 g of NaCl in a total volume of 1000 mL. 
 
2M Tris (pH 9.5) HCl: The solution was made up with 242.2 g of Tris base, adjusted to 
pH 9.5, in a total volume of 1000 mL. 
 
1M Tris (pH 7.5) HCl: The solution was made up with 121.1 g of Tris base, adjusted to 
pH 7.5, in a total volume of 1000 mL. 
 
2M MgCl: The solution was made up with 406.6 g of Magnesium Chloride hexahydrate 
in a total volume of 1000 mL. 
 
2.5.4. Embedding, sectioning and imaging 
 
After WMISH, embryos were rinsed in 1X PBS five times, 5 minutes each wash. 
Then, embryos were incubated in 20% (w/v) sucrose overnight at room temperature, with 
gentle rotation. Embryos were placed in tubes containing O.C.T. embedding medium 
(Miles Inc.) and allowed to settle. They were manually positioned with tweezers, or a 
needle, according to the desired plane of sectioning. Tubes were rapidly placed in cold 
isopentane on dry ice, and then stored at -20°C.  
 
20-30 micron sections were cut at -23°C on a Leica Cryostat. Sections were 
transferred to positively charged-slides (SuperFrost-Plus, Thermo Fisher Scientific) and 
dried at room temperature overnight. Then, the slides were washed twice in 1X PBS, 5 
minutes each wash, and mounted in Hydromount (National Diagnostics). The slides were 
dried overnight at 4°C and then at room temperature.  
Subsequently, microscopic analysis was performed using an upright microscope 
(Zeiss). Images were captured and analysed using AxioVision software, available in the 
Henry Wellcome Laboratory for Cell Imaging.  
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2.6.  Locked-Nucleic Acid (LNA) probes for WMISH 
 
Locked-Nucleic Acids (LNA) are a class of high-affinity RNA analogues in which 
the ribose is ‘locked’ by a methylene bridge connecting the 2’-O atom and the 4’-C atom.  
LNA oligonucleotides consist of a mixture of LNA and DNA or RNA, containing 
the common nucleotide bases (A, T, U, C, and G) and are able to form base pairs 
according to standard Watson-Crick binding. They exhibit thermal stability when 
hybridised to a complementary DNA or RNA strand and can be made shorter (20-25 
nucleotides in length) than traditional DNA or RNA oligonucleotide probes (250-1500 
nucleotides in length). They can be used to discriminate between highly similar 
sequences, and also to detect low abundance nucleic acids.  
Due to their hybridisation properties, LNA probes are the ideal choice for the 
detection of short non-coding RNA such as microRNAs (miRNAs) (Darnell et al. 2006; 
Sweetman et al. 2008). 
 
LNA modified DNA oligonucleotide probes labelled with DIG, at both 5’ and 3’ 
ends, were supplied by Exiqon. As part of the XenmiR project (Wheeler laboratory), the 
positions of the LNAs in their sequences were optimised such that these LNA probes had 
similar melting temperatures (TM), therefore allowing to test them at the same 
temperature of hybridisation in in situ experiments. LNA probes were designed using the 
Primer3 primer design programme (Untergasser et al. 2007) and checked using the LNA 
Oligo Optimizer Tool on the Exiqon website. Each probe sequence was then screened 
against all known chicken sequences using Basic Local Alignment Search Tool (BLAST). 
 
 
2.7. Labelled RNA probe synthesis by polymerase chain reaction (PCR) 
 
2.7.1. DNA template preparation 
 
Fragments of coding sequence of genes of interest were cloned into pGEMT-Easy 
vector (Promega) (Appendix I Table 1). This contains M13 forward and reverse primer 
binding sites, as well as SP6 and T7 RNA polymerase promoters, flanking the insertion 
site. To make a linear DNA template for probe synthesis, with the correct orientation (5’-
3’), appropriate sets of primers were used to amplify by PCR the inserted gene fragments. 
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PCR reaction mix (BioMix Red Kit (Bioline)): 
1 µL Plasmid DNA (1-5 ng/µL) 
5 µL 2X BioMix Red buffer (Bioline) 
1 µL M13 Forward primer (10 µM) 
1 µL M13 Reverse primer (10 µM) 
2 µL H2O (Sigma) 
 
Reaction conditions were: 
95°C 3 minutes 
Next 25 cycles of: 
95°C 1 minute 
55°C 1 minute 
72°C 1 minute 
Followed by: 
72°C 10 minutes 
 
Then 1/10th of the PCR reactions were run on a 1% (w/v) agarose TAE gel to 
ensure that single linear products had been amplified. 
 
2.7.2. Probe synthesis (Transcription Reaction) 
 
Labelled RNA probes were generated from the amplified DNA template using the 
appropriate RNA polymerase. 
 
For polymerases from Promega: 
1 µL PCR product 
10 µL 5X Transcription buffer (Promega) 
5 µL DTT (100 mM; Invitrogen) 
2 µL T7 or SP6 RNA polymerase (20 units/µL; Promega) 
5 µL 10X DIG-UTP Labelling Mix (10 mM; Roche) 
1 µL RNasin (40 units/µL; Promega) 
26 µL H2O (Sigma) 
 
Transcription reactions were incubated for 2 hours at 37°C for T7 polymerases, or 40°C 
for SP6 polymerase. 
54 
 
Following the transcription reactions, DNA templates were degraded by addition 
of 1 µL DNase (2 units/µL; Ambion) per reaction and incubated for 30 minutes at 37°C. 
Then, 1/20th of each transcription reaction was run on a 1% (w/v) agarose TAE gel to 
check the probe integrity. 
 
2.7.3. Probe purification 
 
Probes were purified using Illustra ProbeQuant G-50 Micro Columns (GE 
Healthcare) following manufacturer’s instructions. Finally, 5 µL of probe was added to 1 
mL of Hybridisation Buffer, and then stored at -20°C until use for ISH. 
 
 
2.8. RNA extraction from embryos and dissected somites 
 
After 2, 3, and 4 days of incubation, chicken embryos were harvested and placed 
in 1X DEPC-PBS on ice. Samples were centrifuged at 5,000 rpm for 2 minutes at 4°C, 
1X DEPC-PBS was removed and 1 mL of TRIzol (Ambion), which deactivates RNases, 
was added to 2-5 embryos depending on the stage.  
Embryos were vortexed until homogenisation and complete dissociation of 
nucleoprotein complexes for 5 minutes at room temperature. Chloroform was added (1/5th 
of the TRIzol volume; Sigma) and mixed, and after 5 minutes at room temperature, the 
samples were centrifuged at 12,000 rpm for 10 minutes at 4°C. The aqueous upper phases 
were transferred into new tubes, isopropanol was added (1/2 of the TRIzol volume; 
Fisher) and the samples were centrifuged at 12,000 rpm for 10 minutes at 4°C. The 
supernatant was removed and the pellets gently washed with 70% (v/v) ethanol before 
centrifugation for 5 minutes at 4°C.  
The pellets were then air-dried for no more than 10 minutes and re-suspended in 
20 µL DEPC-H2O warmed up to 55°C. The concentration and quality of RNA samples 
were verified using a NanoDrop spectrophotometer with an expected ratio of over 1.8 for 
readings at 260/280 and 260/230 nm. RNA integrity was analysed by agarose gel 
electrophoresis. 
 
The somites from day-2, -3, and -4 chicken embryos were carefully dissected in 
cold 1X DEPC-PBS, using sharp forceps and needles, and processed as described above, 
in order to get somite-enriched RNAs. 
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2.9.  Reverse transcription  
 
RNA extracted from chicken embryos or dissected somites was used to synthesise 
cDNA. 
 
Reverse transcription reaction mix: 
2 µg RNA 
1 µL Random Hexamer primers (50 µM; Invitrogen) 
x µL H2O (Sigma) (Q.S. 11 µL) 
 
The reaction mix was incubated at 70°C for 10 minutes and then transferred immediately 
on ice. 
 
The following were added: 
4 µL 5X Reverse Transcriptase Buffer (Invitrogen) 
2 µL DTT (100 mM; Invitrogen) 
1 µL dNTP (10 mM; Promega) 
1 µL RNasin Ribonuclease inhibitor (40 units/µL; Promega) 
1 µL SuperScript II Reverse Transcriptase (200 units/µL; Invitrogen) 
 
The samples were then incubated at 42°C for 1 hour, and stored at -20°C. 
 
Following a similar protocol, SuperScript III Reverse Transcriptase Kit 
(Invitrogen) was also used. Due to an increased thermal stability, it was possible to 
synthesise more stable and longer cDNAs. This was particularly useful for the cloning of 
low expression level genes, or full-length genes, longer than 1.5 kb.  
 
 
2.10. Amplification of cDNA by Polymerase Chain Reaction (PCR) 
 
 Polymerase Chain Reaction (PCR) is used to amplify DNA and produce millions 
of copies of a specific DNA sequence based on the repetition of cycles involving three 
different steps at three different temperatures: denaturation, annealing and elongation. 
The success of the PCR reaction was established by electrophoresis using the 
appropriate percentage agarose gel.  
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Molecular weight markers (1 kb and 100 bp DNA ladder; NEB) were used to 
establish product size. Water was used as a negative control in all polymerase chain 
reactions.  
 
Two different kits were used, BioMix Red and Velocity Kit (Bioline). BioMix 
Red Kit contains an ultra-stable Taq DNA polymerase, while the Velocity Kit contains a 
high-fidelity proofreading DNA polymerase from archaeal origin (5’-3’ DNA polymerase 
and 3’-5’ proofreading exonuclease activities). 
  
PCR reaction mix (BioMix Red Kit): 
1 µL cDNA 
5 µL 2X BioMix Red Buffer (Bioline) 
1 µL Forward primer (10 µM) 
1 µL Reverse primer (10 µM) 
2 µL H2O (Sigma) 
 
PCR reaction mix (Velocity Kit): 
1 µL cDNA 
5 µL 5X Hi-Fi Reaction Buffer (Bioline) 
1 µL dNTP (100 mM; Promega) 
1 µL Forward primer (10 µM) 
1 µL Reverse primer (10 µM) 
0.5 µL Enzyme 
16.5 µl H2O (Sigma) 
 
Reaction conditions were specific for each primer set and sample used. In order 
to determine the optimum annealing temperature, gradient PCRs were performed prior to 
the main experiments. The samples were then loaded onto a 1% (w/v) agarose TAE gel.  
 
Primers used for the amplification of cDNA are listed in Appendix I. 
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2.11. Agarose gel electrophoresis of DNA and RNA 
 
Agarose (Sigma) gels were made at 1% (w/v) concentration by pouring a warm 
solution of melted agarose-TAE (Tris base-Acetic acid-EDTA) in 1X TAE buffer. 
Ethidium bromide was added to the gels at 0.5 µg/mL to visualise DNA or RNA using an 
UV trans-illuminator following electrophoresis. Prior to loading the gel, each sample was 
mixed with 1/10th volume of 10X Loading Buffer. Electrophoresis was carried out at 80 
volts for 30-40 minutes. 
 
 
2.12. Restriction digestion 
 
All restriction digestions were carried out at 37°C for 2 hours using the 
recommended amount of restriction enzyme for the amount of DNA used, and the 
appropriate supplied buffer. The digestion products were run on a 1% (w/v) agarose TAE 
gel.  
Restriction enzymes were purchased from Promega (Promega UK) or Roche 
(Roche Biochemical Reagents, Sigma UK). 
 
 
2.13. Purification of PCR products and digested plasmid DNAs 
 
PCR products and digested plasmid DNAs were purified by gel electrophoresis. 
The appropriate band(s), visualised on a UV transilluminator, were excised from agarose 
gel and transferred into 1.5 mL Eppendorf tubes. Each tube was weighted before and after 
the addition of the gel slice. Purification of DNA fragments was performed using Thermo 
Scientific Gene JET Gel extraction Kit (Thermo Fisher Scientific), following the 
manufacturer’s instructions.  
Binding Buffer was added to the gel slice (100µL for every 100 mg of agarose gel 
for 1% (w/v) gel) with its approximate volume determined by the weight. After incubation 
at 55°C for 10 minutes, the gel mixture was briefly vortexed and loaded onto a provided 
column, and centrifuged at full-speed for 1 minute, the flow-through was then discarded. 
The column was washed with 700 µL of Wash Buffer, centrifuged at full-speed for 1 
minute, and again the flow-through was discarded. An additional centrifugation was done 
to completely remove residual Wash Buffer.  
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The column was then transferred to a new tube and the purified DNA was eluted 
from the column with 20-30 µL H2O (Sigma). Sample was quantified using a NanoDrop 
spectrophotometer before storage at -20°C. 
 
 
2.14. Ligation of DNA into a plasmid vector 
 
The PCR products were cloned into the pGEM-T Easy vector (Promega). Once 
validated by sequencing, these constructs could then be used as template to generate 
WMISH probes. The PCR products were then sub-cloned into pGL3-modified vector 
(from Dalmay lab, UEA; Tuddenham et al. 2006) or into the pCAB vector (from Dietrich 
lab, University of Portsmouth), after BglII/NheI or NotI/EcoRI restriction digestions, 
respectively; depending on the experiments they were needed for. 
 
2.14.1. Ligation efficiency 
 
For all the ligations, the optimal amount of insert (ng) to use, taking into account 
the size (kb) and the amount of vector (ng), and the ratio insert:vector (2:1 or 3:1 for 
ligation into pGEM-T Easy vector (~3 kb) or pCAB vector (~5.8 kb); 3:1 or 6:1 for pGL3-
modified vector (~5.3 kb)), was determined using the following equation:  
 
insert (ng) = [vector (ng) x insert (kb) / vector (kb)] x insert:vector ratio 
 
insert (ng): amount of insert  
vector (ng) amount of vector 
insert (kb): size of the insert 
vector (kb): size of the vector 
insert:vector ratio: molar ratio (for example, if 3:1, 3 times more insert than vector) 
 
Negative control ligation reactions were performed with all vectors used to test 
the efficiency of restriction digestion prior ligation. 
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2.14.2. Ligation into pGEM-T Easy vector 
 
 Purified PCR fragments were cloned into pGEM-T Easy vector (3015 bp; 
Promega). This vector is a linearised vector with a single 3’-terminal thymidine at both 
ends which prevents re-circularisation and provides compatible overhangs improving the 
efficiency of ligation of PCR products. 
 
The ligation reaction mix was as follows: 
0.5 µL pGEM-T Easy vector (25 ng) 
5 µL 2X Ligase Buffer (Promega) 
0.5 µL T4 DNA Ligase (3 units/µL; Promega) 
4 µL DNA (depending on the concentration and the insert:vector ratio) and H2O 
 (Sigma) 
 
The ligation was performed at room temperature for 2 hours, or overnight at 17°C. 
 
 
 
 
 
Fig. 2.1: pGEM-T Easy vector map. The 3’-T overhangs prevent self-ligation and 
enable efficient ligation of PCR fragments. The plasmid contains an Ampicillin resistance 
cassette (AmpR) enabling for selection in Escherichia coli (E. coli).  
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2.14.3. Ligation into pGL3-modified vector and pCAB vector 
 
The pGL3-modified vector is a pGL3 control vector (Promega) which was 
modified by deleting the region between SacI and BglII upstream of the SV40 promoter, 
and inserting a multiple cloning site (MCS) into the XbaI site downstream of the 
Luciferase stop codon (Tuddenham et al. 2006).  
For example, 3’UTR fragments of predicted target genes, which had first been 
cloned into pGEM-T Easy vector, were digested out, using BglII and NheI restriction 
enzymes, and then sub-cloned into this vector into the MCS. 
 
 The pCAB vector is an expression vector; containing an internal ribosome entry 
site (IRES) upstream of GFP gene, this vector can be used for expressing a gene together 
with GFP. 
 For example, full-length Gga-Eya4 cDNA, which had been first cloned into 
pGEM-T Easy vector (Appendix I Table 4), was sub-cloned into the pCAB vector using 
NotI and EcoRI restriction enzyme. This construct could then be used to perform 
overexpression experiments.   
 
The ligation reaction mix was as follows: 
x µL pGL3 or pCAB vector (50 ng) 
5 µL 2X Ligase Buffer (Promega) 
0.5 µL T4 DNA Ligase (3 units/µL; Promega) 
4 µL DNA (depending on the concentration and the insert:vector ratio) and H2O 
(Sigma)  
 
 
2.15. Preparation of DH5α Escherichia coli (E. coli) competent cells 
 
Competent cells were spread onto a LB (Lysogeny Broth) plate using a metal 
hoop, and incubated overnight at 37°C.  
A single colony was selected, placed into 5 mL of LB medium and incubated 
overnight at 37°C. 
The 5 mL of culture were added to 200 mL of LB medium in a 2L sterile 
Erlenmeyer flask and grown at 37°C with constant shaking until the optical density (OD) 
at 600 nm reached 0.3-0.4 (approximately 1h30).  
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Then, the culture was split into four 50 mL tubes and kept on ice for 15 minutes. 
After a 15-minute centrifugation at 4,500 rpm at 4°C, the supernatant was removed and 
the pellets resuspended into 16 mL of Buffer TBI per tube. After 15 minutes of incubation 
on ice, and a 10-minute centrifugation at 4,500 rpm at 4°C, supernatant was removed and 
the pellets were resuspended into 4 mL of Buffer TBII per tube. Aliquots of 100 to 200 
µL were prepared, snapped freeze using dry ice and stored at -80°C. 
 
2.15.1. Solutions and Buffers 
 
Buffer TBI: The solution was made up with 15% (v/v) Glycerol, 3 g RbCl2, 2.48 g 
MnCl2.4H20, 0.38 g CaCl2.2H2O, and 30 mM KAc (pH 7.5), in a total volume of 250 mL 
(H2O). 0.2M glacial Acetic acid was used to adjust the pH to 5.8. 
 
Buffer TBII: The solution was made up with 15% (v/v) Glycerol, 3 g RbCl2, 2.75 g 
CaCl2.2H2O, and 10 mM MOPS (pH 6.8), in a total volume of 250 mL (H2O). 
 
1M Potassium Acetate (KAc) (pH 7.5): The solution was made up with 29.44 g of KAc 
in a total volume of 300 mL. 
 
0.5M 3-(N-morpholino) propane sulfonic acid (MOPS) (pH 6.8): The solution was 
made up with 31.40 g of MOPS in a total volume of 300 mL. 
 
0.2M Acetic acid: The solution was made up with 0.58 mL glacial Acetic acid in a total 
volume of 50 mL. 
 
2.15.2. Transfection efficiency test 
 
 To test the efficiency of the newly made competent cells, 1 µL of a known plasmid 
at the concentration of 100 ng/µL was used to transform 100 µL of DH5α cells. After a 
30-minute incubation on ice, and a heat shock at 37°C for 5 minutes, the cells were placed 
5 minutes on ice. 900 mL of LB was added to the cells and after 1-hour incubation at 
37°C, the transformation mix was spread onto LB plates: 
 
 Plate 1: 10 µL of the transformation volume 
 Plate 2: 100 µL of the transformation volume 
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After overnight incubation at 37°C, colonies were counted on each plate based on 
the following calculation: 
 
Transformation Efficiency (TE; cfu/µg) = Colonies / µg plasmid DNA / Dilution 
 
Colonies: number of colonies counted on a plate 
µg plasmid DNA: amount of DNA transformed expressed in µg 
Dilution: total dilution of the DNA before plating 
TE: Colony-forming unit (cfu) per µg of plasmid DNA transformed 
 
 
2.16. Plasmid transformation into DH5α competent cells 
 
 In order to increase the concentration of fragments of interest, competent cells 
were transformed using heat shock method. 
 
5 µL of the ligation mixture were added to 100 µL DH5α competent cells for 30 
minutes on ice. After a heat shock at 37°C for 5 minutes, samples were immediately 
placed back on ice for 5 minutes. 1 mL of LB medium was added and the culture was 
incubated at 37°C for one hour with constant shaking. The bacterial culture was then 
centrifuged at 6,000 rpm for 5 minutes and 80% of the supernatant were removed. The 
pellet was re-suspended in the remaining supernatant. When doing a transformation with 
pGEM-T Easy vector, 5-10 µL of X-gal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside; 20 mg/mL) were added. The cultures were spread onto LB plates with 
carbenicillin, an antibiotic, and incubated overnight at 37°C. An additional condition with 
the vector only was done for each experiment and used as negative control. 
 
2.16.1. Selection of transformants 
 
 Colonies that grew were either white or blue. In pGEM-T Easy vector, the 
multiple cloning site (MCS), where a gene of interest may be ligated, is located within 
the lacZ gene. Successful ligation disrupts the lacZ gene leading to the absence of active 
β-galactosidase resulting in white colonies. 
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At least three white colonies were selected from each plate, transferred into culture 
tubes containing 5 mL of LB medium and 5 µL of carbenicillin (0.1 mg/mL), and 
incubated at 37°C on a shaker overnight. 
 
2.16.2. Colony PCR 
 
Colony PCR reactions were performed to identify positive colonies (with an 
insert) for verification prior bacterial culture, or plasmid isolation. 
A sterile tip was used to pick a colony which was first dipped into a PCR tube 
containing 10 µL of the following PCR mix; the same tip was then used for overnight 
bacterial culture: 
5 µL 2X BioMix Red Buffer (Bioline) 
1 µL Forward primer (20 µM) 
1 µL Reverse primer (20 µM) 
3 µL H2O (Sigma) 
 
The reaction conditions were: 
94°C 4 minutes 
Next 25-35 cycles of: 
94°C 30 seconds 
55°C 30 seconds 
72°C 1-2 minute(s) 
Followed by: 
72°C 7 minutes 
 
For pGEM-T and pCAB constructs, M13 Forward and Reverse primers were used. For 
pGL3 constructs, pGL3 Forward and Reverse primers were used, as well as primer sets 
specific to the inserts (see Appendix I Table 2 and 5). 
 
 
2.17. Plasmid isolation from bacterial cultures 
 
Plasmid DNA extractions were done by using reSource Plasmid Mini Kit 
(LifeScience) and manufacturer’s instructions were followed.  
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For mini preparation of DNA, 1 to 5 mL of overnight bacterial culture was 
transferred into an Eppendorf tube. After centrifugation at 8,000 rpm for 3 minutes, the 
supernatant was removed and the pellet was resuspended in 250 µL of Resuspension 
Buffer (Buffer 1), then 250 µL of Lysis Buffer (Buffer 2) were added and samples were 
incubated. After a 5-minute incubation at room temperature, 350 µL of Neutralisation 
Buffer (Buffer 3) were added and immediately mixed to stop the lysis reaction. After 
centrifugation at 13,000 rpm for 10 minutes, a compact pellet was observed. The 
supernatant was loaded onto a provided column. After 1 minute, the tube was centrifuged 
for 1 minute, and the column was then washed with 750 µL of Washing Buffer (Buffer 
E). After centrifugation for 1 minute, and an additional centrifugation of 2 minutes, the 
column was placed in a new tube and 30 µL H2O (Sigma) were added. After 1 minute 
and centrifugation of 1-2 minutes, DNA was eluted, quantified and stored at -20°C, before 
sequence validation and then used.  
 
Midi preparation were done using the NucleoBond Xtra Midi Plus Kit (Macherey-
Nagel) and manufacturer’s instructions were followed. 
50 mL of overnight bacterial culture were transferred into a 50 mL Falcon tube 
and centrifuged at 4,500 rpm for 15 minutes. After removing the supernatant, the pellet 
was resuspended in 8 mL of Resuspension Buffer (Buffer RES), then 8 mL of Lysis 
Buffer (Buffer LYS) were added and the sample was incubated for 5 minutes at room 
temperature. 8 mL of Neutralisation Buffer (Buffer NEU) were added to stop the reaction. 
Then, 12 mL of Equilibration Buffer (Buffer EQU) were applied onto the rim of a 
provided column filter, and allowed to empty by gravity. The equilibrated column was 
loaded with the homogenised suspension and allowed to empty by gravity. The column 
was washed with 5 mL of Buffer EQU, the filter was removed, and the column was then 
washed with 8 mL of Wash Buffer. 5 mL of Elution Buffer (Buffer ELU) were added to 
the column and the eluted plasmid DNA was collected in a Falcon tube. Then, 3.5 mL of 
isopropanol were added to precipitate the eluted plasmid DNA. The mix was split into 6 
Eppendorf tubes and centrifuged at 13,000 rpm for 15 minutes. The supernatant was 
removed, the pellets were washed with 70% (v/v) ethanol. After centrifugation at full-
speed for 5 minutes, the supernatant was removed. An additional wash with 100% ethanol 
was done. The pellets were then air-dried for 5-10 minutes and resuspended in 50 µL, 
final volume. DNA was quantified and stored at -20°C. 
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2.18. Bioinformatics: databases, software and algorithms 
 
 MiRNA sequences were collected from XenmiR, GEISHA (Gallus Expression In 
Situ Hybridisation Analysis) and miRBase databases. XenmiR is a database of Xenopus 
miRNA expression patterns developed by the Wheeler laboratory (Ahmed et al. 2015). 
GEISHA is an in situ hybridisation gene expression resource for the chicken embryo (Bell 
et al. 2004). miRBase is a miRNA database of published miRNA sequences and 
annotation (Kozomara & Griffiths-Jones 2014).  
 Potential miRNA targets were identified using TargetScan, online software for 
miRNA target prediction and analysis (Lewis et al. 2005; Agarwal et al. 2015). 
TargetScan predicts biological targets of miRNAs by searching for the presence of 
conserved 7-mer and 8-mer sites that match the seed sequence of miRNAs of interest. 
 Identification of potential miRNAs targeting mRNAs of interest was done using 
the miRanda algorithm (John et al. 2004; Betel et al. 2008). The work was done with the 
help of Simon Moxon (Earlham Institute, Norwich UK). 
 GO term analysis (Gene Ontology) was assessed using DAVID bioinformatics 
resources (Database for Annotation, Visualisation and Integrated Discovery) (Huang, 
Sherman, et al. 2009; Huang, Lempicki, et al. 2009), and g:Profiler, a web server for 
functional profiling and interpretation of gene lists (Reimand et al. 2007; Reimand et al. 
2016) These powerful tools provide a significant amount of information to understand 
biological meaning behind large lists of genes. 
 
 
2.19. MiRNA target validation – In vitro interaction 
 
 Putative miRNA targets were identified using several databases. 3’UTR 
fragments of these genes, containing putative miRNA binding site(s) were amplified by 
PCR from somite-enriched cDNA (Appendix I Table 2). They were cloned into pGEM-
T Easy vector, verified by sequencing, and then sub-cloned into pGL3-modified vector 
and verified by sequencing. Cloning was performed using standard procedures as 
previously described. 
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2.19.1. Mutagenesis of inserts cloned into pGL3-modified vector 
 
To generate pGL3 mutant constructs, the FastCloning method was used (Li et al. 
2011). The predicted miRNA target site(s) were replaced by restriction enzyme sites, 
introducing point mutations (1-4 nucleotides modified). 
 
Overlapping Forward and Reverse primers, with the mutation(s) to introduce, 
were designed (Appendix I Table 3), as well as overlapping primers in the Ampicillin 
resistance (AmpR) gene present in the pGL3-modified vector (Appendix I Table 5). The 
PCRs were done with Phusion High-fidelity DNA polymerase (NEB), a 5’-3’ DNA 
polymerase with a 3’-5’ proofreading exonuclease activity. The two products generated 
for each construct were blunt-ended. 
 
Phusion PCR reaction: 
Mix 1: 
 2.5 µL  Forward primer (10 µM) 
 2.5 µL  Reverse primer (10 µM) 
 2 µL     Plasmid DNA (10 ng/µL) 
 7 µL/tube 
 
Where the following primer combinations were used to amplify the 2 fragments: 
Forward primer gene – Reverse primer AmpR 
 Reverse primer gene – Forward primer AmpR 
 
Mix 2: 
10 µL    5X Buffer Phusion High Fidelity (HF) (NEB) 
1 µL    dNTPs (10 mM; Promega) 
 0.5 µL   Phusion enzyme (NEB)  
 31.5 µL H2O (Sigma) 
 43 µL/tube 
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The reaction conditions were: 
 Depending on the size of the fragment to amplify: 
  98°C  30 sec              
  98°C  10 sec 
  59°C  30 sec     22 cycles 
  72°C  15-30 sec / kb* 
  72°C  10 min 
 
*[2-2.5kb: 2 min; 2.5-3.5kb: 3 min; 3.5-4.5kb: 4 min] 
 
To check if the PCRs had worked, 1µL of each PCR product was loaded onto a 
1% (w/v) agarose TAE gel. Then, 5 µL of PCR product Fragment 1 and Fragment 2 were 
mixed together with 0.5 µL of DpnI restriction enzyme (Promega), in order to get rid of 
the methylated template. After two hours of incubation at 37°C, 1 µL of the digestion mix 
was loaded onto a 1% (w/v) agarose TAE gel for verification. 2 µL of the digestion mix 
was then added to 200 µL of DH5α competent cells and processed as described in chapter 
2.16. The DH5α cells are able to recombine the 2 fragments. Then, and as described 
previously, cells were plated, transformants were selected, and plasmid DNA was purified 
from bacterial cultures. Control digestions – using the appropriate restriction enzymes for 
the mutations inserted – were performed, run on gel, and the samples were then sequence 
verified and stored at -20°C.  
 
2.19.2. Cell culture 
 
Chicken DF1 fibroblast cells were cultured in Dulbecco’s modified Eagle medium 
containing 1g/L of D-glucose (DMEM + Glutamax; Gibco), 10% (v/v) heat-inactivated 
foetal bovine serum (FBS) (Gibco), 100 units/mL penicillin and 100 µg/mL streptomycin 
(Gibco) (DMEM complete medium).  
Cells were cultured in a humidified incubator and maintained at 37°C and 5% 
(v/v) CO2. The cells were passaged 1:4 every 2 to 3 days as follows: after removing 
culture medium, cells were rinsed in sterile 1X PBS (Gibco). Then, they were treated with 
1 mL Trypsin/EDTA (0.25%) (Thermo Fisher Scientific) to cover the base of the flask 
for 5-15 seconds. The trypsin was removed from the cells and the flasks were returned to 
the incubator until cells had become dissociated from the base of the flask (~ 1-2 minutes). 
Cells were then resuspended in an appropriate volume of fresh culture medium and split.  
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2.19.3. Cell transfection 
 
For luciferase reporter assays, DF1 cells were plated into 96-well plates. Cells 
were counted using a haemocytometer in order to calculate the volume needed to seed 
7,000 cells/well. Then, DMEM complete medium was added up to 100 µL, and the cells 
were returned to the incubator for 24 hours. 
 
To mimic the miRNA action in the assays, siRNAs were used. The siRNAs 
(Sigma) were designed such that both strands of the siRNA represented the endogenous 
miRNA-3p/miRNA-5p duplexes with all the mismatches present in their sequences. 
 
Transfections were done in serum-free medium (DMEM + Glutamax only). The 
complete medium was removed from the cells, and replaced by serum-free medium (50 
µL/well). The cells were transfected with Lipofectamine 2000 (0.2 µL/well; Invitrogen) 
with either pGL3 wild-type (WT) or mutant constructs (100 ng), with or without siRNA 
(50 nM).  
 
 
 
 
Fig. 2.2: pRL-TK vector map. Vector containing the cDNA encoding Renilla luciferase 
(Rluc) cloned from the anthozoan coelenterate Renilla reniformis. The plasmid contains 
a HSV-thymidine kinase promoter providing neutral constitutive expression of Renilla 
luciferase control reporter, a T7 promoter upstream of Rluc allowing in vitro synthesis of 
Renilla luciferase, SV40 late poly(A) signal sequence and an Ampicillin resistance 
cassette (AmpR).  
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The pRL-TK vector containing the cDNA encoding Renilla luciferase (Renilla 
vector; 25 ng) was co-transfected at the same time to check the transfection efficiency. 
The transfected cells were then returned to the incubator for 24 hours. After 24 hours, the 
Lipofectamine-containing medium was removed and luciferase reporter assays were 
performed. 
 
Transfections with pGL3 vector containing a 3’UTR insert, Renilla vector, and no 
siRNA were done to check the impact of adding a siRNA on the transfection efficiency. 
The pGL3 vector containing a 3’UTR insert, Renilla vector and siC (universal negative 
control siRNA #1; Sigma) treated cells served as negative control. 
 
2.19.4. Luciferase Reporter Assays 
 
The Dual-Luciferase Reporter Assay System (Promega) was used to perform 
luciferase reporter assays. The activities of Firefly (Photinus pyralis) and Renilla (Renilla 
reniformis) luciferases were measured sequentially from a single sample.  
 
After 24-hour transfection, cells were rinsed twice with cold sterile 1X PBS. Then, 
using a multi-pipette, Passive Lysis Buffer (PLB) was added to the cells (50 µL/well) and 
incubated for 15-20 minutes at room temperature on a rocker.  
10 µL of each cell lysate were transferred to a white 96-well plate. The samples 
were organised on the plate such that, using a multi-pipette, WT and mutant samples for 
the same conditions were tested at the same time. The enzymatic reaction was started by 
adding 50 µL/well of Luciferase Assays Reagent II (LARII), and the Firefly luciferase 
activity was measured by using a luminometer (Perkin-Elmer EnVision Applied 
Biosystems ABI 7500). Then, the Renilla luciferase activity was measured by adding 50 
µL of Stop & Glo reagent to the same sample. 
 
2.19.5. Normalisation of luciferase assays data 
 
 All raw Firefly luciferase assays values were normalised to those of the Renilla 
luciferase. At least 3 assays using triplicate samples in each were performed. The activity 
of the pGL3 constructs containing a 3’UTR, with or without mutation, and transfected 
with the siC were set as 100% as shown in chapter 4.  
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The luciferase activities from the sensor constructs, with or without mutation, co-
transfected with siRNAs of interest were then compared to the activity of pGL3(3’UTR) 
+ siC (100%).  
To assess the effect of the siRNA on the target constructs, the ratio values obtained 
by co-transfection of the WT or mutant construct with the siRNA were compared. Two 
tailed Student’s unpaired t-test was performed to compare difference between two groups.  
 
 
2.20. MicroRNA target validation – In vivo interaction 
 
Chicken embryos were used as in vivo model system in order to further validate 
miRNA target genes and to investigate the effect of their inhibition on myogenesis. 
 
2.20.1. Microinjection 
 
 Microinjection needles were prepared by pulling glass capillaries (1.0 mm O.D. x 
0.78 mm I.D.; Harvard apparatus, UK) on a micropipette puller (P-97, Sutter Instrument 
Co., CA). Needles were filled by gravity with 2-4 µL of solution to inject.  
A small hole was performed at the blunt end of the egg shell and the hole was 
enlarged after the embryo had been located. After removing all the membranes covering 
the embryo using fine forceps (Dumont n°5), a micromanipulator was used to direct the 
needle into the somites.  
Fine forceps were used to break the tip of the capillary; the opening generated 
would have to be wide enough to allow the antagomiR solution to go through (viscous), 
but still sharp in order not to damage the targeted somites. Pressure was exerted to fill 
these somites with the injected solution. 
 
AntagomiRs were designed to target specific miRNAs (Appendix Table 6). The 
reverse complementary sequence was synthesized by Dharmacon with all bases replaced 
by 2’O-methyl-bases and, for example for the antagomiR-128 (AM-128), the 
phosphodiester bonds were replaced by thiol bonds between bases 1-2, 2-3, 18-19, 19-20 
and 20-21. The antagomiRs also included a 3’ cholesterol moiety. Scrambled antagomiR 
(AM-scr) was used as control (miR-206 scrambled sequence). For injections the 
antagomiRs were resuspended in H2O (Sigma) at a concentration of 1 mM. For injections 
of two antagomiRs, both antagomiRs were mixed based on a 1:1 ratio. 
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Chicken embryos at stage HH14-15 were injected into the 6 most posterior 
somites on one side. For each injected embryo, the non-injected contralateral side was 
used as control. After injection, the egg shell was re-sealed with tape and returned to the 
incubator at 38-39°C for the desired time. 
 
2.20.2. Harvesting of treated chicken embryos 
 
 The embryos for which the somites have been injected with antagomiRs, were 
incubated for 6, 9, 12 or 24 hours. All the treated embryos were collected in 1X PBS and 
the attached membranes were removed. The antagomiRs are fused to Fluorescein which 
can be detected by using a microscope equipped with GFP filter. Only embryos which 
developed to the expected stage and showed GFP expression in the injected somites were 
selected. 
 For in situ hybridisation, harvested embryos were fixed in 4% (w/v) PFA 
overnight and processed as described in chapter 2.5.  
For Real-time quantitative PCR (RT-qPCR), injected somites were localised by 
detecting the GFP, and dissected out. RNAs were extracted and cDNA synthesised. The 
non-injected contralateral somites were also dissected and used as control. 
 
2.20.3. RNA extraction from dissected somites – qPCR 
 
After dissecting out injected and non-injected somites from antagomiR-treated 
embryos, RNAs were extracted by using the protocol described in chapter 2.8, but with 
additional steps to obtain RNAs of better quality to use for qPCR.  
 
The dissected somites were put in Eppendorf tubes containing cold 1X DEPC-
PBS and kept on ice. After centrifugation at 5,000 rpm for 2 minutes at 4°C, 1X DEPC-
PBS was removed, and 1 mL of TRIzol (Ambion) was added. Samples were vortexed and 
incubated for 5 minutes at room temperature. 200 µL of chloroform (Sigma) was added 
and mixed, and after 5 minutes at room temperature, the samples were centrifuged at 
12,800 rpm for 30 minutes at 4°C. The aqueous upper phases were transferred into new 
tubes, 50 µL 5M NaCl, 1 µL Glycoblue (Invitrogen), and then 500 µL of isopropanol 
were added to each tube and incubated for 10 minutes at room temperature. The samples 
were centrifuged for 30 minutes at 4°C. The supernatants were discarded, the pellets were 
gently washed with 500 µL 70% (v/v) ethanol and centrifuged for 10 minutes at 4°C. 
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After removing the supernatant, an additional wash with 500 µL 100% ethanol was done. 
The pellets were air-dried for no more than 10 minutes and re-suspended in 15 µL H2O 
(Sigma), preliminary warmed up to 55°C. Then the RNAs were DNase treated by adding 
the following mix to each sample: 
2µL 10X DNase Buffer (Ambion) 
1 µL DNase I (2 units/µL; Ambion) 
2 µL H2O (Sigma) 
 
The samples were incubated at 37°C for 1 hour, and then a second RNA 
precipitation was performed using acid phenol-chloroform (Ambion). The steps 
previously described were resumed. Two washes with 70% (v/v) ethanol were done, 
followed by one with 100% ethanol, before to air-dry the pellets and re-suspend them in 
20 µL H2O (Sigma). The concentration and the quality of RNA samples were checked 
using a NanoDrop spectrophotometer (good quality: 260/280 and 260/230 ratios over 
1.8). 
cDNAs were synthesised as described in chapter 2.9, and 100-600 ng of RNA 
were used. Samples with RNA but no RNasin or SuperScript II Reverse Transcriptase 
were also generated and used as negative controls (RT- samples). 
 
2.20.4. Real-Time quantitative PCR (RT-qPCR) 
 
RT-qPCRs were performed in order to quantify potential changes in expression of 
genes of interest after antagomiR injection (see Appendix I Table 7 for qPCR primer 
sequences). The cDNAs were diluted 100 times before being used.  
 
The reaction mix contained: 
7.5 µL 2X SYBR Green Master mix (Applied Biosystems) 
5 µL  cDNA 
0.5 µL primer mix (Forward + Reverse; 10 µM) 
2 µL  H2O (Sigma) 
 
The reaction conditions were as follows:  
50°C 2 minutes 
95°C 10 minutes 
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Followed by 40 cycles:  
95°C 15 seconds 
60°C 1 minute 
 
Reactions were performed in 96-well plates in ABI Prism 7500 (Applied Biosystems).  
 
2.20.5. Normalisation of RT-qPCR data 
 
Results were analysed based on the Relative Standard Curve method (Larionov et 
al. 2005). By using this method, the quantity of each experimental samples was first 
determined by using a standard curve. 
Five 5-fold serial dilutions of cDNA template, known to express the genes of 
interest (somite-enriched cDNAs from 3- or 4-day chicken embryos), was used to 
generate standard curves. A calibration curve was generated for each gene of interest and 
each housekeeping gene (β-actin and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH)), and used to extrapolate the relative expression for these same genes in 
unknown experimental samples. 
Based on their respective calibration curve, the relative quantification results for 
each gene of interest were determined and normalised to the averaged relative 
quantification of β-actin and GAPDH housekeeping genes. Then the normalised values 
were compared between injected and non-injected samples to identify potential fold 
change in expression. 
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CHAPTER 3: MicroRNA CHARACTERISATION AND 
TARGET IDENTIFICATION 
 
 
3.1. Introduction: 
 
 In this chapter, two essential aspects for a better understanding of microRNA 
(miRNA) functions are going to be addressed: miRNA identification and characterisation, 
and target identification. 
 
Since their discovery in 1993, in C. elegans, miRNAs have been increasingly 
studied due to the fundamental role(s) they have in regulating biological processes, 
through reshaping the cellular transcriptome and proteome (Lee et al. 1993); but also 
because of their extensive conservation across species, from nematode to human (He & 
Hannon 2004; Lagos-Quintana et al. 2001). 
 
The first miRNAs – in particular muscle-specific miRNAs, such as the myomiRs 
miR-1/206 and miR-133 – were identified by using conventional techniques including 
cloning (Bentwich et al. 2005), Northern blotting (Sempere et al. 2004; Várallyay et al. 
2007), and in situ hybridisation (Thomsen et al. 2005; Nelson et al. 2006). Although this 
allowed identification of a substantial number of miRNAs, these techniques are time-
consuming and not cost effective (Mendes et al. 2009); they also do not provide much 
information regarding miRNA function(s). 
 
With the idea that knowing the entire repertoire of these small molecules would 
help to gain a better understanding of their function(s), several new methods for DNA 
sequencing were developed leading to the identification of a large number of new 
miRNAs. Next-generation sequencing (NGS), also known as high-throughput 
sequencing, is a reliable and sensitive method to quantify miRNAs and detect less 
abundant miRNAs, which can either be ubiquitously represented or tissue-specific (Bar 
et al. 2008; Rathjen et al. 2009).  
 
For efficient miRNA identification from NGS data, good prediction algorithms 
are necessary.  
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These tools consider some major miRNA characteristics, such as sequence 
conservation, and structural features, like hairpin and minimal folding free energy 
(Akhtar et al. 2016). There are two types of computational identification; in both of these 
methods the main signal used is the hairpin secondary structure of precursor miRNAs 
(pre-miRNAs).  
The first method – comparative identification – is based on sequence conservation 
across different species and has been used for most of the known miRNAs (Lindow & 
Gorodkin 2007). Comparative genomics were used to filter out hairpins that are not 
evolutionary conserved in related species and then, based on sequence similarity, aligned 
unknown RNA sequences to known pre-miRNAs with a BLAST-like algorithm. The 
second method – non-comparative identification – does not rely on phylogenetic 
conservation and thus can be used to find non-conserved and/or species-specific miRNAs 
(Batuwita & Palade 2009); this approach mainly relies on the effective identification of 
pre-miRNAs among the predicted hairpin secondary structures. The first step consists in 
an initial screen identifying millions of hairpin structures from the genome, then, by 
combining bioinformatics predictions with microarray analysis, novel miRNAs were 
detected.  
 
Thousands of miRNAs have now been discovered in several species and tissues 
by combining biological and bioinformatics approaches. All known information has been 
collected in online repositories, like miRBase for precursor sequences, mature miRNA 
sequences, and genomic location (Kozomara & Griffiths-Jones 2014); or species-specific 
databases, such as GEISHA for chicken, ZFIN for zebrafish, MGI for mouse and Xenbase 
for Xenopus, which include LNA probe sequences and expression patterns (Bell et al. 
2004; Howe et al. 2013; Smith et al. 2014; Bowes et al. 2009).  
However, most of these new miRNAs have been identified by ‘prediction tools’ 
using diverse algorithms, and it cannot be guaranteed that all of them are real. Each 
miRNA will have to be validated experimentally. In GEISHA, in addition to next-
generation sequencing (NGS), miRNA microarray and PCR data, published expression 
patterns for most of the known chicken miRNAs are referenced (Bell et al. 2004; Darnell 
et al. 2006); however, except for the most studied miRNAs, expression data are often 
limited to whole-mount in situ hybridisations (WMISH) of a few stages, with hardly any 
sections. Work still need to be done to precisely determine where and when miRNAs are 
expressed in order to fully understand their function(s) in general and in skeletal muscle 
in particular. 
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The development of computational tools was not only important for the discovery 
of new miRNAs, but also for the identification of their targets. However, in animals, the 
complementarity between miRNAs and mRNA target sites is partial, therefore it is more 
difficult to determine potential targets with a high specificity (Axtell et al. 2011).  
 
Numbers of studies have been focused on predicting accurate target mRNAs for 
miRNAs (Ekimler & Sahin 2014).  
They were using various algorithms taking into account Watson-Crick 
complementarity in the seed sequence between miRNA and target mRNA, sequence 
comparison between species, and thermodynamic favourability of the miRNA-mRNA 
duplex (free energy calculations and site accessibility) (Peterson et al. 2014). Although 
seed regions are considered crucial for mRNA targeting, algorithms depending on simple 
base-pairing result in high false positive rates (Bartel 2009).  
Taking into account most of these criteria, algorithms like TargetScan, miRBase, 
and miRanda provide long lists of potential target mRNAs for each miRNA (Agarwal et 
al. 2015; Kozomara & Griffiths-Jones 2014; Betel et al. 2008). Experiments will then 
have to be carried out in order to validate these putative miRNA/mRNA interactions in a 
given biological context. 
 
The first part of the project was dedicated to (1) characterising the expression of 
interesting miRNAs in the chicken embryo during somitogenesis, and to (2) the 
identification of their potential targets. MiRNAs with a potential expression in skeletal 
muscle in various species were selected, with a particular focus on miR-128.  
 
 MiR-128: 
 
 MiR-128 is an intronic miRNA, encoded by two distinct genes, miR-128-1 and 
miR-128-2, which are embedded in the introns of R3HDM1 (R3H domain containing 1) 
and ARPP21 (cyclic adenosine monophosphate (AMP)-regulated phosphoprotein, 21 
kDa) (Bruno et al. 2011). Recently, miR-128 and ARPP21 have been associated with 
neuropsychiatric phenotypes (fear response, anxiety, movement disorders). Highly 
expressed in mammalian central nervous system, ARPP21, a calmodulin (CaM) 
signalling regulator, was shown to be a direct target of miR-128. Calmodulins plays 
important roles at the synapse by regulating the release of neurotransmitters from the 
presynaptic terminal (Ching & Ahmad-Annuar 2015).  
77 
 
In chicken, these genes are located on chromosome 7 and 2, respectively. Both 
miR-128-1 and miR-128-2 are processed to generate the same mature miRNA with 
identical sequence, miR-128.  
 
MiR-128 is a ‘brain-enriched’ miRNA first identified in mouse, where its 
expression level increases during brain development and is maintained in adult brain 
tissues (Lagos-Quintana et al. 2002; Smirnova et al. 2005). Similar results were observed 
in chicken and zebrafish (Xu et al. 2006; Kapsimali et al. 2007). In addition, miR-128 has 
been shown to be involved in the repression of the RNA surveillance pathway, called 
nonsense-mediated decay (NMD); inactivation of NMD being necessary for the 
differentiation of neuronal cells during brain development (Bruno et al. 2011; Karam & 
Wilkinson 2012).  
 
MiR-128 is found in cardiac tissue. A recent study examining newt cardiac 
regeneration by Witman et al, demonstrated that miR-128 regulates the expression of the 
transcription factor Islet1, a transcription factor expressed in cardiac progenitor cells. By 
targeting Islet1, miR-128 could be acting as a negative regulator of progenitor cell 
activity, emphasising a need for differentiation into cardiac cell lineages necessary during 
the process of regeneration (Witman et al. 2013).  
In chicken, miR-128 is found in the developing heart, however its expression in 
this tissue appears to be limited to a short time-window as it is only seen in stage HH13 
embryos (Darnell et al. 2006).  
 
 As well as being involved in neuronal and cardiac development, miR-128 
expression was also detected in skeletal muscle. MiR-128 is found in adult mouse muscle 
(Sempere et al. 2004; Lee et al. 2008); adult and embryo porcine skeletal muscle (Zhou 
et al. 2010); and adult and embryo (somites) chicken skeletal muscle (Darnell et al. 2006; 
Lin et al. 2012; Abu-Elmagd et al. 2015). In mouse, the inhibition of insulin receptor 
substrate 1, Irs1, by miR-128, leads to the inhibition of myoblast proliferation and 
induction of myotube formation (Motohashi et al. 2013). These results are consistent with 
the increase in miR-128 expression observed during myoblast differentiation in 
differentiating mouse C2C12 myoblast cells (Sun et al. 2010). The role of miR-128 in the 
inhibition of proliferation and promotion of myoblast cell differentiation was also 
demonstrated in a recent work from Shi et al. done in mouse.  
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They showed that miR-128 promoted myotube formation by targeting myostatin, a 
negative regulator of myogenesis and muscle growth (Shi et al. 2015). They also showed 
that ectopic miR-128 is able to induce the expression of Pax3/7 and MRFs, like Myf5 and 
MyoG. Although miR-128 appears to be expressed in both adult and developing skeletal 
muscle, only its functions in adult muscle have been studied in these works, mostly in 
mouse and in ex vivo or in vitro experiments.  
 
 Although hundreds of miRNAs have been identified and deposited into miRBase 
repository, only limited data are available on their expression patterns during key 
developmental stages. In order to begin to understand the function(s) of miRNAs during 
embryo development, it is important to characterise their spatiotemporal expression 
patterns throughout development, and identify their targets. 
 A group of miRNAs, predicted to be expressed in skeletal muscle, has been 
studied; the process of their selection, and characterisation of their expression profiles 
will be presented in the first part of this chapter.  
Some of these miRNAs, and in particular miR-128, which have interesting muscle 
expression, were further investigated in order to identify potential targets; results will be 
presented in a second part.  
 
 
3.2. Results and discussion 
 
3.2.1. Characterisation of microRNA expression patterns 
 
 Based on information available from miRBase, GEISHA, and Xenbase database 
(Kozomara & Griffiths-Jones 2014; Bell et al. 2004; Bowes et al. 2009), as well as high-
throughput sequencing data (Rathjen et al. 2009), and information found in the literature, 
a short list of miRNAs potentially expressed in skeletal muscle was established.  
To determine miRNA expression patterns, WMISH were performed in chicken 
embryos at different stages of development (see chapter 2.5.). Due to the small size of the 
miRNAs (20-25 nucleotides in length), performing classic WMISH with conventional 
RNA probes had been technically challenging. The technology developed by Exiqon 
(http://www.exiqon.com/), using modified oligos containing miRCURYTM Locked-
Nucleic Acid (LNA) nucleotides as probes, helped to solve this problem (Nielsen et al. 
1999; Kubota et al. 2006) (details in chapter 2.6).  
79 
 
To date, these probes are one of the most efficient ways to determine miRNA 
expression profiles in tissues and embryos, however their cost is an important limitation 
to any study of a large number of miRNAs.  
 
The XenmiR project – miRNA identification in the model Xenopus:  
 
 The Wheeler laboratory (UEA, Norwich UK) was involved in the development of 
a database, similar to GEISHA for the chicken, entirely dedicated to miRNAs expressed 
in Xenopus (Xenopus tropicalis and laevis), called XenmiR. The aim of the XenmiR 
project was to determine the expression patterns of miRNAs expressed during Xenopus 
development using LNA oligonucleotides (Ahmed et al. 2015). To do so, LNA probes 
were developed by Exiqon. The positioning of the LNAs in the sequences was done such 
that all the LNA probes had a similar melting temperature (Tm) and could be used at the 
same hybridisation temperature (48°C). They determined the expression patterns of 180 
miRNAs in Xenopus laevis and found a large number being expressed in neural tissue 
and in the somites.  
 
a. MicroRNAs: conservation across species 
 
With the XenmiR project, 56 miRNAs were detected in Xenopus laevis (Xla) and 
tropicalis (Xtr), in somites. Based on the fact that most of the miRNAs are predicted to 
be conserved across species, it was tempting to think that these miRNAs could also be 
present in chicken, and their sequences conserved.  
 
The first step was to determine if Xenopus and chicken miRNA sequences were 
conserved. Xenopus miRNA sequences, extracted from the XenmiR project data, and the 
corresponding chicken miRNA sequences, from miRBase, were collected and used for 
comparison. Sequence alignments showed that 42 of the 56 Xenopus miRNAs were 
sequence conserved in chicken, with 23 expressed in somites (based on whole-mount 
analysis). These 23 miRNAs are listed in Table 3.1.  
Within these 23 miRNAs, 14 were completely conserved between the two species 
(100% identity), and 8 were 1-2 nucleotide(s) shorter in chicken at their 3’ end, but the 
5’ ends, containing the seed sequence, were identical. The miRNA Xla-miR-1306 was 
the least conserved with nucleotides missing at both 5’ and 3’ ends.  
 
 XenmiR 
miRNAs X/C chicken miRNAs 
RNAseq 
AEM 
GEISHA 
  Whole-mount in situ hybridisation (WMISH)   Sectioning 
  HH10 HH11 HH12 HH13 HH14 HH15 HH16 HH17 HH18 HH19 HH20 HH21 HH22 HH23   HH10 HH11 HH12 HH13 HH14 HH15 HH16 HH17 HH18 HH19 HH20 HH21 HH22 HH23 
Xla-miR-1306 (-3) x (-2) Gga-miR-1306-3p      x x  x   x x      x  x     x   
Xtr-let-7a x Gga-let-7a-3p YES x      x x       x x x x x       x         x         x   
Xtr-miR-1a x Gga-miR-1a-3p YES       x [S]   x x   x       x   x x         x x     x       x   
Xtr-miR-1b x Gga-miR-1b-3p NO       x [S]   x x       x x x x           x         x      x x       
Xtr-miR-10a        x (-1) Gga-miR-10b-5p*  x   x       x x x   x       x       x          x     
Xtr-miR-15a        x (-1) Gga-miR-15a NO       x [S]   x x       x       x x         x      x       x     
Xtr-miR-15b   Gga-miR-15b-5p YES       x [S]   x       x x   x x   x x x   x         x           x   
Xtr-miR-15c        x (-2)  Gga-miR-15c-5p      x     x x x   x x x   x     x       x        x       
Xtr-miR-17-5p x Gga-miR-17-5p NO       x [S]   x x     x x   x x         x     x       x       
Xtr-miR-18b       x (-1) Gga-miR-18b-5p NO x     x x x   x x x x         x     x         x     
Xtr-miR-23b       x (-1) Gga-miR-23b-3p yes     x x       x x x   x x       x     x   x       x   
Xtr-miR-24a x Gga-miR-24-3p NO     x         x x x       x x   x       x   x       x   
Xtr-miR-30a-5p x Gga-miR-30a-5p YES       x [S]   x   x     x x x x x       x         x      x     
Xtr-miR-31 x Gga-miR-31-5p NO     x x     x x x x x x       x     x         x   
Xtr-miR-128       x (-1) Gga-miR-128-3p YES       x [S]   x x x x x x x x x x x x x x     x         x     x x   
Xtr-miR-130a       x (-2) Gga-miR-130a-3p*        x [S]       x         x x x x             x         x   x       
xtr-miR-133a x Gga-miR-133a-3p YES       x [S]     x x       x x x x x x         x         x     x     
Xtr-miR-133b x Gga-miR-133b YES        x       x    x  x   x  x  x  x        x           x     x   
Xtr-miR-133c x Gga-miR-133c-3p NO x    x x  x       x  x      x x  x         x        x          x   
Xtr-miR-194 x Gga-miR-194 NO x   x   x     x x x x x             x       x     x       
Xtr-miR-203 x Gga-miR-203a NO x     x     x x x x x x x     x    x      x   x     
Xtr-miR-206 x Gga-miR-206 YES       x [S]   x x   x x x x x           x      x       x     
Xtr-miR-223 x Gga-miR-223 YES       x [S]     x  x        x  x   x   x         x         x    x     
 
Table 3.1: Summary – Characterisation of miRNAs during chicken development. XenmiR miRNAs: list of 23 Xenopus miRNAs with an expression 
in somites. X/C: Xenopus vs chicken miRNA sequence comparison. x indicates 100% identity; number of missing nucleotides between sequences is 
indicated in brackets. Chicken miRNAs: Corresponding Xenopus miRNAs in chicken. RNAseq AEM: presence, or not, of the miRNAs in chicken somite 
dataset generated by NGS technology (Rathjen et al. 2009). GEISHA: Available information for a specific miRNA in GEISHA database (indicated by 
x). [S]: miRNA presents in somites. WMISH and Sectioning parts: x indicates the stages used to perform WMISH and for which sectioning was done. 
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With the help from Simon Moxon (Earlham Institute, Norwich UK), these 23 
miRNAs were checked against a chicken somite dataset (RNAseq AEM), previously 
generated by our laboratory using NGS technology (Rathjen et al. 2009). This analysis 
revealed that from these 23 microRNAs found expressed in Xenopus somite and having 
conserved sequence between Xenopus and chicken, 10 were identified by RNA 
sequencing performed on chicken somite samples; amongst them were found the 
myomiRs miR-1a, miR-133a/b and miR-206. In addition, some information was available 
in GEISHA (chicken database) for 17 of these miRNAs, with 11 expressed in somites 
(Bell et al. 2004; Darnell et al. 2006).  
 
b. MicroRNAs: expression patterns 
 
Xenopus laevis and tropicalis LNA oligonucleotides, and chicken LNA probes 
when available, designed for the 23 selected miRNAs, were used to perform LNA 
WMISH in chicken embryos at different stages of development, from HH10 (2 days of 
incubation) to HH23 (4 days of incubation), according to the Hamburger and Hamilton 
table (Hamburger & Hamilton 1992). After LNA WMISH, miRNA expression patterns 
were analysed in whole-mount embryos first, and then on sections (see Table 3.1 for 
details) (Ahmed et al. 2015).  
 
i) New insights into the myomiRs 
 
 The myomiRs family, initially composed of miR-1, miR-133a/b and miR-206, has 
recently been expanded to include miR-208a/b, miR-486, and miR-499 (Lagos-Quintana 
et al. 2002; McCarthy & Esser 2007; McCarthy 2008; van Rooij et al. 2007; van Rooij et 
al. 2009; Small et al. 2010). Compared to the ‘new myomiRs’, miR-1/206 and miR-
133a/b have been extensively studied since their discovery. Conserved across species, 
with well characterised skeletal muscle-specific expression patterns, these miRNAs were 
used as a starting point in the process of learning how to perform LNA WMISH in chicken 
embryos (McCarthy & Esser 2007; McCarthy 2008; Sweetman et al. 2008). Results are 
presented in Fig. 3.1-3. 
 
Consistent with profiles already published in chicken (GEISHA) and in Xenopus 
(XenmiR database; Ahmed et al. 2015), miR-1, miR-206, and miR-133 are strongly 
expressed in the somites.  
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In addition, these series of WMISH provided some new elements to what was 
already known. 
 
According to the expression patterns presented in GEISHA database, miR-1a is 
not detected by ISH before stage HH11 where it is found in the heart; and its somitic 
expression is observed later at about stage HH14.  
Our results showed that miR-1a (Fig. 3.1a) was already expressed and detectable 
in HH9 embryos (i), in the heart, while its expression in somites, although very weak, 
was detected in the most anterior somites of HH12-13 embryos (ii). Its heart expression 
became stronger as the embryos developed (i-iii), as well as in the differentiating somites 
(ii, iii, iii’, iv), and particularly in the myotome, as observed in transverse sections (ii’, 
iii’’, iv’). Interestingly, with only one nucleotide difference in the middle of its sequence 
compare to miR-1a, the expression of miR-1b (Fig. 3.1b) was less specific with a lot of 
background in whole-mount (v, v’, vi). Sectioning showed that miR-1b was expressed in 
somites, in the myotome, at HH14-15 and onwards (v’’, vi’).  
 
 A similar observation was made for miR-206 (Fig. 3.2). In GEISHA database, 
there is no information on the expression of miR-206 before stage HH14.  
Like for miR-1a, we observed that miR-206 is already expressed at HH12-13 in 
the most anterior somites (i); this suggests that miR-1a and miR-206 could already play 
important roles in the undifferentiated epithelial somites. MiR-206 was also found in the 
neural tube.  
 
As the embryo developed, its expression in the neural tube disappeared; miR-206 
was detected in most somites along the anterior-posterior axis by HH14-15 (ii, ii’, iii). In 
transverse sections, miR-206 was strongly expressed in the myotome (ii’’, iii’). MiR-206 
was not detectable in early stage HH10-11 embryos, indicating that it probably starts to 
be expressed between stage HH10-11 and HH12-13.  
While miR-1a and miR-206 are both expressed in the somites, only miR-1a is 
found in the heart. This could be explained by the fact that their sequences, extremely 
similar, differ by 3 nucleotides (see Appendix II Table 1). 
 
 In chicken embryos, miR-133 family is composed of 3 members: miR-133a, and 
miR-133b and miR-133c (Fig. 3.3).  
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Fig. 3.1: Expression patterns of miR-1a (a) and miR-1b (b). LNA WMISH were 
performed on chicken embryos using Xenopus LNA probes. WMISH and transverse 
sections (20x magnification) for miR-1a (a), and miR-1b (b). (a) MiR-1a expression 
pattern at HH9 (i), HH12-13 (ii), HH14-15 (iii), and HH20-21 (iv). MiR-1a was first 
observed in the heart at HH9 (i; *), and later in somites from HH12-13 (ii, iii, iii’ and iv 
(interlimb portion). Transverse sections showed the expression of miR-1a in the 
developing somite (ii’) and in the myotome (iii’’, iv’). (b) MiR1b expression pattern at 
HH14-15 (v-v’’) and HH20-21 (vi, vi’). MiR-1b was expressed ubiquitously in whole-
mount (v, v’, vi). Transverse sections showed its expression in the myotome and the 
notochord at stage HH14-15 (v’’); notochord expression disappearing in later stage 
HH20-21 (vi’). Red dotted line indicates the location of the transverse sections. H: heart; 
My: myotome; NC: notochord; NT: neural tube; S: somite. 
 
 
 
 
 
 
Fig. 3.2: Expression pattern of miR-206. LNA WMISH were performed on chicken 
embryos using Xenopus LNA probes. WMISH (i- iii) and transverse sections (i’-iii’; 20x 
magnification) for miR-206. MiR-206 expression pattern at HH12-13 (i), HH14-15 (ii), 
and HH20-21 (iii). MiR-206 was already expressed in the most anterior somites at HH12-
13 (i). As the embryos developed, this expression was also found in most posterior 
somites (ii, iii). Transverse sections showed the expression of miR-206 in the developing 
somite (i’) and in the myotome (ii’’’, iii’). Red dotted line indicates the location of the 
transverse sections. My: myotome; NC: notochord; NT: neural tube; S: somite. 
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MiR-133a is already expressed at HH10, in the heart tube; whereas its expression 
in somites is only observed from HH15 (GEISHA database).  
With no embryo younger than HH11-12, we could not confirm this observation or 
determine a more precise expression start point, however, we observed that miR-133a 
was already strongly expressed in the heart at this stage (HH11-12); it was also found in 
the most anterior somites, in the neural tube, and notochord (i, i’); the expression in neural 
tube and notochord has also been reported in Xenopus WMISH (Ahmed et al. 2015). In 
older embryos, miR-133a was no longer expressed in the neural tube and the notochord, 
and its expression in somites became restricted to the myotome (i-iii’).  
There is no profile of expression available in GEISHA database for miR-133b, 
and miR-133c is described as ubiquitously expressed.  
WMISH for these miRNAs indicated that miR-133b and miR-133c have 
expression profiles similar to miR-133a. This could be explained by the fact that their 
sequences are extremely similar and only differ by 1 or 2 nucleotides at the 3’ end (see 
Appendix II Table 1). However, their expression profiles were not identical indicating 
that even 1 nucleotide of difference is enough to yield a specific signal when using LNA 
probes. 
Interestingly, miR-133b and miR-133c seemed to start to be expressed with a 
slight delay compared to miR-133a (i’, iv’, vii’). While miR-133a was already strongly 
represented in the somites at HH11-12, miR-133b was not expressed yet, and miR-133c 
was only just becoming detectable. MiR-133c could be observed from HH12-13 in 
somites, miR-133b appeared later at stage HH14-15. From HH14-15, no difference was 
observed between the 3 members of miR-133 family, with a strong expression in somites 
and in particular in the myotome (ii-iii’; v-vi’; viii-ix’). 
 
ii) Characterisation of a group of 16 somitic miRNAs 
 
The same procedure was used to determine the expression patterns of 16 miRNAs 
which were previously shown to have partially conserved (seed sequence not affected) or 
conserved sequences between Xenopus and chicken (Table 3.1).  
 
Xenopus LNA probes were used to perform WMISH in chicken embryos at 
different stages of development. Results are presented in Fig. 3.4 (see also Ahmed et al. 
2015). 
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Fig. 3.3: Expression patterns of miR-133 family members: miR-133a (a), mir-133b 
(b), and miR-133c (c). LNA WMISH were performed on chicken embryos using 
Xenopus LNA probes. WMISH and transverse sections (20x magnification) for miR-
133a (a), miR-133b (b), and miR-133c (c). Expression patterns of miR-133a/b/c at HH12-
13 (i, iv, vii), HH14-15 (ii, v, viii), and HH20-21 (iii, vi, ix). MiR-133a was the first 
member to be detected. It was already strongly represented in the somites, and the neural 
tube at HH12-13 (i’), while miR-133b was not yet expressed (iv’) and miR-133c was just 
starting to be detected (vii’). From HH14-15, they were all expressed in somites (ii, ii’, 
iii; v, v’, vi; viii, viii’, ix) and transverse sections indicated their presence in the myotome 
(ii’’-iii’’; v’’-vi’; viii’’-ix’). Red dotted line indicates the location of the transverse 
sections. My: myotome; NC: notochord; NT: neural tube; S: somite. 
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All the Xenopus probes used worked in chicken embryos and a specific expression 
pattern was observed for each miRNA. Although sometimes a strong background 
interfered with the determination of miRNA patterns in whole-mount embryos, their 
specific expressions were revealed in transverse sections. 
 
For most of these miRNAs there was no information in GEISHA database about 
their expression patterns. When WMISH and, sometimes, transverse section data were 
available, miRNA expressions were often not clear, very weak, with ubiquitous or 
widespread patterns.  
 
MiR-1306:  
This miRNA was described in the literature as being the product resulting from 
the regulation of the microprocessor, which is involved in miRNA synthesis and is 
composed of Drosha and DGCR8 (Ha & Kim 2014). In order to maintain an optimal level 
of miRNA produced, DGCR8 was shown to stabilise Drosha, whereas Drosha was 
destabilising DGCR8 mRNA by cleaving it at a hairpin in its second exon (Han et al. 
2009; Ha & Kim 2014). This cross-regulatory loop, reported to happen in at least certain 
cell types (dog peripheral blood (Friedländer et al. 2008); human embryonic stem cells 
(Morin et al. 2008)), could enable the homeostatic maintenance of the microprocessor 
activity; this process is deeply conserved throughout the animal kingdom. The mRNA 
fragment resulting from this Drosha-mediated cleavage, miR-1306, has not been 
validated as a functional miRNA yet (Ha & Kim 2014).  
Chicken WMISH showed that miR-1306 was very weakly expressed at HH11-12 
in the neural tube, the notochord and the developing somite (Fig. 3.4i).  
 
In HH15-16 embryos, its expression was widespread in whole-mount (i’, i’’) 
(potentially linked to the widespread Drosha-mediated regulation); however on transverse 
section, miR-1306 was clearly still found in the neural tube and the notochord, as well as 
in the myotome of the differentiated somite (i’’’). This could be explained by a potential 
stabilisation of miR-1306 in certain tissue. 
 
Let-7a:  
 Let-7 was one of the first miRNAs discovered in C. elegans (Reinhart et al. 2000). 
In mammals, several isoforms for this miRNA exist (isomiRs), and amongst them let-7a. 
No information was found for this miRNA in databases.  
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Fig. 3.4: Expression patterns of 16 selected miRNAs. LNA WMISH were performed 
on chicken embryos using Xenopus LNA probes. MiRNA expression patterns at HH11-
12 in transverse section (i-xvi; 20x magnification), and HH14-15: whole-mount (i’-xvi’), 
detail of somite expression in dorsal view (i’’-xv’’), and transverse section (i’’’-xvi’’’; 
20x magnification). Red dotted line indicates the location of the transverse sections. My: 
myotome; NC: notochord; NT: neural tube; S: somite. 
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In ISH at HH11-12, let-7a was found weakly expressed in the neural tube (Fig. 
3.4ii); expression maintained as the embryos developed. At HH15-16, let-7a was also 
expressed in the notochord and in the somites, in the myotome (ii’-ii’’’). 
 
MiR-15 family:  
MiR-15 family is composed of 3 members: miR-15a, miR-15b, and miR-15c. 
Some information was available in GEISHA database for miR-15a, indicating an 
expression in the limb buds; miR-15b was described with a widespread expression; and 
there was no information for miR-15c.  
Although their sequences are very close, with just few differences, they showed 
slightly different expression patterns (Fig. 3.4iv-vi’’’). While miR-15b was already 
expressed at HH11-12 in the neural tube and developing somite (v), miR-15a was only 
weakly detected in these tissues (iv), and miR-15c was not even detectable (vi). At HH15-
16, they displayed similar expression patterns (iv’-vi’). They were all expressed in the 
neural tube, the notochord and the myotome (iv’’-vi’’); miR-15c was the most strongly 
expressed of the three (vi’’’). At later stages they were also all expressed in the limb buds. 
 
MiR-24a, miR-30a-5p, and miR-130a:  
No information was found in GEISHA database for miR-24a; miR-30a-5p is 
apparently expressed in somites and limbs (whole-mount data); and widespread 
expression for miR-130a. 
Of the 16 miRNAs studied here, these three miRNAs were the most strongly 
expressed in the early stage HH11-12. They were found in the neural tube, the notochord 
and the developing somite (Fig. 3.4x, xi, xiii).  
MiR-130a did not appear to be expressed in the most dorsal part of the neural tube 
as shown in transverse section (xiii). At HH15-16, they were still expressed in the neural 
tube, the notochord and the differentiated somite, in the myotome (x’-x’’’; xi’-xi’’’; xiii’-
xiii’’’). At later stages, miR-24a, miR-30a-5p, and miR-130a were expressed in the limb 
buds. 
 
MiR-10a, miR-17-5p, miR-18b, and miR-194: 
 There is no information for miR-10a in GEISHA database. MiR-17-5p is found in 
the surface ectoderm in early stages, in the neural tube and the somite (section), and has 
a widespread expression at later stages.  
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MiR-18b and miR-194 are weakly expressed in the somites; despite a widespread 
expression, they are also found in the limb buds at later stages. 
These miRNAs were found weakly expressed in the neural tube and the somite at 
HH11-12 (Fig. 3.4iii; vii; viii; xiv); expression maintained as the embryo developed. At 
HH15-16, they were expressed in the myotome (iii’’’; vii’’’; viii’’’; xiv’’’); miR-10a 
(weakly) (iii’’’) and miR-18b (strongly) (viii’’’) were expressed in the notochord. 
 
MiR-23b, miR-31, miR-203, and miR-223: 
 From GEISHA database, no specific expression was reported for miR-23b and 
miR-31; miR-203 and miR-223 have ubiquitous expression. 
 MiR-31, miR-203 and miR-223 were not expressed at HH11-12 (Fig. 3.4xii; xv; 
xvi). At HH15-16, miR-203 was found in the neural tube, the notochord and the myotome 
(xv’’’), whereas miR-31 (xii’’’) and miR-223 (xvi’’’) were only expressed in the 
myotome. MiR-23b was found very weakly expressed in the neural tube and the somite 
(ix), in the myotome (ix’’’), at all stages tested. These miRNAs were later expressed in 
the limb buds. 
 
 All 16 miRNAs were found expressed in chicken embryos, in the somites. 
Although the expression patterns were similar, depending on the stage and the tissue 
considered, they were not identical. For example, while most of these miRNAs were not 
detected or very weakly detected at HH11-12, miR-24a, miR-30a-5p and miR-130a were 
already strongly expressed, indicating potential important role(s) for these 3 miRNAs in 
neural tube, notochord and somite early in the development. Some of these miRNAs were 
also expressed in other tissues (see Appendix II Table 2). 
 
iii) Characterisation of miR-128 
 
 For this miRNA, both Xenopus and chicken probes were available in the 
laboratory; and miR-128 was shown to be conserved between these two species. 
However, because the 2 probes were not designed at the same time, the position of the 
LNA in their sequences (not communicated by Exiqon) might not be the same; this could 
have possible consequences on their TM and the optimal temperature of hybridisation to 
use, leading to potential differences in affinity and detection of expression. 
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 A series of in situ hybridisations, using both probes, were performed at different 
temperatures (42°C, 48°C = optimal temperature for the Xenopus probes, and 54°C) in 
order to determine the optimal temperature to use for the chicken probe (good signal vs 
background); the range of temperature was determined based on the TM of the chicken 
probe (LNA hybridisation temperature ~ TM - 20°C). It was also a good opportunity to 
confirm that 48°C was the optimal temperature for the Xenopus probe (Fig. 3.5).  
The 2 probes had the best signal (against background), at 48°C, as expected; 
embryos treated with the chicken probe were cleaner, with less background and a stronger 
and more specific pattern. 
 
 According to the information available in GEISHA database, miR-128 is strongly 
expressed in the heart at HH13 (only stage showing heart expression), and as the embryos 
developed it is found in the somites and in the limb buds. 
 In situ hybridisations performed for miR-128 (Xenopus and chicken probes), 
showed no expression in the heart in any of the tested stages (HH10-23; Fig. 3.5i-iii’; iv-
vi). This expression of miR-128 in the heart, might happen at a very specific time-point 
during the development. At HH11-12, miR-128 was found in the neural tube, the 
developing somite, and weakly in the notochord (iv’). At HH16-17, it was strongly 
expressed in the myotome, with no expression detected in the notochord and a weak 
expression in the dorsal part of the neural tube (v’’). At HH20-21 (vi), miR-128 was also 
found in the branchial arches (white arrow), around the eye (white arrowhead) and in the 
limbs (white asterisk). Its expression in the neural tube was consistent with the fact that 
miR-128 has been described in other species as a brain-enriched miRNA. However, 
according to our ISH results, it appears that, in the chicken, miR-128 is only necessary in 
this tissue in early stages, as it was not found in the neural tube at later stages. 
 
 In this first part, 23 miRNAs were studied. Their specific expression patterns in 
the chicken at different stages of development were confirmed and completed with 
additional information, like for the myomiRs miR-1a, miR-133a and miR-206; or 
determined for most of the other miRNAs, like for miR-128, as no, or few expression 
patterns could be found in the databases.  
 
All the miRNAs tested were expressed in the myotome in somites. Their 
expression patterns were similar but not identical. This indicates that even with short, and 
sometimes closely related sequences, LNA technology permits specific detection of 
miRNAs and their spatiotemporal expression patterns can be determined.  
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Fig. 3.5: Expression pattern of miR-128. (a) MiR-128 expression pattern, using 
Xenopus LNA probe, at HH11-12 (i), HH15-16 (ii; dorsal view (ii’)), and HH20-21 (iii; 
dorsal view (iii’)). (b) MiR-128 expression pattern, using chicken LNA probe, at HH11-
12 (iv; transverse section (iv’)), HH16-17 (v; dorsal view (v’); interlimb transverse 
section (v’’)), and HH20-21 (vi; dorsal view (vi’’); interlimb transverse section (vi’’)). 
MiR-128 was expressed in the neural tube, the notochord at HH11-12, in the developing 
somites and in the myotome. At HH20-21, it was also found in the branchial arches (white 
arrow), around the eye (white arrowhead), and both fore and hind limbs (white asterisk) 
(vi). Red dotted line indicates the location of the transverse sections. Transverse sections: 
20x magnification. My: myotome; NC: notochord; NT: neural tube; S: somite. 
 
 
 
 
 
 
92 
 
 The following part of this chapter aimed to identify lists of potential targets for 
these miRNAs.  
 
3.2.2. Identification of microRNA targets 
 
After having characterised the expression of these 23 miRNAs by LNA ISH, 
different computational strategies (see chapter 2.18) were used to identify their targets in 
order to get a better understanding of their functions.  
 
For reasons of clarity, only the analysis done for miR-128 target identification will 
be presented here. A summarised analysis for the other miRNAs can be found in 
Appendix II Table 3.  
By using bioinformatics tools (DAVID Bioinformatics resources and g:Profiler), 
this analysis allowed identifying interesting targets, and a particular interest was given to 
predicted targets with an expression in skeletal muscle, such as for example Eya4.  
 
Eya4 is a member of the EYA family, part of the PSED network. Together with 
the other members of this network, from the PAX, SIX, and DACH superfamilies, they 
have been implicated in the regulation of myogenesis (Heanue et al. 1999; Bajard et al. 
2006; Buckingham & Relaix 2015). In addition, experiments performed in chicken 
embryos have shown that the expression of Pax3 was regulated by miR-1a and miR-206 
(Goljanek-Whysall et al. 2011) suggesting that more miRNAs could potentially play a 
role in the regulation of this network. However, the regulation of the PSED network by 
miRNAs has not been really investigated.  
In chicken, the 3’untranslated region (UTR) sequences of the PSED members – 
important for miR targeting – have not been completely annotated. So by using the 
miRanda algorithm, predicted miRNA sites were identified. This will be presented in a 
second part.  
 
a. Eya4: a candidate target for miR-128 
 
To identify potential target genes of miR-128, TargetScan (release 7.1; June 
2016), an online computational program for miRNA target identification and analysis 
(http://www.targetscan.org/), was used and a list of 507 genes was generated. 
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The molecular functions of miR-128 predicted targets was determined by 
comparing the results from two analyses:  
- Gene Ontology (GO) term and Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway annotation analysis in the Database for Annotation, Visualisation and 
Integrated Discovery tool (DAVID Bioinformatics resources: https://david.ncifcrf.gov/) 
(Huang, Lempicki, et al. 2009; Huang, Sherman, et al. 2009); 
- and g:GOSt (GO Statistics), for pathway enrichment analysis, in g:Profiler, a 
web server for functional profiling and interpretation of gene lists 
(http://biit.cs.ut.ee/gprofiler/) (Reimand et al. 2007; Reimand et al. 2016).  These 
powerful tools provide a significant amount of information to understand biological 
meaning behind large lists of genes. 
 
GO term annotation analysis showed that nearly 70% of the 507 miR-128-
predicted targets were classified directly as ‘cellular process’, while other GO terms, like 
‘biological regulation’ and ‘developmental process’ were also enriched, including 55.3% 
and 28.8% of the targets, respectively [GOTERM_BP_1] (Table 3.2). About a quarter of 
miR-128 targets were indicated as implicated in the regulation of transcription (125), 
transcription (102), and regulation of RNA metabolic process (83) [GOTERM_BP_FAT] 
(Table 3.3). KEGG pathway annotation analysis also revealed that some of its predicted 
targets were involved in the mitogen-activated protein kinase (MAPK) signalling 
pathway (17), in Insulin signalling pathway (14) and in mTOR signalling pathway (7) 
[KEGG_PATHWAY] (Table 3.4).  
 
For example, recent work done by Motohashi et al. showed that the miR-128 
regulation of IRS1 (insulin receptor substrate 1), involved in IRS1/Akt insulin signalling, 
had an effect on myogenesis; they demonstrated that miR-128 is able to regulate myoblast 
proliferation and myotube hypertrophy through IRS1-dependent insulin signalling 
(Motohashi et al. 2013). 
 
The g:GOSt analysis performed using g:Profiler tool showed similar results, with 
more than 70% of miR-128 targets involved in biological regulation (73.9%), regulation 
of biological process (72.3%) and cellular process (69.4%); nearly 50% of miR-128 
targets were classified as involved in ‘developmental process’ (Table 3.5).  
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CATEGORY TERM COUNT % P-value 
GOTERM_BP_1 Cellular process 322 69.2 2.5E-6 
GOTERM_BP_1 Biological regulation 257 55.3 7.2E-9 
GOTERM_BP_1 Metabolic process 234 50.3 2.9E-3 
GOTERM_BP_1 Multicellular organismal process 144 31.0 1.3E-3 
GOTERM_BP_1 Developmental process 134 28.8 7.9E-9 
GOTERM_BP_1 Cellular component organisation 97 20.9 1.2E-4 
GOTERM_BP_1 Cellular component biogenesis 37 8.0 4.8E-2 
GOTERM_BP_1 Locomotion 21 4.5 1.3E-2 
GOTERM_BP_1 Growth 10 2.2 6.0E-2 
 
Table 3.2: GOTERM_BP_1 results (465 out of 507 targets were included in the 
analysis). 
 
 
 
CATEGORY TERM COUNT % P-value 
GOTERM_BP_FAT Regulation of transcription 125 26.9 8.9E-12 
GOTERM_BP_ FAT Transcription 102 21.9 1.2E-9 
GOTERM_BP_ FAT Regulation of RNA metabolic 
process 
83 17.8 1.5E-4 
GOTERM_BP_ FAT Regulation of transcription, DNA-
dependent 
80 17.2 3.0E-6 
GOTERM_BP_ FAT Intracellular signalling cascade 54 11.6 6.4E-4 
GOTERM_BP_ FAT Phosphate metabolic process 52 11.2 3.1E-6 
GOTERM_BP_ FAT Positive regulation of nitrogen 
compound metabolic process 
43 9.2 9.4E-8 
GOTERM_BP_ FAT P sitive regulation of ma romolecule 
biosynthetic process 
42 9.0 3.9E-7 
GOTERM_BP_ FAT Positive regulation of transcription 39 8.4 1.8E-7 
 
Table 3.3: GOTERM_BT_FAT results (252 out of 507 targets were included in the 
analysis). 
 
 
 
CATEGORY TERM COUNT % P-value 
KEGG_PATHWAY Focal adhesion 17 3.7 3.6E-5 
KEGG_PATHWAY MAPK signalling pathway 17 3.7 9.7E-4 
KEGG_PATHWAY Insulin signalling pathway 14 3.0 2.8E-5 
KEGG_PATHWAY Pathways in cancer 14 3.0 6.8E-2 
KEGG_PATHWAY Neurotrophin signalling pathway 11 2.4 1.0E-3 
KEGG_PATHWAY Regulation of actin cytoskeleton 11 2.4 4.3E-2 
KEGG_PATHWAY Endocytosis 9 1.9 9.1E-2 
KEGG_PATHWAY mTOR signalling pathway 7 1.5 1.8E-3 
KEGG_PATHWAY ErbB signalling pathway 7 1.5 2.2E-2 
 
Table 3.4: KEGG_PATHWAY results (465 out of 507 targets were included in the 
analysis). 
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Based on different algorithms, g:Profiler was including more targets in its analysis 
compare to the DAVID one; a larger number of targets were classified as playing a role 
in the development in the g:GOSt analysis (256 (g:GOSt) vs 134 (GOTERM_BP_1)).  
The miR-128 targets listed in the category ‘Developmental process’ from the two 
analysis, GOTERM_BP_1 (134) and g:GOSt (236) were compared; 126 targets were 
common between the two analysis.   
  
These 126 targets were then used to perform a new GOTERM analysis. More than 
50% of these miR-128 targets were found in the brain (65), interesting because miR-128 
was described as a brain-enriched miRNA, about 10% in the eye (12), 8% in muscle (10) 
and less than 2% in the heart (2) [UP_TISSUE] (Table 3.6).  
 
A closer look was given at the ‘muscle’ category; the 10 predicted miR-128 
‘muscle’ targets, which includes EYA4, are listed in Table 6. For each of these targets, 
information found in the literature about potential role(s) in muscle are summarised 
below. No information was found for NUS1. 
  
MSTN: 
 Myostatin, member of the TGFβ protein family, is the only validated miR-128 
target of this list. Shi et al. recently showed, in mouse, that by targeting Myostatin, miR-
128 was involved in the inhibition of proliferation and the promotion of myoblast cell 
differentiation (Shi et al. 2015). In chicken, Myostatin is found in somites, in the 
dermomyotome, and during limb bud development (Amthor et al. 2002). In addition, 
ectopic expression of Myostatin in the developing limb bud results in a downregulation 
of Pax3 and Myf5, both associated with proliferation of myogenic cells.  
 
BMI1:  
In mouse, Bmi1 was found expressed in postnatal myogenic satellite cells, where 
it has been involved in their maintenance and plays an essential role in repeated muscle 
regeneration (Robson et al. 2011). 
In Bmi1-/- mice, a depletion in Pax7+/Myf5- stem cell population was observed, 
with a reciprocal increase in Pax7+/Myf5+ committed myogenic progenitor population, 
leading to a reduction in postnatal muscle fibre size and impaired regeneration upon 
injury.  
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CATEGORY TERM COUNT % P-value 
g:GOST Biological regulation 357 73.9 2.0E-9 
g:GOST Regulation of biological process 349 72.3 1.4E-10 
g:GOST Regulation of cellular process 335 69.4 3.7E-10 
g:GOST Regulation of metabolic process 256 53.0 7.9E-14 
g:GOST Developmental process 236 48.9 3.6E-15 
g:GOST Positive regulation of biological 
process 
206 42.7 6.4E-9 
g:GOST Gene expression 198 41.0 2.8E-7 
g:GOST Regulation of gene expression 187 38.7 6.3E-14 
g:GOST Regulation of developmental process 109 22.6 4.4E-10 
g:GOST Tissue development 83 17.2 1.2E-5 
 
Table 3.5: g:GOSt results (483 out of 507 targets were included in the analysis).  
 
 
 
 
CATEGORY TERM COUNT % P-value 
UP_TISSUE Brain 65 51.6 2.0E-2 
UP_TISSUE Placenta 31 24.6 4.1E-2 
UP_TISSUE Epithelium 28 22.2 1.1E-2 
UP_TISSUE Foetal brain 12 9.5 1.4E-2 
UP_TISSUE Eye 12 9.5 7.6E-2 
UP_TISSUE Amygdala 11 8.7 7.5E-3 
UP_TISSUE Muscle 10 7.9 8.9E-2 
UP_TISSUE Frontal cortex 3 2.4 1.5E-2 
UP_TISSUE Foetal lung 3 2.4 7.1E-2 
UP_TISSUE Embryonic heart 2 1.6 5.9E-2 
UP_TISSUE Thyroid carcinoma 2 1.6 7.8E-2 
 
 
GENE SYMBOL GENE NAME 
BMI1 BMI1 polycomb ring finger oncogene 
EYA4 eyes absent homolog 4 (Drosophila) 
HOXA10 homeobox A10 
MEIS2 Meis homeobox 2 
MSTN myostatin 
MYH10 myosin, heavy chain 10, non-muscle 
NUS1 nuclear undecaprenyl pyrophosphate synthase 1 homolog (S. 
cerevisiae) 
RORA RAR-related orphan receptor A 
RYBP RING1 and YY1 binding protein 
SPRY2 sprouty homolog 2 (Drosophila) 
 
Table 3.6: UP_TISSUE results (a) and list of the 10 ‘muscle’ targets (b). 
 
a. 
b. 
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In chicken, Bmi1 is found early in development in the primitive streak; and then 
in the heart, neural tube, and in somites, in the dermomyotome (Fraser & Sauka-Spengler 
2004). 
  
HOXA10: 
 HoxA10 was shown to play a role in the regulation of the timing of cardiac 
differentiation by cooperating with Nkx2-5, involved in mesodermal patterning (Behrens 
et al. 2013). It has also been implicated as a regulator for hematopoietic stem cells and 
erythroid/megakaryocyte development (Magnusson et al. 2007).  
In chicken, HoxA10 is found in somites and limb buds (Alvares et al. 2003). 
 
MEIS2: 
 MEIS2 plays important role in formation of embryonic brain, eye, heart, cartilage 
and hematopoiesis. Mouse embryos lacking Meis2 display defects in tissues derived from 
neural crests, such as abnormal heart outflow tract, and cranial nerves (Machon et al. 
2015). Perturbations in craniofacial skeleton development were also observed, with 
anomalies in cranial bones and cartilages. Cecconi et al. also showed that Meis2 plays a 
role in the cascade of induction leading to somitic mesoderm differentiation as well as in 
brain regionalisation (Cecconi et al. 1997).  
In chicken, Meis2 is found in the somites and limb buds (Sánchez-Guardado et al. 
2011). 
 
RYBP: 
 Rybp was implicated in transcriptional regulation, apoptotic signalling and, as a 
member of the polycomb repressive complex 1 (PRC1), in regulating pluripotency and 
differentiation of embryonic stem cells (ESCs). As well as playing an important role in 
mouse brain development, it has been identified as a critical regulator of heart 
development (Ujhelly et al. 2015).  
In addition, work done by Zhou et al. showed that Rybp, as a negative regulator 
of skeletal myogenesis, is targeted by miR-29, a pro-myogenic miRNA, in order to 
downregulate its expression during myogenesis (Zhou et al. 2012). 
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RORA (or RORα): 
 The only information available for RORα was found in mouse, where it has been 
involved in regulating the Akt2/adenosine monophosphate (AMP)-activated protein 
kinase (AMPK) signalling pathways in the context of lipid homeostasis in skeletal muscle 
(Raichur et al. 2010).  
 
MYH10: 
 MYH10 encodes for non-muscle myosin heavy chain II B (NMHC-IIB); member 
of the non-muscle myosin IIs (NM IIs), a group of ubiquitously expressed proteins. 
NMHC-IIB is critical for cardiac and brain development (Ma & Adelstein 2014); it is 
expressed in cardiac myocytes, and enriched in neuronal tissue where it is thought to be 
important in neuronal migration.  
In mouse, the knock-out of NMHC-IIB lead to embryonic death (E14.5) with 
severe cardiac defects and neurodevelopmental disorders. This phenotype was also 
observed in zebrafish (Huang et al. 2013; Gutzman et al. 2015) and in human (Tuzovic et 
al. 2013). 
 
SPRY2: 
 In chicken, Spry2 is found in early stages in the primitive streak, in the neural 
tube, mesoderm of the branchial arches, retina, in somites in the myotome, and in later 
stages in the limb buds (Chambers & Mason 2000).  
In addition, Abu-Elmagd et al. recently showed that overexpression of Spry2 
results in reduction of somite myogenesis indicated by a loss of MyoD expression; 
suggesting that Spry2 could play a crucial role during chicken myogenesis by regulating 
myogenic cell proliferation (Abu-Elmagd et al. 2015). 
 
EYA4: 
In mouse, Eya4 is strongly expressed in skeletal muscle. It is found in somites, in 
the dermomyotome (Y. Zhang et al. 2004). Borsani et al. reported that at limb level, Eya4-
positive cells appear to be migrating away from the dermomyotome into the limb 
structures in a pattern resembling that of migrating muscle precursor cells (Borsani et al. 
1999); suggesting a potential role for Eya4 in limb muscle development.  
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In addition, eya4 has also been reported as being important in the regulation of 
Na+/K+-ATPase, essential for zebrafish heart development. In eya4 morphant fish, 
Na+/K+-ATPase level was decreased and amongst other phenotypes, heart failure was 
observed (L. Wang et al. 2008).  
EYA4 is also known to be part of the PAX-SIX-EYA-DACH (PSED) network of 
transcriptional regulators acting early in the myogenesis, and upstream of the MRFs.  
 
b. Identification of microRNAs targeting PSED members 
 
EYA4 is a member of the PSED network, and, as shown in the previous part, it 
appears that its expression might be regulated by miR-128. But what about the other 
members of this network?  
 
The 3’UTR information and annotations found in databases, like TargetScan, are 
sometimes incomplete and often based on human sequences, which is most likely not 
highly conserved with the chicken (miRNA response elements (MREs) might be 
conserved, but not the surrounding sequence). In chicken, the 3’UTR sequences of the 
PSED members – important for miR targeting – have not been completely annotated. So 
by using the miRanda algorithm, predicted MREs were identified. 
 
 The miRanda algorithm, developed by Enright et al., is an interesting 
computational tool for the prediction of miRNA targets (Enright et al. 2003; Betel et al. 
2008).  
For each miRNA, targets are selected on the basis of three properties: (1) sequence 
complementarity using a position-weighted local alignment algorithm taking into account 
moderate mismatches and complementarity at the 5’ end (seed sequence location); (2) 
free energies of miRNA-mRNA duplexes with calculation of optimal interaction; and (3) 
conservation of target sites in related genomes including UTR matches between species, 
nucleotide identity, and equivalent target site positions according to a cross-species UTR 
alignment. 
 
 In order to identify potential MREs in the 3’UTRs of PSED members, the 
miRanda algorithm was used; it was run by Simon Moxon (Earlham Institute, UK). 
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MiRNA 
3’UTR 
Eya1 Eya2 Eya3 Eya4 Six1 Six4 Dach1 
gga-miR-1306-3p NO NO NO YES NO YES YES 
gga-let-7a-3p YES NO NO YES YES YES YES 
gga-miR-1a YES YES YES YES # YES YES YES 
gga-miR-1b NO YES NO YES # YES YES YES 
gga-miR-10b YES # YES NO NO NO YES YES 
gga-miR-15a YES # NO YES YES YES YES YES 
gga-miR-15b-5p YES # NO YES YES YES YES YES 
gga-miR-15c-5p YES # YES YES YES YES YES YES 
gga-miR-17-5p YES YES NO YES YES YES  YES 
gga-miR-18b YES YES YES YES YES YES YES 
gga-miR-23b YES # YES YES YES NO YES YES # 
gga-miR-24a YES YES YES YES #* NO YES YES 
gga-miR-27b-3p YES # YES YES YES # YES YES YES 
gga-miR-30a-5p NO NO NO YES NO YES # YES 
gga-miR-31 YES YES NO YES NO YES YES # 
gga-miR-128 YES YES NO YES # NO YES NO 
gga-miR-130a YES NO NO YES  NO YES YES 
gga-miR-133a NO YES YES YES # NO YES YES 
gga-miR-133b NO YES YES YES # NO YES YES 
gga-miR-133c NO YES YES YES # NO YES YES 
gga-miR-194 YES YES YES YES YES YES YES 
gga-miR-203 YES YES YES YES YES YES YES # 
gga-miR-206 NO NO YES YES # YES YES YES 
gga-miR-223 YES NO YES YES NO YES YES 
gga-miR-499-5p YES  NO NO YES # NO YES YES 
 
Table 3.7: MiRanda analysis. (a) Example of raw miRanda data (miR-128 against Eya4 
3’UTR). Score: alignment score based on complementarity between the sequences. The 
alignment score threshold used was 125. Only alignments with score greater or equal to 
this value have been considered for further analysis. Position of the interaction, 
conservation between sequences (identity and similarity percentages), and free energy 
score (the smaller, the better) were also indicated. (b) Table summarising the results 
generated from the miRanda analysis. Each miRNA was used to scan the 3’UTR 
sequences of chicken Eya1 [ENSGALT00000025181.4], Eya2 [ENSGALT00000007180.4], 
Eya3 [ENSGALT00000001127.4], Eya4 [ENSGALT00000022662.4], Six1 
[NM_001044685.1], predicted Six4 [XM_003641442.2], and Dach1 
[ENSGALT00000027373.3]. #: MRE annotated in human sequence (TargetScan ‘human’), 
and conserved in chicken (TargetScan ‘chicken’). MiRNAs of particular interest for this 
project are indicated in bold. 
 
 
=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-= 
Performing Scan: gga-mir-128 (21 nt) vs gga-Eya4-3UTR (3962 nt) 
=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-= 
 
Score: 130.000; Query: 2-19; Position: 493-513 
Alignment: Length: 17; Identity: 58.82%; Similarity: 70.59% 
 
      gga-mir-128:   3' uuuCUCUGGCCAAGUGACACu 5' 
                           || | :   |:||||||  
   gga-Eya4-3’UTR:   5' gatGAAAATAACTTACTGTGa 3' 
 
Energy: -11.480 kCal/Mol 
a. 
b. 
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The 3’UTR sequences of Gga-Eya1, Gga-Eya2, Gga-Eya3, Gga-Eya4, Gga-Six1, 
Gga-Six4, and Gga-Dach1 were collected from Ensembl and NCBI, and the miRNA 
sequences, from miRBase.  
The miRNAs previously selected for their expression in skeletal muscle (somite), 
and presented in section 3.2.1, were used for this analysis; two other miRNAs were added 
to the initial selection of 23: miR-27b (it has the same seed sequence as miR-128), and 
miR-499 (a cardiac myomiR). The complete list of miRNAs can be found in Appendix II 
Table 1.  
 
The generated data from the algorithm run were then analysed, and the results are 
presented in Table 3.7.  
 These results were then compared to the information already available in 
TargetScan. In TargetScan, human sequences are the best annotated and therefore the 
most detailed; alignment with 3’UTRs of other species are also provided showing the 
position of the MREs in human sequences and the corresponding MRE positions in other 
species, when conserved.  
However, 3’UTR sequences are usually not highly conserved between human and 
chicken: sometimes sequences are different, MRE positions are different, and sometimes 
only a part of the MRE sequence is conserved. Adding to the complexity of miRNA/target 
interaction identification, TargetScan ‘chicken’ does not always use the same sequence 
as the one used for alignment in TargetScan ‘human’. Moreover, in some cases, ‘chicken’ 
MRE identified in TargetScan ‘human’ alignments, cannot be find in TargetScan 
‘chicken’.  
In Table 3.7b, ‘chicken’ MRE predicted by miRanda, annotated in human 
sequence and conserved in chicken (TargetScan ‘human’ and TargetScan ‘chicken’) are 
indicated by #.  
 
Most of the interesting sites predicted by TargetScan were also found by miRanda; 
it was the case, for example, for Gga-Eya4 3’UTR with miR-1/206, miR-27b/128, miR-
133 and miR-499 sites. However, due to differences in their algorithms and in alignment 
score threshold used (threshold set at 125 for this analysis), the miRanda algorithm was 
able to predict additional miRNA sites.  
Specific miRNAs were focused on, such as the myomiRs miR-1a, miR-133a, 
miR-206, and miR-499, but also miR-128 and miR-27b as they have the same seed 
sequence; they are indicated in bold in Table 3.7b. 
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MiR-27b/miR-128 sites were identified in the Eya1 3’UTR sequence; a miR-133 
site was also found, but only predicted by TargetScan.  
No 3’UTR sequence was available in TargetScan chicken for Gga-Eya2. An 
Ensembl sequence was found and used for miRanda analysis, and predicted sites for miR-
1, miR-27b/128, and miR-133a were identified. With no annotation of its 3’UTR 
sequence in TargetScan, Gga-Eya3 was predicted by miRanda analysis to be targeted by 
miR-133a. Gga-Six1, Gga-Six4, and Gga-Dach1 were predicted to be the target of miR-
1a and miR-206; as well as miR-133a and miR-499 for Gga-Six4. Interestingly, while 
Gga-Dach1 was predicted to be a target of miR-27b, it did not seem to be a miR-128 
predicted target even though these two miRNAs have the same seed sequence. 
 These results show that several miRNAs, such as the myomiRs and miR-128, 
might be able to target several members of the PSED network.  
 
 
3.3. Conclusion 
 
 In this chapter, 23 selected miRNAs have been studied. Their expression patterns, 
characterised by performing LNA ISH, have been established at different stages during 
chicken embryonic development. All expressed in skeletal muscle, they displayed similar 
but also specific patterns in the somites, as well as other tissues for some of them. One of 
these miRNAs, miR-128, gave interesting results. At HH11-12, miR-128 was expressed 
in the neural tube and developing somites. At HH15-16 and onwards, its expression in 
the neural tube disappeared; miR-128 was mostly expressed in skeletal muscle tissues, 
such as differentiating somites, myotome, and the limb buds.  
In order to better understand ‘muscle’ miRNA function(s), and miR-128 
function(s) in particular, predicted miR-128 targets were collected from TargetScan 
(507). By using a combination of different computational tools (DAVID and g:Profiler), 
‘muscle’ targets were identified (n=10); amongst them, Eya4, member of the PSED 
network, was of particular interest. 
Eya4, as well as members of the PSED network (Six1/4, Eya1/2/3, and Dach1), 
were investigated further, due to the interesting role(s) they seem to play with Pax3/7 
during skeletal myogenesis. The miRanda algorithm was used to scan selected miRNA 
sequences against their 3’UTR sequences; and locations of predicted miRNA sites were 
determined.  
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This analysis showed that most of the members of the PSED network could 
potentially be targeted by miRNAs; most importantly, miR-128 and myomiR sites were 
found in the 3’UTR sequences of most of these PSED members. 
 
Although computational approaches help narrow down the number of targets for 
a miRNA, they are only predictions. Interactions between miRNAs and mRNA targets 
still need to be validated by performing in vitro and in vivo experiments.  
  
 In chapter 4, some of the miRNA/mRNA target interactions identified in chapter 
3 are going to be investigated further. By using molecular cloning strategies, constructs 
will be generated in order to (1) determine expression patterns of relevant targets, and (2) 
validate miRNA/mRNA interactions by performing in vitro experiments.  
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CHAPTER 4: CHARACTERISATION OF MicroRNA TARGETS 
AND in vitro INTERACTION INVESTIGATION 
 
 
4.1. Introduction: 
  
In chapter 3, relevant microRNA (miRNA) targets have been identified by using 
bioinformatics tools. Although prediction algorithms have become more precise and 
efficient at identifying miRNA targets, it is essential to experimentally validate these 
miRNA/mRNA target interactions.  
 
In this chapter, two important aspects are going to be developed: characterisation 
of miRNA targets, and investigation of miRNA/mRNA target interactions using an in 
vitro model. 
 
MiRNAs like the myomiRs (miR-1a, miR-206, and miR-133a) and miR-128 were 
predicted to target members of the PAX-SIX-EYA-DACH (PSED) network, which has 
been shown to play key regulatory roles in skeletal muscle development (Relaix & 
Buckingham 1999). 
 
Pax3 and Pax7 have been shown to be directly targeted by miR-1 and miR-206 
leading to delayed myogenic differentiation in developing somites, indicated by a 
transient loss of MyoG (Myogenin) expression (Hirai et al. 2010; Goljanek-Whysall et 
al. 2011). In addition, miR-1 and miR-206 also play a role in facilitating the 
differentiation of satellite cells, adult muscle stem cells, through regulation of the 
transcription factor Pax7 (Chen et al. 2010); Goljanek-Whysall et al. showed that a 
sustained expression of miR-1 and/or miR-206 targets resulted in increased proliferation 
and inhibition of myogenesis in mouse myoblast C2C12 cells (Goljanek-Whysall, Pais, 
et al. 2012).  
 
We focused our investigations on Eya4 and the other members of the PSED 
network, Six1/4, Eya1-3, and Dach1/2; together they constitute the Six-Eya-Dach 
cascade. 
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Eya4 and the other PSED members: 
 
 Similar to Pax3/7, the transcription factors Six1/4, Eya1/2/4, and Dach1/2 have 
been shown to synergistically regulate myogenesis and play a key role in the migration 
of myogenic precursors (Heanue et al. 1999). Moreover, Heanue et al. showed that 
ectopic expression of Six1 and Eya in chicken embryo resulted in the activation of Pax3 
and the myogenic regulatory genes, suggesting an upstream function in myogenesis for 
these factors (Heanue et al. 1999).  
 
Six1/4: 
 In vertebrate embryos, Six1 and Six4 are found in neural placodes, dorsal root 
ganglia, limb bud mesenchyme, and in migrating myogenic precursors (Oliver et al. 1995; 
Esteve & Bovolenta 1999; Fougerousse et al. 2002; Grifone et al. 2005). They are also 
co-expressed in the newly formed somites, developing dermomyotome, and the myotome 
(Grifone et al. 2005; Wu et al. 2014).  
In the chicken embryo, at HH4, Six1 is expressed in the non-somitic head 
mesoderm and the pre-placodal ectoderm. At HH8-HH10, Six1 is also found in the 
developing somites, and in differentiating somites, in the dermomyotome. At later stages, 
Six1 is expressed in the dorsomedial and ventrolateral lips of the dermomyotome and the 
myotome (Heanue et al. 1999; Berti et al. 2015). Six4 is expressed at HH4 where it is 
found in the ectoderm surrounding the developing axial midline. At stage HH8-HH12, it 
is expressed in the pre-placodal ectoderm, the newly formed optic vesicle, the otic, 
olfactory and neural placodes, and in the eyes. From HH14, Six4 is found in the trigeminal 
ganglia and developing limb buds, as well as in the notochord. Six4 is also strongly 
expressed in the paraxial mesoderm and the developing somites, first in the dorsal portion, 
then the dermomyotome and become finally limited to the myotome (Esteve & Bovolenta 
1999). 
 
Six4 knock-out mice have no developmental defects (Ozaki et al. 2001), while 
Six1 knock-out mice die at birth and show multiple organ developmental defects, 
including kidney, thymus, ear and rib, craniofacial and muscle deficiencies (Ozaki et al. 
2004; Laclef et al. 2003). However, Six1/Six4 double knock-out mice show an 
aggravation of the phenotype previously reported for the single Six1 knock-out (Grifone 
et al. 2005). Six1/Six4 double knock-out mice are characterised by severe craniofacial, 
rib and muscle defects.  
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In addition, at the limb bud level, in the absence of Six1/4 in the myotome, no 
muscle is detected. Myogenic progenitor cells are lost and the expression of Pax3 in the 
hypaxial dermomyotome is lacking; the expression of the MRFs MyoG and MyoD1 is 
impaired, and Mrf4 expression becomes undetectable (Grifone et al. 2005). These data 
suggest that Six1/4 is an upstream regulatory factor of Pax3 and is essential for the genesis 
of muscle progenitors. Six1 is also expressed at high levels in adult skeletal muscle where 
it participates, in synergy with Eya1, in the establishment of the fast/glycolytic phenotype 
of the myofibre (Grifone et al. 2004; Niro et al. 2010; Richard et al. 2011). More recently, 
in zebrafish, O’Brian et al. found a microRNA-mediated regulatory mechanism for Six1; 
miR-30a regulates myogenesis via direct targeting and inhibition of Six1a/b expression 
(O’Brien et al. 2014). 
 
Dach1/2: 
 In vertebrates, DACH1 and DACH2 are expressed in similar tissues to those 
observed in Drosophila (Davis et al. 1999). DACH1 and DACH2 are detected in multiple 
adult human tissues including kidney and heart. In mouse, Dach1 is expressed in the 
developing kidneys, eyes, and ear; it is also found in the somites, the anterior and 
proximal mesenchyme and the apical ectodermal ridge (AER) of the limb buds, as well 
as in gut and heart (Ayres et al. 2001; Heanue et al. 2002). Mouse Dach2 displays a similar 
pattern to those of Dach1 suggesting potential redundant roles for these genes during 
development (Davis, Shen, Sandler, Heanue, et al. 2001).  
In chicken, Dach1 is found expressed in the developing eye and ear, and in the 
neural tube (Heanue et al. 2002; Kida et al. 2004; Litsiou et al. 2005); in the limb buds, 
Dach1 is expressed in migrating myoblast precursors. Dach1 is not expressed in the early 
stages of limb development (Heanue et al. 1999); its expression starts to be detected at 
HH20 in the AER, suggesting a role in the maintenance of the AER rather than in its 
initiation (Kida et al. 2004). In early epithelial somites, Dach2 is expressed dorsally as 
well as in the dorsal neural tube and in the intermediate mesoderm. In the differentiating 
somites, Dach2 is detected throughout the dermomyotome; it is also found in the 
nephrogenic ducts. At the limb level, Dach2 is also found in the migrating hypaxial 
myoblast precursors (Heanue et al. 1999). 
 
 Dach2 mutant mice are viable and fertile, and they do not exhibit gross defects in 
eye development or brain function, and although Dach1 mutant die postnatally, these 
mutants seem to have a normal development (Davis et al. 2006).  
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The lack of significant phenotype in Dach1 mutants may be due to functional 
redundancy with Dach2 as their expression profiles overlap in many tissues. Interestingly, 
Dach1/Dach2 double mutant mice die after birth with a similar phenotype to Dach1 
homozygotes. Unlike Drosophila dachshund mutants that lack eyes and exhibit leg 
truncations, the eyes and limbs of Dach double mutant mice are present, suggesting 
potential differences between Dach and dachshund gene function during embryonic eye 
and limb formation (Davis et al. 2006).  
 
Eya1/2/3: 
Widely expressed during development, in mouse, Eya1 and Eya2 are co-expressed 
in the dermomyotome, and later in the myotome; they are also found in developing limbs, 
migrating muscle precursors and tendons (Xu, Cheng, et al. 1997). Similar expression 
patterns have been reported in Xenopus, and zebrafish; however, in  chicken, Eya1 and 
Eya2 display differential expression profiles (Ishihara et al. 2008).  
In chicken, Eya1 and Eya2 are expressed early during development. Eya1 is found 
in the primitive streak at HH4, and appears in the ectoderm, the mesenchyme and the 
somites at HH6-HH11; at HH11, Eya1 is expressed in the dermomyotome. At HH17 and 
HH19-20, in the trunk region, Eya1 is detected in the dorsomedial and ventrolateral lips 
of the dermomyotome and in the myotome (Berti et al. 2015). In contrast, Eya2 is already 
expressed in the endoderm at HH4, and is found in the endoderm and cranial placodes at 
HH6-HH11, earlier than Eya1 (Ishihara et al. 2008). At HH11, Eya2 is weakly expressed 
in the somites. At HH15, Eya2 is only expressed in a restricted region of the olfactory 
placode; at the trunk level, Eya2 is expressed in the myotome, and throughout the entire 
newly formed somites. At HH17, Eya2 is restricted to the myotome in the somites at the 
anterior region of the trunk, whereas the whole somite region is positive for Eya2 in the 
posterior region (Heanue et al. 1999). At later stage, Eya2 is also found in the limb buds 
and the eyes (Mishima & Tomarev 1998). Eya1 and Eya2 are expressed in distinct 
locations of the chicken embryo with little overlap, suggesting distinct and unique 
functions in chicken early development. 
 
 In human, EYA1 gene mutations have been associated with the dominant inherited 
branchio-oto-renal (BOR) syndrome, which alter the formation of branchial derivatives, 
ear and kidney (Vincent et al. 1997; Abdelhak, Kalatzis et al. 1997a; Abdelhak, Kalatzis 
et al. 1997b). Eya1-deficient mice show similar phenotypes with ear, kidney and branchial 
organ defects (Xu et al. 1999), and delayed myogenesis (Grifone et al. 2007).  
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Eya1 mutants of zebrafish also display defective development of the inner ear and 
lateral line (Kozlowski et al. 2005). 
 
In mouse and zebrafish, Eya3 showed an abundant and widespread expression 
throughout development in brain, eyes, heart, somites and limbs. This is in contrast to the 
restricted expression pattern observed in Xenopus embryos (Söker et al. 2008).  
 
Eya3-deficient mice showed minor phenotypes with weak effects on respiratory, 
heart and muscle function, with a decrease in locomotion activity. In vitro experiments 
showed that Eya3 was important for cell-autonomous proliferation of murine C2C12 cells 
(Li et al. 2003). There is no information for Eya3 in chicken. 
 
Eya4: 
 By northern blot performed on various mouse adult tissues, Eya4 was found 
expressed in skeletal muscle; data consistent with the fact that a large number of EYA4 
cDNAs were isolated from human skeletal muscle cDNA library, suggesting a potential 
similar expression pattern in human (Borsani et al. 1999). In the developing mouse 
embryo, Eya4 is expressed in the craniofacial mesenchyme, the dermomyotome and at 
later stages in the limbs. Expressed in the nasal placode and the otic vesicle at E9.5; from 
E10.5, Eya4 is found in the branchial arches and the somites. At E11.5, Eya4 is strongly 
expressed in the region of the somites, in the dermomyotome, and in cells migrating away 
from the dermomyotome to populate the limbs. Like Eya1-3, Eya4 is widely expressed 
during development; however, there is no evidence for expression of Eya4 in the 
developing eye, contrary to what was observed for Eya1, Eya2, and Eya3 (Borsani et al. 
1999; Xu, Woo, et al. 1997). In human and zebrafish, EYA4 has also been shown to be 
involved in cardiac processes (Schönberger et al. 2005). 
 
 Mutations of the EYA4 gene resulting in truncated EYA4 proteins have been 
associated with the human autosomal non-syndromic sensorineural hearing loss (SNHL), 
which may be associated with dilated cardiomyopathy (DCM) (Wayne et al. 2001; Y. 
Zhang et al. 2004; Schönberger et al. 2005; Hildebrand et al. 2007; Makishima et al. 
2007). Depreux et al. produced Eya4-deficient mice and showed that these mice have 
severe hearing deficits, similar to those observed in human (Depreux et al. 2008).  
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Injection of morpholino oligonucleotides against eya4 into zebrafish embryos 
indicated an abnormal morphological and physiological phenotype of the heart 
(Schönberger et al. 2005; L. Wang et al. 2008). Surprisingly, no Eya4 transcripts were 
detected in mouse embryonic and adult heart and no heart defects have been reported in 
the Eya4-/- knock-out mice (Borsani et al. 1999; Depreux et al. 2008). These different 
phenotypes could suggest that Eya4 functions may not have been conserved during 
evolution.  
 
One conserved feature of EYA4 is its expression in skeletal muscle tissue, 
although no muscle alteration has been yet associated to EYA4 mutations (Borsani et al. 
1999; Schönberger et al. 2005). Because the other three EYA genes are also expressed in 
this tissue (Xu, Woo, et al. 1997; Heanue et al. 1999; Söker et al. 2008; Berti et al. 2015), 
the absence of muscle phenotype may be due to functional redundancies. This is 
consistent with the results observed in Eya1/Eya2 double mutant mice; Eya1/Eya2-
deficient mice have no diaphragm and present severe limb muscle hypoplasia (Grifone et 
al. 2007). There is no information for Eya4 in the chicken. 
 
 In vertebrates, SIX1/4, EYA1-4, and DACH1/2 are, like PAX3/7, all expressed in 
cells prior to skeletal muscle differentiation, and their overlapping expression continues 
in skeletal muscle derivatives where the cells are maintained in an undifferentiated state. 
Acting together upstream of the myogenic regulatory factors, they regulate early phases 
of skeletal myogenesis. 
 
 The regulatory PSED network plays a very important role in the regulation of 
myogenesis. However, in the chicken, not all the members of this network have been 
characterised and their function(s) investigated. Moreover, little is known about the 
potential miRNA regulation of the PSED network. 
  Found in human, mouse, and zebrafish, Eya4 has not been characterised in the 
chicken. By using molecular cloning strategies, fragments of the coding sequence and the 
3’ untranslated region (UTR) of chicken Eya4 (Gga-Eya4) were cloned. They were used 
to (1) determine its expression pattern and (2) perform luciferase reporter assays in order 
to investigate the ability of miR-128, in particular, but also other miRNAs like miR-1a, 
miR-206, miR-133a, and miR-499, previously identified in chapter 3, to target Gga-Eya4 
and regulate its expression in vitro. Results will be presented in the first part of this 
chapter. 
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 The same approach was used to identify miRNA/target interactions for the other 
PSED members, Gga-Six1/4, Gga-Eya1-3, and Gga-Dach1/2. Although most of these 
genes have been studied and their expression patterns determined in several species, such 
as mouse, chicken and zebrafish, RNA probes were generated and whole-mount in situ 
hybridisation (WMISH) performed in order to confirm, complete or determine their 
specific expression profiles. Results will be presented in a second part.  
 
 
4.2. Results and discussion 
 
4.2.1. Validation of Eya4 as a target for miR-128 
  
In order to study the interaction between miR-128 and Eya4, the first step was to 
clone Gga-Eya4. At the time this cloning was done, the chicken genome sequence was 
not completely annotated; Eya4 sequence was pulled out from the chicken Genebuild 
provided by Ensembl. This sequence, generated using the most reliable data available in 
the databases, contains the coding sequence, and the 5’ and 3’UTR sequences; Gga-Eya4 
sequence is now referenced on Ensembl as ENSGALT00000022662.4. The strategy used 
for the cloning of Gga-Eya4, coding sequence and 3’UTR fragments, is summarised in 
Fig. 4.1.  
 
a. Cloning of a fragment of the coding sequence of Gga-Eya4 
 
 In order to characterise the expression profile of Gga-Eya4, it was first necessary 
to clone all or part of its coding sequence.  
 
 The sequences of human, mouse and Xenopus for EYA4 were collected from 
Ensembl and NCBI, and by performing sequence alignment, conserved portions between 
the different sequences were identified. A conserved portion in the EYA domain was used 
to scan against the chicken Genebuild (Ensembl) allowing extracting a sequence, being 
potentially Gga-Eya4.  
 
A protein sequence alignment with the predicted Gga-Eya4, and those of human, 
mouse, and Xenopus, as well as an alignment with the three other members of the chicken 
Eya family, were performed. 
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Fig. 4.1: Cloning of Gga-Eya4. (Top panel) Schematic of Gga-Eya4 transcript (6000 
base pairs (bp)) representing the coding (box) and 3’UTR (dotted line) sequences. Red 
and green arrows indicate the position of the pairs of primers used to clone the fragments 
of coding and 3’UTR sequences, respectively. The fragment of the coding region (~950 
nucleotides (nt)) was used to perform whole-mount in situ hybridisation (WMISH). The 
fragment of the 3’UTR region (~1000 bp) was used to do luciferase reporter assays. The 
positions of miR-27b/128, miR-1a/206, miR-133a, and miR-499 sites are indicated on the 
3’UTR sequence. (Bottom panel) Structure of Gga-Eya4 protein (~2000 bp) with 
variable domain and, at the C-terminal end, the conserved EYA domain.  
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The percentage of identity and similarity between protein sequences was 
determined using The European Molecular Biology Open Software Suite (EMBOSS) 
Needle software (http://www.ebi.ac.uk/Tools/psa/emboss_needle/) (Hancock et al. 2004; 
Li et al. 2015); results are presented in Table 4.1. 
It appeared that the predicted Gga-Eya4 protein shares a lower percentage of 
identity with its homologous Gga-Eya1, Gga-Eya2, and Gga-Eya3 (Table 4.1a), than with 
its human, mouse, and Xenopus orthologous (Hsa-EYA4, Mmu-Eya4, Xla-eya4) (Table 
4.1b). With 72.1% identity, the predicted Gga-Eya4 is closer to Gga-Eya1, than to Gga-
Eya2 and Gga-Eya3, which have 52.7% and 48.8% identity, respectively (Table 4.1a). 
The predicted Gga-Eya4 shows more than 85.8% identity with Xla-eya4, 91.3% with 
Mmu-Eya4, and up to 94.7% with Hsa-EYA4 (Table 4.1b).  
 
EYA4 proteins have been highly conserved across species during evolution. This 
is particularly true in the EYA domain localised in the C-terminal region; this domain 
being common to all the EYA family members. Based on nucleotide alignment (not 
shown), a pair of primers was designed according to the following criteria: ~ 20 base pairs 
(bp) with about 50% of GC, generating a product of approximately 800-1000 bp in length, 
and localised in highly conserved sequence, but outside the EYA domain. These criteria 
have been defined in order to maximise the chances to specifically amplify Gga-Eya4 
(Fig. 4.1). 
 
 Total RNAs, from whole chicken embryos (day 2, day 3, and day 4), dissected 
somites (day 3 and day 4), as well as dissected forelimbs and hindlimbs from day 7 
embryos, were in vitro transcribed (see chapters 2.8 and 2.9; Appendix III). Generated 
cDNAs, with the specifically designed Gga-Eya4 pair of primers, were then used in a 
polymerase chain reaction (PCR) (see chapter 2.10); PCR products of about 950 bp were 
amplified from all the tissue samples tested. The product from the ‘forelimbs day 7’ 
cDNA sample was used to do the rest of the experiments as it was the one with the 
strongest expression (data not shown). 
 
 After excision from gel and purification (see chapters 2.11 and 2.13), the PCR 
product was ligated into pGEMT-Easy vector (Promega), a linearised vector with single 
3’ terminal thymidine at both ends providing a high efficiency of insertion (see chapter 
2.14). DH5α competent cells were transformed with the construct (see chapter 2.16). 
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Table 4.1: Percentage identity and similarity between EYA protein sequences. (a) 
Percentage identity (ID) and similarity (SIM) between predicted Gga-Eya4 
[ENSGALT00000022662.4] and the three other chicken Eya members, predicted Gga-
Eya1 [XP_418290.3], Gga-Eya2 [NP_990246.1], and predicted Gga-Eya3 
[XP_417715.2]. (b) Percentage ID and SIM between predicted Gga-Eya4 and human 
(Hsa) [NP_004091.3], mouse (Mmu) [NP_034297.2], and Xenopus tropicalis (Xtr) 
[ENSXETT00000000214.3] EYA4 protein sequences. Percentage identity (ID) and 
similarity (SIM) were determined using EMBOSS Needle software 
(http://www.ebi.ac.uk/Tools/psa/emboss_needle/)  (Hancock et al. 2004; Li et al. 2015). 
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After selection of 2 clones (or recombinants) by blue/white screening (white colonies 
contain an insert),  they were purified, and a restriction digestion using EcoRI enzyme 
allowed to verify the presence of an insert of about 900-1000 bp in length into the vector 
(see chapter 2.12). The two plasmid DNAs cloned were validated by sequencing (Source 
BioScience, Cambridge UK).  
 
The two identical sequences, which were not 947 bp long as expected, but 873 bp 
long, were identified by Basic Local Alignment Search Tool (BLAST) as EYA4 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The cloned Gga-Eya4 sequence (Cloned_seq) 
was aligned with the Eya4 sequence pulled out from the chicken Genebuild 
(Gga_Eya4_GB) showing a gap in its sequence (Fig. 4.2). A comparison with the human, 
mouse and Xenopus EYA4 sequences indicated that this gap corresponds to exon 5.  
 
 Interestingly, information found in the databases revealed the existence of 
different EYA4 transcripts with differences in exon 5. Alternative transcripts have been 
identified in human and mouse, displaying sequences with or without exon 5; other 
isoforms of EYA4 with truncated exon 6, 8 or 16, as well as substitution between exon 
19 and 20, were also reported. For example, exon 5 is always absent in mouse transcript 
sequences (Borsani et al. 1999; Y. Zhang et al. 2004).  
The Gga-Eya4 cloned from skeletal muscle-enriched sample corresponds to the 
isoform a, where exon 5 is absent; this is consistent with the fact that this isoform was 
also found in a large number of cDNA clones identified from a human skeletal muscle 
cDNA library.  
 
The functional relevance for these alternative transcripts is not yet known, but 
their conservation across species and the fact that they appear to be tissue-specific, might 
indicate potential interesting roles that still remain to be discovered. 
 
b. Characterisation of Gga-Eya4 
 
 Sense and antisense RNA probes for Gga-Eya4 were synthesised by PCR using 
the plasmid containing the fragment of 947 bp, previously cloned, as a template (see 
chapter 2.7; Appendix III List 1). 
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Fig. 4.2: Multiple protein sequence alignment of EYA4. Alignment of the cloned Gga-
Eya4 sequence (Cloned_seq) with the chicken Genebuild (Gga-Eya4_GB), human (Hsa-
EYA4), mouse (Mmu-Eya4) and Xenopus (Xtr-eya4) sequences. Residues conserved in 
all sequences are indicated by dark background. Residues conserved in 4 or 3 orthologous 
are indicated in dark or light grey, respectively. The cloned Gga-Eya4 sequence is shorter 
than the others; the missing part of the sequence (indicated by a red frame) corresponds 
to the exon 5. For accession numbers see Fig. 4.1. 
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  The plasmid was first linearised by PCR with M13 forward and reverse primers, 
then sense and antisense RNA probes were synthesised and Digoxigenin (DIG)-labelled 
by in vitro transcription with SP6 and T7 RNA polymerases, respectively. Sense probe 
was used as a negative control (Appendix III Table 1).  
 
Eya4 WMISH was performed on chicken embryos fixed at different stages of 
development, from HH10 to HH23; expression pattern in whole-mount and on transverse 
sections at HH11-12, HH16, and HH21-22 are presented in Fig. 4.3a. Embryos treated 
with the sense RNA probe display no specific expression pattern; the trapping in the head 
being non-specific (data not shown). Expression pattern of miR-128, predicted to target 
Gga-Eya4, is also presented for comparison (Fig. 4.3b). 
At HH11-12, Gga-Eya4 was mainly expressed in the head region in some cranial 
placodes, such as the nasal and otic vesicles (Fig. 4.3i). Eya4 was also expressed in a pool 
of cells, close to the heart region; non-identified, they seem to be migrating in an anterior-
to-posterior fashion. No expression was detected in the somites. As the embryo 
developed, Gga-Eya4 was detected in the branchial arches and in the somites.  
At HH16, Gga-Eya4 was expressed in the myotome; expression becoming even 
stronger at HH21-22.  
At HH21-22, Gga-Eya4 was strongly expressed in the ventromedial lip of the 
dermomyotome and in the myotome; it was also found in the dorsal root ganglia, and in 
a restricted posterior region of the developing limbs. This expression was stronger in the 
hindlimbs (arrowhead), probably due to the fact that the hindlimbs start to develop before 
the forelimbs.  
 
 The expression of Gga-Eya4 in the otic vesicle, branchial arches and in the somites 
are consistent with the profile previously found in mouse. However, although Eya4 was 
not observed in the developing eye in mouse, Gga-Eya4 is expressed in this tissue and at 
all stages studied; this is similar to what was described for Gga-Eya1, Gga-Eya2 and Gga-
Eya3 (Borsani et al. 1999; Xu, Woo, et al. 1997).  
In addition, while Eya4 in mouse was found in the dermomyotome, in chicken, it 
is weakly present in the dorsomedial lip of the dermomyotome, and strongly expressed in 
the myotome. The expression in the otic vesicle is in line with the mouse pattern, and the 
hearing deficit associated to the mutation of EYA4 in human (Wayne et al. 2001; Zhang 
et al. 2004; Hildebrand et al. 2007; Makishima et al. 2007).  
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Fig. 4.3: Expression profile of Gga-Eya4 (a), and comparison with miR-128 pattern 
(b). (a) WMISH performed with antisense DIG-labelled RNA probe, and transverse 
sections at HH11-12 (i, i’), HH16 (ii-ii’’), and HH21-22 (iii-iii’’). At HH11-12, Gga-
Eya4 is expressed in the eye (e), the otic vesicle (vOt), and in a pool of non-identified 
migrating cells close to the heart region (i; star). At HH16, Gga-Eya4 is expressed in the 
eye, the branchial arches (ii; arrow) and in the somites (s), in the myotome (ii’’; My). At 
HH21-22, Gga-Eya4 is still expressed in the branchial arches (iii; arrow), and is strongly 
expressed in the myotome (iii’’). Gga-Eya4 is also found in the dorsal part of the limb 
buds (iii; arrowhead). Embryos treated with the sense probe (negative control) did not 
show any expression (data not shown). (b) MiR-128 expression pattern determined by 
LNA ISH in whole-mount and transverse sections at HH11-12 (iv, iv’), HH16 (v-v’’), 
and HH21-22 (vi-vi’’). At HH11-12, miR-128 is expressed in the neural tube (NT) and 
the developing somites (iv’). At HH16 and HH21-22, mir-128 is in the branchial arches, 
in the myotome, and the developing limbs (v-vi’’). At HH21-22, miR-128 is also 
expressed around the eye, and in the limbs (vi; white asterisk). Red dotted lines indicate 
the location of the transverse sections. Transverse sections: 20x magnification. e: eye; 
My: myotome; NC: notochord; NT: neural tube; S: somite; vOt: otic vesicle. 
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However, Eya4 was not observed in the heart at any stages studied during chicken 
development, differing from the mouse and human phenotypes (Schönberger et al. 2005). 
  
 Because Eya4 was predicted to be targeted by miR-128, their expression patterns 
were compared. While Eya4 was only starting to be expressed at HH11-12, mainly in the 
head region (i, i’), miR-128 was already strongly expressed in the neural tube, notochord, 
and the somites (iv’). At HH16 and HH21-22, they were also both expressed in the 
branchial arches, and in the somites, in the myotome (ii-iii’’; v-vi’’). At HH21-22, they 
were both found in the developing limbs, with miR-128 being expressed in the entire limb 
buds, and Eya4 restricted to the dorsal part of the limb buds (iii, vi).  
 
 MiRNAs are fundamental regulators that can silence gene expression at post-
transcriptional level. Multiple modes of miRNA-mediated regulation have been described 
and include translational inhibition, increased mRNA de-adenylation and degradation, 
and/or mRNA sequestration (Nilsen 2007; Selbach et al. 2008); this is dependent on the 
target and its function, the stage of development, and the tissue considered.  
Gga-Eya4 and miR-128 display very similar profiles, especially in the somites 
from HH16. Therefore, because Gga-Eya4 and miR-128 expression patterns are not 
exclusive, miR-128 is more likely to be a regulator/modulator of Eya4 expression rather 
than an absolute repressor, if a direct interaction could be confirmed (see section 4.2.1e).  
  
c. Cloning of a fragment of the 3’ untranslated region (UTR) of Gga-Eya4 
  
 In order to identify a potential interaction between miR-128 and Gga-Eya4 by 
luciferase reporter assays, it was necessary to clone the 3’UTR of Gga-Eya4 (Fig. 4.1; 
Appendix III List 2). Gga-Eya4 3’UTR was used to generate reporter constructs, wild-
type (WT) and mutants, and perform luciferase reporter assays (see chapter 2.19). 
 
Localised in the 5’ part of the 3’UTR sequence, a potential miR-128 site was 
predicted using different bioinformatics tools and algorithms (TargetScan, MiRanda); 
analysis was presented in chapter 3. Using a similar strategy, other miRNAs have also 
been predicted to target Gga-Eya4 3’UTR, including the myomiRs miR-1a, miR-206 and 
miR-133a, the cardiac miRNA miR-499, or miR-27b which has the same seed sequence 
as miR-128 and is predicted to target the same site. All these sites are located within the 
first 1,000 bp of Gga-Eya4 3’UTR sequence. 
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The 3’UTR of Gga-Eya4 is extremely long, 6,000 bp in length; too long to be 
cloned and used for the luciferase reporter assays. Taking into account that predicted 
miRNA sites located at the 5’ and 3’ extremities of a 3’UTR sequence are more likely to 
be functional (Long et al. 2007; Ekimler & Sahin 2014), a pair of primers was designed 
in order to clone a fragment of about 1,000 bp, in the 5’ part of Gga-Eya4 3’UTR, 
containing miR-27b/128, miR-1a/206, miR-133a, and miR-499 sites (Fig. 4.1). BglII and 
NheI restriction sequences were added to the forward and reverse primers, respectively.  
 
 Following the same strategy previously described for the cloning of a fragment of 
Gga-Eya4 coding sequence, a fragment of Gga-Eya4 3’UTR was amplified by PCR. The 
PCR product was cloned into pGEMT-Easy vector; the construct was purified, quantified, 
and verified by sequencing. Then, Gga-Eya4 3’UTR fragment was excised from pGEMT-
Easy vector by restriction digestion using BglII and NheI enzyme, and sub-cloned into 
linearised pGL3-Luciferase modified vector, which had also been previously BglII/NheI 
digested (see chapter 2.14) (Tuddenham et al. 2006). Gga-Eya4 3’UTR was inserted 
downstream of the Luciferase gene.  
With this disposition, the pGL3(Gga-Eya4 3’UTR) construct is a good tool to 
study how a gene – in this case the Luciferase gene – can be regulated by action on its 
3’UTR (Gga-Eya4 3’UTR), and how miRNAs – miR-27/128, miR-1a/206, miR-133a 
or/and miR-499 – which potentially interact with the Gga-Eya4 3’UTR can modulate its 
expression. This construct was then used to perform luciferase reporter assays. 
 
d. Mutagenesis: Gga-Eya4 3’UTR mutants 
 
In addition to pGL3(Gga-Eya4 3’UTR) construct, four mutant constructs were 
generated: 27b/128mut, 1a/206mut, 133amut, and 499mut. MiR-27b and miR-128, and 
miR-1a and miR-206, respectively, have the same seed sequence and are predicted to 
recognise the same target site. Mutagenesis was performed based on the FastCloning 
strategy (Li et al. 2011).  
Developed by Li et al., this PCR-based cloning technique can be used to insert 
any DNA fragment into a plasmid vector or into a gene in a vector at any desired position. 
Purification-free, sequence- and ligation-independent, the FastCloning technique is 
simple, fast, economic and as efficient as commercial assembly kits, like the Gibson 
assembly one (Gibson et al. 2009; Gibson 2011). Mutagenesis strategy is summarised in 
Fig. 4.4 (also see chapter 2.19). 
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Fig. 4.4: Mutagenesis strategy. (a) Schematic of pGL3(Gga-Eya4 3’UTR-128mut) 
construct. The position of the miR-128 site is indicated, as well as the position of the 
overlapping primers used to introduce to mutation. (b) MiR-128 site in the Gga-Eya4 
3’UTR sequence. The overlapping primers (forward and reverse) containing the mutation 
(restriction enzyme site; in this case: NcoI) are indicated in purple. Red stars represent 
what is left of the target site after insertion of the mutation. (c) Alignments of Gga-Eya4 
3’UTR sequence at the different miRNA sites with the seed sequence of their respective 
miRNA; mutated nucleotides are indicated in red. Vertical lines and stars indicate 
complementarity and identity between sequences, respectively. (d) Protocol used to 
generate mutant based on the FastCloning technique (Li et al. 2011). 
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The pGL3(Gga-Eya4 3’UTR) construct was used as a template (Fig. 4.4a). 
Overlapping primers were designed to introduce a mutation in place of the target site (Fig. 
4.4b); 1-3 nucleotides were replaced in order to create a restriction enzyme site preventing 
the miRNA from binding its target (Fig. 4.4c). The restriction sites to introduce were 
determined based on three main criteria: destruction of the target site with a minimum of 
nucleotides to change; no site for this enzyme in the 3’UTR fragment sequence, and a 
maximum of one site for this enzyme in the pGL3-Luciferase modified vector.   
 
For each mutant construct, two PCR products were amplified using Phusion High-
Fidelity polymerase (NEB) and a combination of primers (specific primers introducing 
the mutation (forward and reverse) + primers designed in the Ampicillin resistance 
(AmpR) gene (forward and reverse)). The PCR products were then mixed together (1:1 
ratio), and DpnI digested to destroy methylated templates. After transformation into 
DH5α competent cells, which are able to recombine the two fragments together, several 
colonies were tested. The presence of the mutation (introduction of a restriction site) in 
the recombined constructs was controlled by restriction digestions; samples were 
validated by sequencing. These mutant constructs were then used to perform ‘rescue 
experiments’ in luciferase reporter assays.  
 
e. Luciferase reporter assays: miRNA/target interaction in vitro 
 
To identify potential interaction between Gga-Eya4 3’UTR and the six miRNAs, 
miR-128, miR-27b, miR-1a, miR-206, miR-133a and miR-499, luciferase reporter assays 
were performed (Promega; see chapter 2.19). This bioluminescence assay is a quantitative 
method based on sequential measurement of Firefly and Renilla luciferases activities in a 
single sample. 
 
WT or mutant constructs (100 ng) were co-transfected, into chicken DF1 
fibroblast cells, with Renilla vector (25 ng; used as an internal control of the transfection) 
and either without or with one of the following siRNAs (50 nM; Sigma): si-128; si-27b; 
si-1a; si-206; si-133a; si-499; siRNAs are used in these assays to mimic miRNA action. 
A universal negative control siRNA (siC; Sigma) was used as negative control; it also 
allowed to check the impact of adding siRNA on the transfection efficiency. Results are 
presented in Fig. 4.5 and Table 1.  
 
122 
 
 
 
 
 
 
 
 
 
Fig. 4.5: Luciferase reporter assays – miRNA/Gga-Eya4 3’UTR interaction. 
Luciferase activity for Gga-Eya4 3’UTR constructs, wild-type (WT) and mutants, co-
transfected with control siRNA (siC) or one of these siRNAs: si-128 (a); si-27b (b); si-
206 (c); si-1a (d); si-133a (e); si-499 (f). Normalised luciferase activity was plotted 
relative to the condition [WT or mutants construct + siC] (in blue in the graphics). 
Experiments were repeated 4 times independently with triplicate samples in each; 5 times 
for experiments with si-128, si-1a, and si-206. Error bars represent the standard error of 
the mean (SEM) (n=12 or 15). T-test: p<0.05: , p<0.001: . 
 
 
 
 
 
 
123 
 
Experiments were repeated 4 times with triplicate samples; 5 times for 
experiments with miR-128, miR-1a, and miR-206. The normalised luciferase activity 
(Firefly/Renilla) was plotted relative to the condition [WT or mutants construct + siC]. 
 
i) MiR-128 targets Gga-Eya4 3’UTR 
 
 Luciferase reporter assays showed that miR-128 targets the Gga-Eya4 3’UTR, 
leading to a relative decrease in luciferase activity of 32% (68% activity; t-test: p<0.001). 
This was rescued significantly by mutating the miR-128 site; the luciferase activity going 
back to 93% of control (Fig. 4.5a).  
Interestingly, with the same seed sequence and predicted target site as miR-128, 
miR-27b did not seem to be able to interact with Gga-Eya4 3’UTR (Fig. 4.5b). This 
indicates that miR/target interactions are not based only on a match between the seed 
nucleotides and target sequences, additional elements needs to be taken into account, such 
as partial complementarity of the rest of the miRNA sequence with the target sequence. 
 
 Furthermore, miR-206 could target Gga-Eya4 3’UTR. A decrease of 24% in 
luciferase activity was observed (76% activity; t-test: p<0.05); this was rescued 
significantly by mutating the miR-206 site (92.5% activity) (Fig. 4.5c). 
 
 Similar to what was observed for miR-27b and miR-128, miR-1a and miR-206, 
which have the same seed sequence and target the same site, showed different profiles; 
miR-1a did not seem to interact with Gga-Eya4 3’UTR (Fig. 4.5d).  
 
 No effect on luciferase activity was observed in the experiments performed with 
si-133 and si-499; thus Gga-Eya4 could not be validated as a target of miR-133 and miR-
499 (Fig. 4.5e, f).   
 
ii) Potential synergism between miRNAs in the regulation of Gga-
Eya4 expression 
 
Due to their short sequences, miRNAs can interact and regulate several hundred 
targets. On the other hand, multiple miRNAs can simultaneously regulate the expression 
of a specific gene by targeting different sites on the 3’UTR of its mRNA (Selbach et al. 
2008; Bartel 2009).  
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Fig. 4.6: Luciferase reporter assays – miRNA combinations and interaction with 
Gga-Eya4 3’UTR. Luciferase activity for Gga-Eya4 3’UTR constructs, WT and mutants, 
co-transfected with control siRNA (siC), si-128 alone or in combination with either siC, 
si-27b, si-1a or si-206. Normalised luciferase activity was plotted relative to the condition 
[WT or mutants construct + siC] (in blue in the graphs). Experiments were repeated two-
three times with triplicate samples. Error bars represent the standard error of the mean 
(SEM) (n=6 or 9). 
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However, the concept of synergism between miRNAs has not been really 
investigated.  
 In order to test if Gga-Eya4 could be regulated by a combination of miRNAs, a 
pilot experiment was performed.  
 
Previous experiments showed that miR-128, and miR-206, were able to interact 
with Gga-Eya4 3’UTR, resulting in a decrease in luciferase activity. Combinations of two 
siRNAs were prepared (1:1) such that the same final concentration of total siRNA was 
used in the transfection; therefore each siRNA was half-concentrated compared to the 
previous experiments.  
WT and mutant construct mut27b/128 were co-transfected with Renilla, and a 
combination of si-128 with either siC, si-27b, si-1a, or si-206. Only 2-3 experiments were 
performed, each of them with triplicate samples. The normalised luciferase activities 
(Firefly/Renilla) were plotted relative to the condition [WT or mutants construct + siC]. 
Results are presented in Fig. 4.6. 
 
First, luciferase reporter assays combining si-128 and siC were performed in order 
to determine the luciferase activity with half the amount of si-128; siC being added to 
maintain the final siRNA molarity of 50 nM. Transfections with only si-128 were also 
performed in parallel.  
In the condition [WT + si-128], the luciferase activity was decreased by 38.5% 
(Fig. 4.6a); decrease similar to the one observed in the previous set of experiments (32%; 
Fig. 4.5a). However, contrary to the previous experiments showing rescue to 94% activity 
when mutating the miR-128 site, the luciferase activity was only partially rescued 
(82.5%). This may be due to the low number of repeats. As expected, the experiment with 
a combination of si-128 and siC showed a smaller decrease in luciferase activity of 17.5%, 
which was rescued by mutating the miR-128 site (95%); less si-128 leading to less impact 
on luciferase activity, with a better rescue.  
 
Luciferase reporter assays were then performed with a combination of si-128 and 
si-206, both shown to interact, on their own, with Gga-Eya4 3’UTR. When these two 
siRNAs were transfected together with the WT Gga-Eya4 construct, the luciferase 
activity level was lower than the one observed after transfection with si-128 alone (51% 
in decrease compare to 32% with si-128 alone) (Fig. 4.6d).  
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The luciferase activity was not rescued after mutation of the miR-128 site (only 
11% rescue; luciferase activity decrease: 40%). 
 
 The previous experiments showed that miR-128 and miR-206 alone were able to 
target Gga-Eya4 3’UTR leading to a decrease in luciferase activity by 32% and 24% 
respectively (Fig. 4.5a, c). The synergy experiments showed that when they are used in 
combination, with half the amount for each siRNA, the luciferase activity was decreased 
by 51% (Fig. 4.6d); rescue experiments showed that the luciferase activity was rescued 
by only 11%. 
The weak rescue observed could be explained by the fact that the mutant construct 
used for these experiments was mutated for miR-128 site only; miR-206 site was intact. 
Moreover, if the results for this rescue experiment (Fig. 4.6d) are compared to the one 
observed in the experiment [WT construct + si-206 alone] (Fig. 4.5c), the level of 
luciferase activity is still much lower (51% decrease compared to 24% decrease (si-206 
alone)); this result was observed with half the amount of si-206. This suggests that miR-
128 and miR-206, which can target Gga-Eya4 3’UTR on their own (Fig. 4.5a, c) (38.5% 
and 24% decrease in luciferase activity, respectively (50 nM each)), might also be able to 
work in cooperation, in an additive manner, in order to have a stronger effect on the 
regulation of Gga-Eya4 expression (Fig. 4.6d); their combined effect being similar to the 
sum of their separate effect at the same doses (miR-128+miR-206: 51% decrease in 
luciferase activity (25 nM each)) (Ivanovska & Cleary 2008; Lu & Clark 2012). 
 
From the previous experiments, although miR-128 and miR-27b, and miR-206 
and miR-1a, respectively, were predicted to target Gga-Eya4 (same seed sequence, same 
site), miR-1a and miR-27b, did not seem to be able to interact with Gga-Eya4 3’UTR 
(Fig. 4.5b, d). Luciferase assays were performed with a combination of si-128 and si-27b 
(Fig. 4.6b), or si-1a (Fig. 4.6c). For each combination experiment (si-128/si-27b and si-
128/si-1a), a luciferase activity level similar to the one observed in the condition [WT 
construct + si-128 + siC] (Fig. 4.6a), around 17.5%, was expected; with si-27b or si-1a 
having no effect, and half the amount of si-128.  
Interestingly, when these two pairs of siRNAs were transfected together with the 
WT Gga-Eya4 construct (Fig. 4.6b, c), the luciferase activity level was similar to the one 
observed after transfection with si-128 alone  (si-128/si-27b pair: 64% and 36% decrease; 
si-128/si-1a pair: 58% and 42% decrease; si-128 alone: 61.5% and 38.5% decrease); the 
luciferase activity was rescued (90-100%) after mutation of the miR-128 site.  
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These results suggest that miR-1a and miR-27b, when in combination with miR-
128, respectively (Fig. 4.6b, c), could potentially improve the interaction between miR-
128 and Gga-Eya4 3’UTR. The complete rescue observed with the combination si-128/si-
1a seems to confirm that even with the same seed sequence than miR-206, miR-1a does 
not target Gga-Eya4 3’UTR. 
 
These combination experiments suggest that miR-128 and miR-206, as well as 
targeting Gga-Eya4 3’UTR on their own, could work in cooperation, in an additive 
manner, to regulate the expression of Gga-Eya4; miR-27b and miR-1a could also be 
involved in this regulation.  
Part of a pilot experiment aiming at investigating potential cooperative actions 
between miRNAs in order to regulate targets, these assays, although showing promising 
trend results, would have to be repeated to make the results statistically significant. 
Experiments using different constructs, such as a miR-128/206 double mutant construct 
with both target sites mutated, could provide interesting additional information.  
 
 In this first part, Gga-Eya4, a predicted miR-128 target, was validated as a target 
in vitro. The cloning of a fragment of its coding sequence allowed to generate a specific 
RNA probe and its expression pattern was determined by RNA ISH. A comparison 
between Gga-Eya4 and miR-128 profiles revealed similar expressions, in particular in the 
somites, in the myotome.  
 
 A fragment of Gga-Eya4 3’UTR, containing miR-27b/128 site, but also miR-
1a/206, miR-133a and miR-499 sites, was cloned and used to perform luciferase reporter 
assays. This quantitative method allowed investigation of the predicted interaction 
between these miRNAs and Gga-Eya4 3’UTR. MiR-128 and miR-206 were validated as 
miRNAs able to target Gga-Eya4. In addition, a pilot experiment looking at potential 
miRNA synergism, gave an insight into the complex collaboration that could exist 
between these miRNAs (miR-128, miR-27b, miR-206, and miR-1a) for target regulation; 
preliminary data showing that miR-128 and miR-206 could potentially work in an 
additive manner to more efficiently regulate Gga-Eya4 expression.  
 
 The following part of this chapter will focus on the miRNA regulation of the other 
members of the PSED network, specifically Six, Eya and Dach, including new insights 
into their expression patterns. 
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4.2.2. MicroRNA regulation of members of the PSED network, and their 
expression patterns 
 
 In this part, the same approach used to validate miR-128 and miR-206/Gga-Eya4 
3’UTR interactions was applied to investigate potential miRNA interactions with some 
other PSED members: Six1/4, Eya1-3, and Dach1/2.  
 
a. Cloning of 3’UTR fragments of PSED members and mutagenesis 
 
In order to study potential miRNA interactions with Six1/4, Eya1-3, and Dach1/2, 
the first step was to clone their 3’UTR. 
Gga-Six1, Gga-Six4, Gga-Eya1, Gga-Eya2, Gga-Eya3 and Gga-Dach1 3’UTR 
sequences were found in Ensembl and NCBI databases; no 3’UTR sequence was found 
for Gga-Dach2, most likely due to the fact that Gga-Dach2 has not been annotated yet. 
 
Based on the information available in TargetScan database and the analysis 
performed on data generated by running the miRanda algorithm (analysis presented in 
chapter 3), several miRNAs were identified and predicted to target the PSED members; 
relevant predicted miRNAs are listed in Table 4.2; they were selected for further 
investigation. For example, Eya1 is predicted to be targeted by miR-27b and miR-128, 
but also miR-133a; Six1, Six4 and Dach1 by miR-1a and miR-206.  
 
Pairs of primers were designed for PCR-mediated cloning of these 3’UTRs. 
Similar to Gga-Eya4 3’UTR, several fragments were cloned for some of these 3’UTRs, 
which were very long (Appendix III List 2). For example, in the case of Gga-Six4 3’UTR 
(4518 bp in length), 3 overlapping fragments were cloned. However, the intermediate 
fragment was not investigated further. This was due to the presence of the most interesting 
miRNA sites for this study, in the 5’ and the 3’ regions of the 3’UTR, and because 
predicted miRNA sites located at the 5’ and 3’ extremities of a 3’UTR sequence are more 
likely to be functional (Long et al. 2007; Ekimler & Sahin 2014).  
 
 
  
 
Table 4.2: Summary – Luciferase reporter assays. GENE: List of the genes, members of the SED network, selected for investigation. 3’UTR 
FRAGMENTS and miR: 3’UTR fragments cloned and their respective length (bp), and lists of interesting miRNAs predicted, by bioinformatics tools 
(TargetScan, MiRanda), to target the 3’UTR of Eya1, Eya3 and Eya4, Six1 and Six4, and Dach1. DECREASE: Number of independent experiments 
performed (N(exp)) and percentage of decrease in luciferase activity (%). T.TEST (p value). MUTANTS and miR: List of mutants generated for each 
3’UTR (DM: double mutant) and miRNAs which were predicted to target these 3’UTR before introduction of the mutations. RESCUE: Number of 
independent experiments performed (N(exp)) and percentage of luciferase activity (%).T.TEST (p value). : no t-test performed due to rescue values 
going over 100%; - indicates that no t-test was performed due to insufficient number of experiments.
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All the 3’UTRs, except for Gga-Eya2, were cloned into pGEMT-Easy vector, and 
then sub-cloned into pGL3-Luciferase modified vector by BglII/NheI restriction 
digestion (Tuddenham et al. 2006). Gga-Eya2 could not be successfully cloned even after 
several attempts and optimisations; this is maybe due to a problem with the sequence used 
to design primers, as although Ensembl provides a sequence for Gga-Eya2 3’UTR, in 
TargetScan it is mentioned that Gga-Eya2 does not appear to have a 3’UTR, thus the 
annotation may be incorrect.  
The pGL3 constructs were validated by sequencing, and then used to perform 
luciferase reporter assays. 
 
Mutagenesis: 
 
In addition to the WT pGL3 constructs, mutant constructs for Gga-Six1, Gga-
Six4, Gga-Eya1, Gga-Eya3 and Gga-Dach1, and their respective miRNA sites were 
generated; this was done using the same strategy used to generate Gga-Eya4 3’UTR 
mutant constructs and presented in Fig. 4.4.  
 
Overlapping primers were designed, containing a restriction enzyme site as 
mutation to introduce in place of the miRNA targeted site, and by using the FastCloning 
technique single or multiple miRNA sites were mutated.  
In the case of Gga-Eya1, miR-128 and miR-27b are both predicted to target two 
sites in its 3’UTR. Single mutant constructs were generated for each site; a double mutant 
was also generated by using one of the single mutant constructs as a template and the 
appropriate set of primers. All the mutant constructs generated (listed in Table 4.2) were 
checked by restriction digestion and validated by sequencing, before being used to 
perform luciferase reporter assays. 
 
b. Luciferase reporter assays: miRNA/target interaction in vitro 
 
For each predicted miRNA/target interaction mentioned in Table 4.2, luciferase 
reporter assays were performed, following the protocol described previously (see chapter 
2.19).  
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Fig. 4.7: Luciferase reporter assays – Gga-Eya1 and Gga-Eya3. Luciferase activity 
for Gga-Eya1 3’UTR (a-c) and Gga-Eya3 3’UTR (d, e) constructs, WT and mutants, co-
transfected with control siRNA (siC), or one of these siRNAs: si-133 (a; d); si-128 or si-
27b (b). Normalised luciferase activity was plotted relative to the condition [WT or 
mutants construct + siC] (Eya1: in blue; Eya3: in green). Experiments were repeated 3-4 
times with triplicate samples. Error bars represent the standard error of the mean (SEM) 
(n=9 or 12). T-test: p<0.05: , p<0.01: , p<0.001: . Alignments of Gga-Eya1 (c) 
and Gga-Eya3 3’UTR (e) sequences at the different miRNA sites with the seed sequence 
of their respective miRNA; mutated nucleotides are indicated in red. Vertical lines and 
stars indicate complementarity and identity between sequences, respectively.  
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i) MiR-128 and miR-133a target Gga-Eya1 3’UTR 
 
 Luciferase reporter assays showed that miR-133 targets Gga-Eya1 3’UTR leading 
to a decrease in luciferase activity of 19% (81% activity; t-test: p<0.01), which was 
significantly rescued by mutating the miR-133 site; with relative luciferase activity going 
back to 91% (Fig. 4.7a).  
 
Interestingly, while no effect was observed with miR-27b, miR-128 was able to 
target Gga-Eya1 3’UTR (Fig. 4.7b). A decrease of 37% of the luciferase activity was 
observed (63% activity), however after mutation of this site, the luciferase activity could 
only be partially rescued (73%; t-test: p<0.001). This was due to the presence of a second 
site. The mutation of this second site gave a similar or slightly better rescue (83%) and 
mutation of both sites brought the luciferase activity up to 89% (t-test: p<0.01). The 
significance of these promising results could be improved by performing an additional 
independent experiment; 4 independent experiments were performed with the WT and 
each single mutation constructs, while only 3 for the double mutant construct.  
 
ii) MiR-133a targets Gga-Eya3 3’UTR 
 
Luciferase reporter assays showed that miR-133 targets Gga-Eya3 3UTR (Fig. 
4.7d); a decrease in luciferase activity of 22% (78% activity; t-test: p<0.001) was 
observed, and 98% activity was restored after mutation of miR-133 site.  
 
iii) Gga-Six1, Gga-Six4 and Gga-Dach1 3’UTRs, and miRNA 
regulation 
 
 Luciferase reporter assays were performed and showed that although Gga-Six4 
3’UTR is predicted to be a target of miR-133a and miR-499, no variation in luciferase 
activity was observed, suggesting that these miRNAs are not involved in the regulation 
of Gga-Six4 (Fig. 4.8c, d).  
 
Luciferase reporter assays, aiming at validating Gga-Six1, Gga-Six4 and Gga-
Dach1 as miR-1a and miR-206 targets were also performed (Fig. 4.8a, d and 4.9a).  
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Fig. 4.8: Luciferase reporter assays – Gga-Six1 and Gga-Six4. Luciferase activity for 
Gga-Six1 3’UTR (a, b) and Gga-Six4 3’UTR (c-e) constructs, WT and mutants, co-
transfected with control siRNA (siC), or one of these siRNAs: si-1a or si-206 (a; d); si-
133 (c); si-499 (d). Normalised luciferase activity was plotted relative to the condition 
[WT or mutants construct + siC] (Six1: in red; Six4: in blue). Experiments were repeated 
3-4 times with triplicate samples. Error bars represent the standard error of the mean 
(SEM) (n=9 or 12). T-test: p<0.001: . Alignments of Gga-Six1 (b) and Gga-Six4 
3’UTR (e) sequences at the different miRNA sites with the seed sequence of their 
respective miRNA; mutated nucleotides are indicated in red. Vertical lines and stars 
indicate complementarity and identity between sequences, respectively.  
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Fig. 4.9: Luciferase reporter assays – Gga-Dach1. (a) Luciferase activity for Gga-
Dach1 3’UTR constructs, WT and mutants, co-transfected with control siRNA (siC), si-
1a or si-206. Normalised luciferase activity was plotted relative to the condition [WT or 
mutants construct + siC] (in brown). Experiments were repeated 1-6 times with triplicate 
samples depending on the constructs tested. Error bars represent the standard error of the 
mean (SEM) (n=9 or 12). T-test: p<0.001: . (b) Alignments of Gga-Dach1 sequence 
at the different miRNA sites with the seed sequence of their respective miRNA; mutated 
nucleotides are indicated in red. Vertical lines and stars indicate complementarity and 
identity between sequences, respectively.  
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With all putative target 3’UTRs an important decrease in luciferase activity was 
observed when either si-1a or si-206 was used; the decrease being even more dramatic 
with si-206 (si-1a: 32-35% decrease; si-206: 45-54% decrease) (Table 4.2). However, in 
all cases no rescue or weak rescue was observed when performing the assays with the 
mutant constructs. This could be explained by the possibility that either the mutated sites 
were not functional, or by the presence of additional cryptic/non-canonical miR-1a/206 
sites, which were not predicted by the bioinformatics tools. However, the first possibility 
appears unlikely given that the decrease in luciferase activity observed with the WT 
constructs was highly reproducible and based on a minimum of 3 independent 
experiments, with little variation between each experiment. Further investigations would 
have to be done in order to further confirm Gga-Six1, Gga-Six4 and Gga-Dach1 as targets 
of miR-1a and miR-206. 
 
c. Chicken Six1/4, Eya1-3, Dach1 expression patterns 
 
 In parallel to the cloning of the 3’UTR sequences of the PSED members, 
fragments of their coding sequences were also cloned in order to study their expression 
profiles (see Appendix III List 2).  
 
Gga-Eya1, Gga-Eya2, Gga-Eya3, Gga-Six1, Gga-Six4 and Gga-Dach1 were 
collected from Ensembl and NCBI. Sequence alignments of members of the Eya and Six 
families, respectively, from several species (human, mouse and chicken), were performed 
in order to design specific pairs of primers for each gene (data not shown); criteria for 
choosing the position of the primers were that the sequence was conserved between 
species, but sufficiently different from the other members of their respective family to be 
able to discriminate each member. 
 
 Total RNAs, from dissected chicken somites (day 4), were in vitro transcribed 
(see chapters 2.8 and 2.9; Appendix III Table 1). The cDNAs generated were used to do 
PCRs (see chapter 2.10); PCR products were then ligated into pGEMT-Easy vector 
(Promega), and used to produce DIG-labelled antisense and sense RNA probes by PCR 
(see chapter 2.7).  
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For Gga-Eya1, Gga-Six1 and Gga-Dach1, the cloning of cDNAs containing open 
reading frame sequences failed; instead pGEMT-Easy constructs containing a fragment 
of their 3’UTRs were used as template to generate probes; the 3’UTR being often quite 
AT-rich, these probes could potentially be more challenging to use in RNA ISH, 
compared to classic probes made from coding sequences.  
 
RNA ISH were performed on chicken embryos fixed at different stages of 
development, from HH10 to HH23. Expression patterns at HH11-12, HH16 and HH21-
22, are presented in Fig. 4.10. Sense probes were used as negative controls.  
 
i) Gga-Eya1, Gga-Eya2 and Gga-Eya3 
  
At HH11-12, while Gga-Eya1 was not found expressed (Fig. 4.10a), and Gga-
Eya4 was only detected in the head region (Fig. 4.3), Gga-Eya2 and Gga-Eya3 were 
already strongly expressed in the developing somites (Fig. 4.10b; c). At this stage, Gga-
Eya3 was also found in the neural tube and the notochord (vii’); and Gga-Eya2 was 
expressed in the head region, in the presumptive cranial placodes (iv).  
At HH16, Gga-Eya1 and Gga-Eya3 displayed a similar expression in the 
notochord, and a weak expression in the differentiating somites (ii’’; viii’’); Gga-Eya3 
also appeared to be present in the developing limbs (viii). With a dynamic pattern, Gga-
Eya2 was strongly expressed in the entire newly formed somites in the posterior region 
(v, v’), then as the somites differentiated, this expression became restricted to the 
dermomyotome (v’’); Gga-Eya2 was also found in the branchial arches, but not in the 
limb buds (v).  
 At later stage (HH21-22), although Gga-Eya1 and Gga-Eya3 showed a 
widespread expression in whole-mount (iii; ix), on transverse sections Gga-Eya3 was 
found in the dermomyotome, in its dorsomedial lip, and in the myotome (ix’’); Gga-Eya1 
was still expressed in the notochord and displayed a weak expression in the myotome 
(iii’’). At HH21-22, Gga-Eya2 was found strongly expressed in the ventromedial and 
dorsolateral lips of the dermomyotome, and in the myotome (vi’’). 
 
The differential expression profiles observed for Gga-Eya1 and Gga-Eya2 (Fig. 
4.10a, b), at the different stages of development tested, are consistent with the published 
expression patterns described in chicken (Ishihara et al. 2008; Heanue et al. 1999; 
Mishima & Tomarev 1998).  
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Fig. 4.10: Expression patterns of Gga-Eya1 (a), Gga-Eya2 (b) and Gga-Eya3 (c). 
(Part one). WMISH performed with antisense DIG-labelled RNA probes, and transverse 
sections at HH11-12 (i, i’; iv, iv’; vii, vii’), HH16 (ii-ii’’; v-v’’; viii-viii’’), and HH21-22 
(iii-iii’’; vi-vi’’; ix-ix’’). Embryos treated with the sense probes (negative control) did not 
show any expression (data not shown). Red dotted lines indicate the location of the 
transverse sections. Transverse section: 20x magnification. e: eye; DM: dermomyotome; 
My: myotome; NC: notochord; NT: neural tube; S: somite. 
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Gga-Eya2, expressed earlier than Gga-Eya1, and Gga-Eya4, displays a strong and 
dynamic expression in the developing somites, the dermomyotome and the myotome; 
however, Gga-Eya1 could not be detected in the dermomyotome, and neither Gga-Eya1 
nor Gga-Eya2 were found in the limb buds. Although Gga-Eya3 displays a widespread 
expression in whole-mount, its expression at HH11-12 and HH21-22 is similar to those 
of Gga-Eya2 in the developing and differentiating somites. At HH16, only Gga-Eya3 
appears to be expressed in the developing limb buds. 
 
ii) Gga-Six1, Gga-Six4 and Gga-Dach1 
 
 Gga-Six1 and Gga-Six4 displayed differential expression patterns at the different 
stages of development studied (Fig. 4.10d, e). At HH11-12, while Gga-Six1 was just 
becoming detectable (x, x’), Gga-Six4 was already well expressed in the neural tube, the 
notochord and the developing somites (xvi; xvi’).  
 At HH16, they were both expressed in the notochord and in the neural tube (xi-
xi’’; xiv-xiv’’); Gga-Six1 being expressed in the most ventral part of the neural tube (xi’’), 
and Gga-Six4 in the most dorsal part (xiv’’).  
From HH16, their respective expression in the notochord decreased (xi’’, xii’’; 
xiv’’, xv’’). Gga-Six4 was strongly expressed in the differentiating somites, in the 
dermomyotome and in the myotome (xiv’’); Gga-Six1 was only weakly detected in these 
tissues (xi’’). At this stage, Gga-Six4 was also expressed in the developing limbs (xiv); 
at HH21-22, this expression became restricted to the posterior part of the limbs (xv). 
 
In these experiments, Gga-Dach1 was only detected at HH11-12 in the neural 
tube, the notochord and the developing somites (Fig. 4.10f; xvi, xvi’); no expression in 
the somites was observed at later stages (xvii-xviii’).  
 
The expression pattern observed for Gga-Six4 is consistent with the published 
expression pattern described in chicken (Esteve & Bovolenta 1999); Gga-Six4 is present 
in the head region, the notochord, in the somites, in the dermomyotome and the myotome. 
The expression profiles observed for Gga-Six1 and Gga-Dach1 are consistent with 
previously published patterns (Heanue et al. 1999; Heanue et al. 2002; Kida et al. 2004). 
 
Gga-Six1 is expressed in the somites, in the myotome, however it is not found in 
the dermomyotome; and Gga-Dach1 is expressed in the neural tube at HH11-12, however 
it is not found in the somites or the developing limb buds as previously reported. 
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Fig. 4.10: Expression patterns of Gga-Six1 (d), Gga-Six4 (e) and Gga-Dach1 (f). 
(Part two). WMISH performed with antisense DIG-labelled RNA probes, and transverse 
sections at HH11-12 (x, x’; xiii, xiii’; xvi, xvi’), HH16 (xi-xi’’; xiv-xiv’’; xvii-xvii’’), and 
HH21-22 (xii-xii’’; xv-xv’’; xviii-xviii’’). Embryos treated with the sense probes 
(negative control) did not show any expression (data not shown). Red dotted lines indicate 
the location of the transverse sections. Transverse section: 20x magnification. e: eye; DM: 
dermomyotome; My: myotome; NC: notochord; NT: neural tube; S: somite. 
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4.3. Conclusion 
 
 In this chapter, Eya4, predicted target of miR-128, has been examined further and 
fragments of its coding region and 3’UTR sequences were cloned.  
 
Gga-Eya4 expression pattern was characterised for the first time in the model 
chicken. Found in the somites, in the dorsomedial lip of the dermomyotome and the 
myotome; its expression is similar to those of miR-128 in these tissues.  
 The predicted interaction between Gga-Eya4 and miR-128 was investigated. Gga-
Eya4 3’UTR constructs, WT and mutants, generated by FastCloning technique (Li et al. 
2011), were used to perform luciferase reporter assays. These assays showed that miR-
128 can target Gga-Eya4 3’UTR and reduce its expression activity; activity which can be 
rescued after mutation of miR-128 site. Other miRNAs were also tested, and amongst 
them miR-206 was also shown to be able to target Gga-Eya4 3’UTR, with slightly weaker 
effect than observed for miR-128. However, this effect was stronger when si-128 and si-
206 were used in combination. This could suggest that miR-128 and miR-206, which can 
target Gga-Eya4 3’UTR on their own, might also be able to work in cooperation, in an 
additive manner, in order to have a stronger effect on the regulation of Gga-Eya4 
expression. This will need to be investigated further following on from the pilot 
experiment described here. 
 
 Using the same strategy, fragments of coding and 3’UTR sequences were cloned 
for Gga-Six1, Gga-Six4, Gga-Eya1, Gga-Eya3 and Gga-Dach1. 
 Luciferase reporter assays showed that miR-128 and miR-133a can target Gga-
Eya1 3’UTR, while miR-27b cannot, although it has the same seed sequence as miR-128 
and was predicted to target the same site; miR-133 is also able to target Gga-Eya3 3’UTR. 
However, miR-133a and miR-499 did not seem to be able to target Gga-Six4 3’UTR. 
Other experiments were performed to determine if miR-1a and miR-206 could target Gga-
Six1, Gga-Six4 and Gga-Dach1. Although a decrease in luciferase activity was observed; 
this decrease could not be rescued after mutation of the different miRNA sites in their 
respective 3’UTR sequences. 
 RNA probes were also generated for Gga-Six1, Gga-Six4, Gga-Eya1, Gga-Eya2, 
Gga-Eya3, and Gga-Dach1, and RNA ISH performed on chicken embryos at different 
stages of development. Similar expression to those already published were observed.  
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Gga-Eya3, which had not been characterised in chicken before, seems to have a 
similar expression than what was described in mouse and zebrafish; widespread 
expression in whole-mount, neural tube and developing somites at HH11-12, 
dermomyotome and myotome at HH21-22.  
 
 Predicted by bioinformatics tools (chapter 3) and validated by in vitro luciferase 
reporter assays (this chapter), the interaction between Gga-Eya4 and miR-128 is going to 
be investigated further in chapter 5. MiRNA loss-of-function experiments, using 
antagomiRs (miRNA inhibitors), will be performed in order to (1) validate Gga-
Eya4/miR-128 interaction in vivo, and (2) determine the impact of this interaction on 
myogenesis. 
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CHAPTER 5: MicroRNA/mRNA TARGET INTERACTIONS in 
vivo AND THEIR ROLE(S) DURING MYOGENESIS 
 
 
5.1. Introduction 
 
 In chapter 4, miRNA/mRNA target interactions were investigated by luciferase 
reporter assays. Gga-Eya4 was identified as a target of miR-128 and miR-206; and miR-
133a was shown to target Gga-Eya1 and Gga-Eya3. Although these experiments showed 
pertinent results, they were generated by using a cell-based approach, and needed to be 
confirmed in vivo. 
  
 In this chapter, miRNA/mRNA target interactions are going to be investigated 
using an in vivo model, the chicken embryo. The potential impact(s) of such interactions 
on myogenesis is also going to be assessed. 
 
MicroRNAs, the PSED network and myogenesis: 
 
PSED network and myogenesis: 
 The myogenic determination factors control entry into the myogenic program, 
which leads to the formation of skeletal muscle. Upstream of this obligatory step, other 
transcription factors, part of the regulatory PSED network, direct cells toward 
myogenesis; PAX, SIX, EYA and DACH are referred to as pre-myogenic factors. 
 In vertebrates, SIX1/4, EYA1/2/4, and DACH1/2, with overlapping expression 
patterns, are co-expressed in the myogenic precursor cells in the somites, in the 
dermomyotome and the myotome; at limb level, with PAX3/7, they play a crucial role in 
ensuring that the migrating myogenic precursor cells remain committed to their fate until 
they reach their final destination (Christ & Ordahl 1995; Xu, Cheng, et al. 1997; Oliver 
et al. 1995). 
 
Since Heanue et al. showed in the chicken embryos that ectopic expression of Six 
and Eya resulted in activation of Pax3 and myogenic regulatory genes (Heanue et al. 
1999), mouse mutants for the different PSED members have provided insight into their 
complex upstream roles in the activation and regulation of the myogenic programme. 
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As previously reported, Pax3 and Pax7 play an important role in the activation 
and control of the myogenic regulatory factors (MRFs) expression (Myf5 and MyoD1) 
(Williams & Ordahl 1994; Maroto et al. 1997; Bajard et al. 2006). While in Pax7-/-  
mutant mice skeletal muscle forms normally (Mansouri et al. 1996), Pax3-/- mutants have 
abnormal myotome formation, trunk muscle defects and absence of limb muscle (Bober 
et al. 1994; Goulding et al. 1994). Moreover, Pax3/Pax7 double mutants have major 
defects in myogenesis (Relaix et al. 2005).  
Similarly, while in Six4 and Eya2 knock-out mice no developmental defects were 
observed (Ozaki et al. 2001; Grifone et al. 2007), Six1 and Eya1 mutants mice have 
important muscle deficiencies (Ozaki et al. 2004; Laclef et al. 2003; Grifone et al. 2007). 
In Six1/4 and Eya1/2 double mutants, defects are even more important with absence of 
all muscles derived from hypaxial dermomyotome (trunk muscles and limbs). In Six1/4 
double mutant embryos, no Pax3-positive cells are detectable in the forelimb, and just a 
few in the hindlimb; Myf5 and MyoD-positive cells are absent (Tremblay et al. 1998; 
Giordani et al. 2007; Relaix et al. 2013). In addition, Six1/4/Myf5 mutants, with no 
expression of MyoD and no skeletal muscle formed, display a similar phenotype to what 
was observed in Pax3/Myf5 mutants (Relaix et al. 2013; Tajbakhsh et al. 1997). These 
results suggest that SIX and EYA are upstream of PAX. 
 
Ohto et al. showed that transcription regulation of certain target genes by Six 
proteins requires cooperative interaction with Eya proteins (Ohto et al. 1999). In mouse, 
Six1/4 bind to Eya1/2 in the cytoplasm and translocate Eya into the nucleus. SIX, often 
associated with DACH, has been described as a repressor or weak activator, however, 
when interacting with EYA, the complex formed becomes a strong activator; this 
complex is then able to activate SIX target genes, such as Pax3 and MyoD1 (Grifone et 
al. 2005). Heanue et al. reported similar results in the chicken model where Eya2 interacts 
with Six1 and Dach2 in order to regulate Pax3 and therefore influence myogenic 
differentiation (Heanue et al. 1999).  
In addition, it has also been shown that SIX/EYA complex can directly up-
regulate MyoD and MyoG expression by targeting enhancer elements on their respective 
promoters (Tapscott 2005; Giordani et al. 2007; Spitz et al. 1998); activation being 
independent of Pax3. These results are consistent with the severe decrease of Myf5 and 
MyoD1 expression, in the myotome, observed in the Six1/Six4 double mutant mice 
(Tajbakhsh et al. 1997). 
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These effects on the activation of downstream transcription factors and muscle 
genes distinguish SIX/EYA from PAX regulation of myogenesis. While PAX3/7 control 
upstream events leading to myogenesis, with Pax3 actives in the somite prior to SIX/EYA 
intervention; SIX/EYA complex plays a major role in the onset of hypaxial myogenesis, 
both directly through activation of MRFs (MyoD1 and MyoG), and indirectly through 
control of PAX3 (Buckingham & Rigby 2014). 
 
MiRNAs and myogenesis: 
Myogenesis starts in the dermomyotome and requires the commitment of a pool 
of cells into the skeletal muscle lineage. This process is associated with the activation of 
the MRFs (MyoD1, Myf5, Mrf4 and MyoG), and the downregulation of Pax3 (Williams 
& Ordahl 1994; Goulding et al. 1994; Gros et al. 2004). 
Downregulation of Pax3 is essential to ignite the myogenic programme. Goljanek-
Whysall et al. showed in the chicken that miR-1 and miR-206 directly target Pax3 and 
inhibits its expression (Goljanek-Whysall, Pais, et al. 2012). Consistent with this, the 
inhibition of miR-1 and miR-206 leads to de-repression of Pax3 and delayed myogenic 
differentiation in the somites (Goljanek-Whysall et al. 2011). 
In skeletal muscle stem cells, miR-27b has also been identified to target the 
transcription factor Pax3. In vivo overexpression of miR-27b, leads to Pax3 down-
regulation in the myotome and premature differentiation, whereas in cell culture the 
inhibition of miR-27b permits Pax3 to induce increased proliferation and delay the 
differentiation process (Crist et al. 2009). Moreover, inhibiting miR-27b in regenerating 
muscle leads to an increase in Pax3 expression and fibres with smaller diameter. 
 
 Other miRNAs have also been shown to play a role in myogenesis. An increase 
in miR-128 expression was reported during myoblast differentiation (Sun et al. 2010). In 
addition, Shi et al. recently showed in mouse that ectopic expression of miR-128 induces 
the expression of skeletal muscle proliferation and differentiation related genes, such as 
Pax3/7 and the MRFs (Myf5 and MyoD1) (Shi et al. 2015). Conversely, these genes were 
down-regulated when miR-128 was repressed.  
O’Brian et al. identified, in zebrafish, an upstream miRNA regulatory mechanism 
where miR-30a directly regulated myogenesis via inhibiting Six1a/b expression (O’Brien 
et al. 2014). 
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 Functional experiments: 
 
 To study miRNA/mRNA target interactions and investigate their potential role(s) 
in skeletal development, the chicken embryo, relatively large and accessible, is an ideal 
tool. Somites can be targeted with great precision by microinjection or/and 
electroporation, in order to enable the delivery of oligonucleotides or gene expression 
constructs. 
 
 Different approaches, involving loss-of-function and gain-of-function 
experiments, can be used to study the function(s) of miRNAs, and any target genes.  
The silencing of miRNAs in vivo has been made possible by the development of 
chemically engineered oligonucleotides, called ‘antagomiRs’ (AM; Dharmacon) 
(Krützfeldt et al. 2005; McGlinn et al. 2009). These antagomiRs bind to their specific 
miRNAs and prevent them from interacting with their targets. MiRNAs can also be 
overexpressed by using mature miRNA mimics, or expression constructs containing 
miRNA-hairpin precursors; in addition to the endogenous miRNAs they will bind to their 
targets and prevent their expression.  
The expression of target genes can be ‘knocked-down’ by vector-based approach 
using siRNA, or antisense morpholinos (MO) specifically designed to bind their 
respective mRNA 5’UTR regions, and block their translation (Voiculescu et al. 2008; 
Mende et al. 2008). Overexpression of target genes is also possible by using expression 
constructs containing cDNAs.  
 
Followed by in situ analysis, or somite dissection and biochemical/molecular tests, 
such as western blot, RT-qPCR, or high-throughput sequencing, the results generated 
provide important information on miRNA function(s). 
 
 In order to validate in vivo the interaction between miR-128 and Eya4 (described 
in chapter 4), loss-of-function experiments were performed. Embryos, injected with an 
antagomiR (miRNA inhibitor) directed against miR-128 was then used to perform RNA 
in situ hybridisation (ISH) and identify potential phenotypes.  
In parallel, injected somites, as well as non-injected contralateral somites (used as 
control) were dissected out and RT-qPCRs were performed, providing an insight into the 
potential role of miR-128 in the regulation of the PSED network. RNA ISH and RT-qPCR 
results will be presented in the first part of this chapter.  
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Fig. 5.1: Functional experiments: miRNA loss-of-function – AntagomiR strategy. 
Injection of antagomiR into the 6 most posterior somites (newly formed; indicated in 
green), on one side (right side), of HH14-15 chicken embryos. Embryos were incubated 
for 24 hours and harvested at HH19-20. Embryos were either fixed in paraformaldehyde 
(PFA) in order to perform RNA whole-mount in situ hybridisation (WMISH), or the 
injected somites were dissected out and used for real time quantitative PCR (RT-qPCR). 
The contralateral somites, from the non-injected side, were also dissected out and used as 
control.    
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Other miRNAs, miR-206 and miR-133, and their respective interactions with 
Eya4, and Eya1 and Eya3, were also investigated (described in chapter 4). RT-qPCR 
results will be presented in a second part.  
 
 
5.2. Results and discussion 
 
In order to investigate the function(s) of miRNAs in skeletal muscle development, 
loss-of-function experiments were performed using antagomiRs. HH14-15 chicken 
embryos were injected in the 6 most posterior and newly formed somites, on one side, 
with one of the following antagomiRs: AM-128, AM-206, AM-133 or AM-scr. 
Scrambled antagomiR (AM-scr) was used as a control (scrambled miR-206 sequence). 
After 24-hour incubation, HH19-20 embryos were collected, and either fixed in 
paraformaldehyde (PFA) in order to perform RNA ISH, or the injected somites were 
dissected out and used for real-time quantitative polymerase chain reaction (RT-qPCR) 
(summarised in Fig. 5.1) (see chapter 2.20).  
The optimal stage for injection was determined based on the respective expression 
of the different PSED genes we wanted to look at. As previously described in the literature 
and according to the profiles observed in chapter 4, Pax3, Six1/4 and Eya1-4 are all 
expressed at HH14-15. The antagomiR injections were performed in developing somites, 
before they start to differentiate.  
 
5.2.1. MiR-128 regulates myogenesis via its interaction with Gga-Eya4 
 
a. MiR-128 targets Gga-Eya4 in vivo 
 
RNA ISH: 
A first experiment was performed to determine for how long the embryos would 
have to be incubated in order to see a phenotype. After AM-128 injection, 4 groups of 10 
embryos were incubated for 6h, 9h, 12h, and 24h, respectively. Embryos from each group 
were collected, and using a microscope with GFP filter, the somites injected with FITC-
labelled AM-128 were localised.  
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Fig. 5.2: Expression patterns of Gga-Eya4, Gga-Six4, Gga-Pax3 and Gga-MyoD1 
after antagomiR-128 injection. AntagomiR-128 (1 mM) was injected into the 6 most 
posterior somites, on one side (right side), of HH13-14 embryos. After 24h incubation, 
HH19-20 embryos were collected and fixed. Double RNA WMISH were performed using 
Digoxigenin (DIG)-labelled probes for Gga-Eya4 (a), Gga-Six4 (b), Gga-Pax3 (c), and 
Gga-MyoD1 (d) (purple). FITC labelled-antagomiR was detected by alkaline 
phosphatase coupled anti-FITC antibody developed with Fast Red. This localised the 
injected somites (red). Expression patterns on dorsal view. Transverse sections (red 
dotted lines in top panel) at the interlimb level showing Gga-Eya4 (e), Gga-Six4 (f), Gga-
Pax3 (g) and Gga-MyoD1 (h) expression; antagomiR location was detected by 
fluorescent filter Alexa-Fluor-568 on the same sections. The contralateral non-injected 
side (left side), was used as control. (i) Quantification of phenotype observed. KD: knock 
down; O/E: overexpression. Transverse sections: 20x magnification. 
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Embryos which had reached the expected stage and were successfully injected 
(GFP-positive somites), were then used to perform a double ISH for Eya4 (Digoxigenin 
(DIG)-labelled antisense probe; revealed in Alkaline phosphatase/NTMT buffer) and for 
AM-128 (FITC-labelled; revealed in Fast Red buffer) (see chapter 2.5). The expression 
pattern for each embryo was analysed in whole-mount, and after sectioning, in the 
injected somites. 
 
As antagomiRs are repressing miRNA activity, with a repression of miR-128 by 
AM-128, and given the fact that Gga-Eya4 is a potential target of miR-128, a de-
repression of Gga-Eya4 expression was expected.  
Embryos incubated for 24h after injection displayed the strongest phenotype with 
a stronger expression signal detected for Gga-Eya4 transcript in the myotome. After 24h, 
the injected somites were localised in the region facing the dorsal part of the developing 
forelimb and the anterior part of the interlimb region (Fig. 5.1).  
 
AM-128 injection experiments with 24-hour incubation were repeated to increase 
the number of embryos (n=47) and an example of the strongest encountered phenotype is 
presented in Fig. 5.2a, e. The expression of Gga-Eya4 did not seem to be strongly different 
when compared to the contralateral non-injected side (left side) in whole-mount (Fig. 
5.2a); however, on transverse section, Gga-Eya4 expression signal was increased, 
especially in the central part of the myotome. The phenotype was observed in 55.3% of 
the embryos: 7 embryos out of 47 (15%) with an overexpression similar to the one 
presented in Fig. 5.2a, e; 19 embryos with partial overexpression (40.4%). However, 
44.7% of the embryos showed no change in expression on the injected side compared to 
the non-injected side (Fig.5.2i).  
 
These results indicated that when miR-128 was inhibited by AM-128, Gga-Eya4 
expression was de-repressed in the differentiating somite, in the myotome; suggesting 
that miR-128 could regulate the expression of Gga-Eya4 in vivo.  
 
RT-qPCR: 
In order to quantify potential changes in expression of Gga-Eya4, and consolidate 
the ISH results, RT-qPCRs were performed.  
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Fig. 5.3: RT-qPCR results - PSED and MRF (MyoD1 and Myf5) transcript levels in 
somites injected with antagomiR (AM)-128. Results are expressed in log(fold change). 
For each gene and each experiment, the injected somite data have been normalised to 
(GAPDH + β-actin) housekeeping gene, and then compared to the contralateral non-
injected somite data of the same embryo. Number of independent experiments for each 
gene tested after AM-128 injection: Eya1, Eya2, Six1 (n=10); Eya4, Pax3 (n=8); Six4, 
MyoD1 (n=7); Myf5 (n=12). T-test: p<0.05: , p<0.001:  Dotted lines indicate a 2-
fold change. 
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Injected somites from 3-4 HH19-20 embryos of 10 independent experiments were 
dissected out. The contralateral non-injected somites were also dissected out and used as 
control. Their total RNA were extracted and cDNAs synthesised (see chapter 2.20).  
 
RT-qPCRs were performed using SYBR Green Master mix and specific designed 
primers for Gga-Eya4. Results were analysed based on the Relative Standard Curve 
method (Larionov et al. 2005); method allowing to quantify differences in the expression 
level of a specific target gene (for example Gga-Eya4) between different samples (in this 
study: injected vs non-injected somites). Two housekeeping genes were used for these 
experiments: Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), an important 
glycolytic pathway enzyme, and β-actin, essential for the structure and kinetics of the 
cytoskeleton (Choi et al. 1991; Kozera & Rapacz 2013).  
Although housekeeping genes should not vary in the tissue under investigation, or 
in response to experimental treatment, many studies showed that their expressions can 
vary considerably (Vandesompele et al. 2002). In order to minimise these unwanted 
variations, data obtained for GAPDH and β-actin were averaged. For all samples, levels 
of both target and housekeeping genes (GAPDH, β-actin) were assessed. Gga-Eya4 data 
were normalised to the averaged relative quantification of β-actin and GAPDH 
housekeeping genes. Results for injected somite samples were then compared to their 
respective contralateral non-injected somite samples. Results, expressed in log(fold 
change) were then plotted on a linear scale where the x-axis corresponds to the non-
injected condition set at 0 (log(1)=0).  
 
RT-qPCR results, presented in Fig. 5.3, showed a 1.5-fold higher expression level 
of Gga-Eya4 in somites after AM-128 injection (8 independent experiments; t-test: 
p<0.05); this also suggests that miR-128 may play a role in the regulation of Gga-Eya4 
in vivo.  
 
The results of these functional experiments (RNA ISHs and RT-qPCRs) are 
consistent with the luciferase reporter assays results presented in chapter 4.  
In the reporter assays, the luciferase activity was reduced when Gga-Eya4 3’UTR-
containing construct was co-transfected with si-128, and rescued after mutation of the 
miR-128 site in Gga-3’UTR; these results suggested that miR-128 was able to target Gga-
Eya4 3’UTR and decrease its expression in vitro, and that an intact seed site was required 
for this interaction 
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The RNA ISHs and RT-qPCRs performed after AM-128 injections in somites of 
chicken embryos, showed that inhibiting miR-128 resulted in a significant de-repression 
of Gga-Eya4 expression in vivo. 
Overall, these experiments validated miR-128/Gga-Eya4 interaction in vitro, and 
confirmed Gga-Eya4 as a target of miR-128 in vivo. 
 
b. MiR-128, Gga-Eya4 and myogenesis 
 
In order to investigate the potential effect of miR-128/Gga-Eya4 interaction on 
the PSED network and myogenesis, functional experiments combining RNA ISH and 
RT-qPCRs were performed on the same AM-128 injected somites samples, and examined 
the expression of Gga-Eya1 and Gga-Eya2, Gga-Six1 and Gga-Six4, Gga-Pax3, Gga-
MyoD1 and Gga-Myf5 (Fig. 5.3).  
 
Eya1/2: 
 RT-qPCR showed that while no variation in expression was observed for Gga-
Eya2, Gga-Eya1 expression level was 1.2-fold higher than the control (10 independent 
experiments; t-test: p<0.05) after AM-128 injection (Fig. 5.3).  
This increase of Gga-Eya1 expression is consistent with the luciferase reporter 
assays results presented in chapter 4 (Fig. 4.7b). However, there was only a partial rescue 
after mutating the seed sites. Two miR-128 sites were identified in Gga-Eya1 3’UTR. 
The co-transfection of Gga-Eya1 construct with si-128 showed a decrease in luciferase 
activity of about 40%, and after mutation of these 2 miR-128 sites the luciferase activity 
was still reduced (73%) compared to control. It is possible that sequences outside the seed 
mediate interaction between miR-128 and the Gga-Eya1 3’UTR. 
Taken together, these results indicate that miR-128 may interact with Gga-Eya1 
in vitro and in vivo. 
 
Six1/4: 
 Although Gga-Six1 and Gga-Six4 were not predicted to be targeted by miR-128, 
a de-repression of their expression levels was observed after antagomiR injection; Gga-
Six4 expression level was increased by 1.25-fold (7 independent experiments; t-test: 
p<0.05) (Fig. 5.3). In addition, RNA ISH performed on AM-128 injected embryos also 
showed an increase in Gga-Six4 expression in the somites, in the dorsomedial lip of the 
dermomyotome and the myotome (Fig. 5.2b, f).  
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This phenotype was observed in 5 of 7 embryos (71.4%); no phenotype was 
observed for the 2 other embryos (Fig. 5.2i).  
These results are consistent with a potential indirect effect and cross-regulation 
between SIX and EYA co-factors, which have been shown to form a strong activator 
complex that activates SIX target genes (Heanue et al. 1999; Ohto et al. 1999; Grifone et 
al. 2005). For example, with more Gga-Eya4 available, more SIX/Gga-Eya4 complex 
could potentially be formed, thus promoting Gga-Six4 expression. Gga-Six4 could be a 
potential partner for Gga-Eya4. 
 
Pax3: 
RT-qPCR results showed a relative increase in Gga-Pax3 expression level after 
AM-128 injection in the somites; this was statistically significant (8 independent 
experiments; 1.3-fold change; t-test: p<0.001). Moreover, RNA ISH also showed an 
increase of Gga-Pax3 in the dermomyotome, especially in its central part where its 
expression is usually weak (contralateral non-injected side) (Fig. 5.2c, g). An increase in 
Gga-Pax3 was observed in the majority of the embryos (85.8%): 3 of 7 embryos with an 
overexpression similar to the one presented in Fig. 5.2c, g; and another 3 embryos with 
partial overexpression (42.9%). One of the embryos showed no change in expression on 
the injected side compared to the non-injected side (Fig.5.2i).  
This increase in Gga-Pax3 expression is consistent with the fact that PAX3 is a 
known target of SIX (Grifone et al. 2005). Moreover, it is also possible that Gga-Pax3 
was a target of miR-128; a miR-128 site having been predicted, by TargetScan, in the 
human PAX3 3’UTR.  
 
MRFs (MyoD1 and Myf5): 
 RT-qPCR results showed that while Gga-Myf5 expression did not seem to be 
affected by AM-128 injection, Gga-MyoD1 expression level was decreased by 0.78-fold 
compared to its expression in the contralateral non-injected somites (7 independent 
experiments; t-test: p=0.07). RNA ISH also showed a decrease in Gga-MyoD1 expression 
in the somite, in the myotome (Fig. 5.2d, h). A decrease in Gga-MyoD1 was observed in 
the majority of embryos (59.2%): 3 of 27 embryos with a phenotype similar to the one 
presented in Fig. 5.2d, h; and 13 of 27 embryos with partial loss of MyoD1 expression 
(Fig.5.2i). 
 These results are consistent with the fact that Gga-Pax3 remained expressed in the 
injected somites after antagomiR injection.  
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Thus, because Gga-Pax3 was not efficiently downregulated, the myogenic 
programme could not be activated, and therefore myogenic differentiation markers, 
including MyoD1 could not be expressed (Williams & Ordahl 1994; Goulding et al. 1994; 
Gros et al. 2004). 
 
5.2.2. MiR-206/Gga-Eya4, miR-133/Gga-Eya1 and miR-133/Gga-Eya3 
interactions in vivo 
  
a. MiR-206/Gga-Eya4 interaction and myogenesis 
 
In chapter 4, a potential interaction between miR-206 and Gga-Eya4 was 
identified by luciferase reporter assays (Fig. 4.5). In order to assess whether this 
interaction plays a role in vivo, a loss-of-function experiment, using AM-206 was 
performed, following the same strategy previously described.  
 
The 6 most posterior and newly formed somites, on one side, of HH14-15 embryos 
were injected with AM-206. After 24h incubation, HH19-20 embryos were collected, 
analysed, and injected somites were dissected in order to perform RT-qPCR. 
  
Although these results are only based on 1 experiment, they provided pertinent 
information (Fig. 5.4a). No modification in Gga-Eya4 expression was observed (maybe 
due to the n=1), however, Gga-Six4 and Gga-Pax3 expression levels were de-repressed, 
with a strong 8-fold change increase for Gga-Six4 and nearly 2-fold change increase for 
Gga-Pax3. Importantly, a relative decrease in Gga-MyoD1 and Gga-Myf5 expression 
(about 2-fold change) was also observed.  
 
Gga-Pax3 increase, and Gga-MyoD1 and Gga-Myf5 decrease, are consistent with 
previous work showing, in chicken, that miR-206 directly targets Pax3 and inhibits its 
expression leading to a delayed myogenesis (Goljanek-Whysall et al. 2011). The de-
repressed Gga-Pax3 expression could also be explained by the strong expression of Gga-
Six4; PAX3 being a target of SIX.  
More experiments will have to be performed in order to confirm these 
observations. 
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Fig. 5.4: RT-qPCR results - PSED and MRF (MyoD1 and Myf5) transcript levels in 
in somites injected with antagomiR (AM)-206 (a) and AM-133 (b). Results are 
expressed in log(fold change). For each gene and each experiment, the injected somite 
data have been normalised to (GAPDH + β-actin) housekeeping gene, and then compared 
to the contralateral non-injected somite data of the same embryo. (a) Number of 
independent experiments for each gene tested after AM-206 injection: n=1. (b) Number 
of independent experiments after AM-133 injection was n=5 for Eya1, Eya3, Six4, Pax3 
and MyoD1. T-test: p<0.001:  Dotted lines indicate a 2-fold change. 
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b. MiR-133/Gga-Eya1 and miR-133/Gga-Eya3 interactions in vivo 
 
In chapter 4, Gga-Eya1 and Gga-Eya3 were identified as potential targets of miR-
133 by luciferase reporter assays (Fig. 4.5). In order to assess whether this interaction 
plays a role in vivo, loss-of-function experiments, using AM-133 were performed, 
following the same strategy previously described; the 6 most posterior and newly formed 
somites, on one side, of HH14-15 embryos were injected with AM-133.  
 
RT-qPCR results showed a significant 1.25-fold increase in the expression of Gga-
Eya1 after antagomiR injection (5 independent experiments; t-test: p<0.001) (Fig. 5.4b). 
However, no change in Gga-Eya3 expression level was observed. Although not 
statistically significant, results also showed weak increase of Gga-Pax3 expression level, 
and a 1.5-fold decrease in Gga-MyoD1 and Gga-Myf5 expression levels. More 
independent experiments will have to be done in order to confirm these observations.  
These results are consistent with study done in mouse, zebrafish and Xenopus 
reporting potential role(s) for miR-133 in promoting skeletal muscle differentiation (Kim 
et al. 2006; Chen et al. 2006; Mishima et al. 2009; Liu et al. 2008; Liu et al. 2011).   
 
5.2.3. Control experiments – Scrambled antagomiR (AM-scr) injections 
 
Although the contralateral non-injected side of each tested embryo was used as a 
control, additional experiments using a scrambled antagomiR (AM-scr; scrambled AM-
206 sequence) were performed in order to determine the potential impact of the procedure 
and of injecting an antagomiR into somites. 
Following the same procedure previously described, the 6 most posterior somites, 
on one side, of HH14-15 embryos were injected with AM-scr.  
However, due to limited availability of the AM-scr, it was not possible to generate 
enough material in order to perform RNA ISH for all the genes of this study.  
 Instead, RT-qPCRs were performed on AM-scr injected somite samples. Since 
this is more sensitive and uses less material, this method allowed to look at expression 
level changes for several genes. Results, presented in Fig. 5.5, showed no significant 
change in expression, for all the PSED and MRF genes tested, between injected and non-
injected somites.  
RNA ISH experiments after AM-scr injection will be done in order to complete 
the study and validate the results observed in the different functional experiments. 
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Fig. 5.5: RT-qPCR results - PSED and MRF (MyoD1 and Myf5) transcript levels in 
in somites injected with antagomiR scrambled (AM-scr). Results are expressed in 
log(fold change). For each gene and each experiment, the injected somite data have been 
normalised to (GAPDH + β-actin) housekeeping gene, and then compared to the 
contralateral non-injected somite data of the same embryo. Number of independent 
experiments for each gene tested after AM-scr injection: Eya1, Six1 (n=3); Eya2, Eya3 
(n=2); Eya4, Six4, Pax3, MyoD1 (n=5). Dotted lines indicate a 2-fold change. 
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5.3. Conclusion 
 
 In this chapter, miRNA/mRNA target interactions were investigated by 
performing miRNA loss-of-function experiments, using antagomiRs, followed by RNA 
ISH and/or RT-qPCR. 
 
 MiR-128/Gga-Eya4 interaction, previously validated by luciferase reporter assays 
in chapter 4 (in vitro), was validated in this chapter by RNA ISH and RT-qPCR after AM-
128 injection (in vivo). After AM-128 injection, a significant increase in Gga-Eya4 was 
observed (1.5-fold increase; 8 independent experiments; t-test: p<0.05). In addition, a 
significant increase in Gga-Six4 and Gga-Pax3 expression levels was observed (Gga-
Six4: 1.25-fold increase; 7 independent experiments; t-test: p<0.05; Gga-Pax3: 1.3-fold 
increase; 8 independent experiments; t-test: p<0.001), whereas Gga-MyoD1 expression 
was decreased. 
 MiR-128/Gga-Eya1, miR-206/Gga-Eya4, miR-133/Gga-Eya1 and miR-133/Gga-
Eya3 interactions were also investigated by RT-qPCR. After AM-128 and AM-133 
injections, a significant increase in Gga-Eya1 expression level was observed (after AM-
128 injection: 1.2-fold increase; 10 independent experiments; t-test: p<0.05; after AM-
133 injection: 1.25-fold increase; 5 independent experiments; t-test: p<0.001), but not for 
Gga-Eya3. No change in Gga-Eya4 expression was observed after AM-206 injection; 
however this result was only based on one experiment. After AM-128, AM-133 and AM-
206 injection, the expression levels of Gga-Six4 and Gga-Pax3 were de-repressed, and 
Gga-MyoD1 and Gga-Myf5 were relatively decreased; no change in Gga-Myf5 was 
observed after AM-128 injection. 
 
 Although Gga-Eya4 appears to be a direct target of miR-128 in vitro and in vivo, 
the observed effects after AM-128 injection on the expression of the other members of 
the PSED network and MRFs could only be indirect; to the exception of Gga-Pax3 (to be 
validated) any other PSED members or MRFs were predicted to be targeted by miR-128.  
 
 Based on elements from the literature and on the previous observations, a model 
was proposed to explain the impact that miR-128/Gga-Eya4 interaction could have on the 
PSED network, the MRFs, and on myogenesis (Fig. 5.6).  
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Fig. 5.6: Proposed model – MiR-128/Eya4 interaction and potential effect on the 
PSED network and the MRFs. AM-128 inhibits miR-128. In the absence of miR-128-
mediated negative regulation, Eya4 expression is de-repressed. More Eya4 transcripts 
become available to interact with Six4 and both proteins can form a strong transcriptional 
activator complex. This complex can then activate SIX target genes, like Pax3. Pax3 
expression is maintained or up-regulated by SIX action, and potentially also through the 
lack of direct repression by miR-128. In addition, the MRF MyoD1 is negatively 
regulated, possibly due to the maintained expression of Pax3. 
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From the literature it is known that: SIX and EYA can interact together to form a 
transcriptional activator complex, and one of the targets of SIX is PAX3 (Heanue et al. 
1999; Ohto et al. 1999; Grifone et al. 2005); PAX3 downregulation is essential to ignite 
the myogenic programme, and myogenic differentiation is characterised by the activation 
of the MRFs (Goulding et al. 1994; Williams & Ordahl 1994; Maroto et al. 1997; Gros et 
al. 2004; Bajard et al. 2006). 
 
After injection of AM-128 in developing somites of HH14-15 chicken embryos, 
and 24h incubation, the embryos are at HH19-20. At HH19-20, the injected somites are 
located in the region facing the dorsal part of the developing limb and the anterior part of 
the interlimb region. The RNA ISH and RT-qPCR performed on these AM-128 injected 
somites showed that they express more Gga-Eya4, Gga-Six4, and Gga-Pax3, but less 
Gga-MyoD1, compared to the contralateral non-injected somites. 
 
 We propose that after knock-down of miR-128 (inhibited by AM-128), Gga-Eya4 
could be de-repressed (fails to be downregulated) (miR-128 directly targets Gga-Eya4). 
More Gga-Eya4 transcripts would become available, and the chances for interacting with 
one of its SIX co-factors (SIX1 and/or SIX4), probably Gga-Six4 (based on RNA ISH 
and RT-qPCR results), would be increased (overexpression of Gga-Six4 in injected 
somites). Considering that Gga-Eya4 and Gga-Six4 could interact together, they would 
form a strong transcriptional complex able to potentially activate Gga-Pax3 
(overexpression of Gga-Pax3 in injected somites). This increase in Gga-Pax3 expression 
would prevent Gga-MyoD1 from being expressed (downregulation of Gga-MyoD1 in 
injected somites).  
 
What would happen in the context of a normal myogenesis when the different 
tissues composing a somite and the location of the different actors potentially involved in 
the proposed model are taken into account?  
MiR-128 would be necessary to downregulate Gga-Eya4 expression in the 
myotome. Gga-Eya4 being repressed, it could no longer interact with Gga-Six1/4 and 
form the SIX/EYA complex. Expressed in the dermomyotomal lips (dml and vll) and in 
the myotome, Gga-Six1/4, either repressor or weak activator on its own, would no longer 
be able to regulate the expression of its target Gga-Pax3 (de-repression of Gga-Pax3 in 
the dermomyotome after AM-128 injection (Fig. 5.2g)).  
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Pax3 being expressed in the dermomyotome it could suggest potential indirect 
mechanisms (FGF signalling) implying myotome/dermomyotome crosstalk/interaction. 
It is also possible that, similarly to what Goljanek-Whysall et al. showed with the 
regulation of Gga-Pax3 by miR-1/miR-206 (Goljanek-Whysall et al. 2011), miR-128 
could also regulate Gga-Pax3, either directly or not, in the dermomyotomal progenitor 
cells migrating to populate the central part of the myotome. With a decrease in Gga-Pax3, 
the initiation of the myogenic programme would become possible, with activation of the 
MRFs, such as MyoD1, in the myotome.  
 
 These functional experiments provided the first elements in order to better 
understand miR-128 functions in skeletal muscle development, in the chicken. 
Additional functional experiments will have to be done in order to consolidate the 
results presented in this chapter, and try to obtain more support for the proposed model. 
For example, a Gga-Eya4 expression construct has been generated (pCAB-Gga-Eya4 full 
length-HA tag) and could be used in overexpression experiments in order to see if it gives 
the same phenotype observed in the miR-128 loss-of-function experiments. An Eya4 
morpholino could also be used to try to rescue the phenotype observed after AM-128 
treatment.  
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CHAPTER 6: DISCUSSION AND CONCLUSION 
 
 
6.1. Summary and discussion 
 
 The aim of this project was to better understand the mechanisms underlying 
interactions between miRNAs and their mRNA targets, during skeletal muscle 
development. The investigation focused on miR-128, the interaction with one of its 
candidate targets, Eya4, and the potential impact of this interaction on myogenesis in the 
chicken embryo.  
 
6.1.1. MicroRNA characterisation 
 
 The expression patterns of 23 miRNAs, predicted to be expressed in skeletal 
muscle, were characterised by locked-nucleic acid in situ hybridisation (LNA ISH).  
 
The expression patterns observed for the muscle-specific miRNAs, or myomiRs, 
miR-1a, miR-133a/b, and miR-206 were consistent with profiles already published in 
chicken (Goljanek-Whysall et al. 2011; GEISHA database) and in Xenopus (Ahmed et 
al. 2015; XenmiR database). Moreover, these LNA ISH also provided new insights into 
their respective expressions. No expression information had been reported for miR-1a 
and miR-206 at early stages, and no somitic expression had been detected for miR-1a, 
miR-206 or miR-133a in the somites before HH14-15 (Geisha database).  
We observed that miR-1a was already expressed at HH9, in the heart. At HH11-
12, miR-133a was already strongly expressed in the heart and the most anterior somites, 
while miR-1a and miR-206 were just starting to be detectable in the most anterior somites 
at HH12-13 (Fig. 3.1; Fig. 3.2).  
 
Interestingly, with only one nucleotide of difference in the middle of its sequence 
compared to miR-1a, the expression of miR-1b was less specific with a lot of background 
in whole-mount. Sectioning showed that miR-1b was expressed in somites, in the 
myotome, at HH14-15 and onwards (Fig. 3.1).  
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MiR-133b and miR-133c had expression profiles similar to miR-133a. This could 
be explained by the fact that their sequences are extremely similar and only differ by 1 or 
2 nucleotides. However, their expression profiles were not identical indicating that even 
1 nucleotide of difference is enough to make a difference. This is also likely to be 
dependent on the positioning of the LNA within the probe, however the supplier (Exiqon) 
does not reveal this information. 
Interestingly, miR-133b and miR-133c seemed to start to be expressed with a 
slight delay compared to miR-133a. While miR-133a was already strongly represented in 
the somites at HH11-12, miR-133b was not expressed yet, and miR-133c was only just 
becoming detectable (Fig. 3.3). 
 
16 somitic miRNAs were also characterised, providing for most of them the first 
description of their expression patterns in the chicken embryo. All expressed in skeletal 
muscle, they displayed similar but also specific patterns in the somites, as well as other 
tissues for some of them (Fig. 3.4) (Ahmed et al. 2015). 
 
MiR-128, expressed in the neural tube and the developing somites at HH11-12, 
and from HH15, mostly in skeletal muscle tissues (differentiating somites, myotome, and 
limb buds) (Fig. 3.5), was selected for further investigation.  
 
MiR-128: myomiR? 
  
MiRNAs can be divided into two categories: miRNAs that are exclusively or 
preferentially expressed in muscle, the myomiRs (McCarthy 2008); and miRNAs 
expressed exclusively in non-muscle tissue or broadly expressed across many cell types. 
Both categories have significant impacts on muscle proliferation and differentiation 
(Wang 2013). 
The first miRNAs classified as myomiRs, were miR-1a, miR-133a and miR-133b, 
and miR-206 (Lagos-Quintana et al. 2002; McCarthy & Esser 2007; McCarthy 2008) due 
to their specific expression in skeletal muscle tissue. MiR-206 is expressed specifically 
in somites; miR-1a and miR-133a/b, as well as being expressed in the somites, are also 
found in the heart (Sempere et al. 2004; Sweetman et al. 2008). 
 
However, recently, the myomiR group has been extended to include miR-208a/b, 
miR-486 and miR-499 (van Rooij et al. 2007; van Rooij et al. 2009; Small et al. 2010).  
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To the exception of miR-208a, expressed predominantly in the heart (van Rooij et 
al. 2007), they are all expressed in both cardiac and skeletal muscles.  
Some studies have reported evidence that not all myomiRs are solely expressed in 
a muscle-specific manner but may be detected in low levels in other tissues; however, 
their main function has to be confined to muscle. For example, miR-486 is sometimes 
considered ‘muscle-enriched’ rather than ‘muscle-specific’ as it is also expressed in other 
tissues (lung, bladder in adult mouse) (Small et al. 2010; Lee et al. 2008). 
 
 MiR-128 was first identified in mouse, where its expression level increases during 
brain development, and is maintained in adult brain tissues (Lagos-Quintana et al. 2002; 
Smirnova et al. 2005). Xu et al. and Kapsimali et al. reported similar observations in 
chicken (18-day embryos) and zebrafish (3-day embryos) (Xu et al. 2006; Kapsimali et 
al. 2007).   
 MiR-128 was found in cardiac tissue. A study done by Witman et al, demonstrated 
that miR-128 regulates the expression of the transcription factor Islet1, a marker for 
cardiac progenitor cells, during newt cardiac regeneration (Witman et al. 2013). 
MiR-128 was also found in adult mouse muscle (Sempere et al. 2004; Lee et al. 
2008); adult and embryo porcine skeletal muscle (Zhou et al. 2010); and adult and embryo 
(somites) chicken skeletal muscle (Darnell et al. 2006; Lin et al. 2012; Abu-Elmagd et al. 
2015). In mouse, the inhibition of insulin receptor substrate 1, Irs1, by miR-128, leads to 
the inhibition of myoblast proliferation and induction of myotube formation (Motohashi 
et al. 2013). These results are consistent with the increase in miR-128 expression observed 
during myoblast differentiation in differentiating mouse C2C12 myoblast cells (Sun et al. 
2010). In addition, Shi et al. recently showed in mouse that ectopic expression of miR-
128 affected the expression of skeletal muscle proliferation and differentiation related 
genes, such as Pax3/7 and the MRFs (Myf5 and MyoD1) (Shi et al. 2015).  
 
With this present work, we showed by LNA ISH that miR-128 was expressed in 
skeletal muscle, but also in the neural tube at early stages during chicken development 
(Fig. 3.5). No expression in the heart was detected at any stages included in this study. 
 
Based on these observations, miR-128 does not seem to match the requirements 
for being classified as a skeletal muscle-specific myomiR, like miR-1a, miR-133a/b, and 
miR-206. However, it would be reasonable to classify miR-128 as a brain and muscle-
enriched miRNA. 
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6.1.2. MiR-128 target identification 
 
In order to better understand miR-128 function(s), predicted miR-128 targets were 
collected from TargetScan database (n=507). By using a combination of different 
computational tools (DAVID and g:Profiler), 10 ‘muscle’ targets were identified (Table 
3.6), and amongst them, Eya4, member of the PAX-SIX-EYA-DACH (PSED) network.  
 
Eya4, as well as other members of the PSED network (Six1/4, Eya1/2/3, and 
Dach1), were investigated further, due to the interesting role(s) they seem to play together 
with Pax3/7 during skeletal myogenesis.  
The miRanda algorithm was used to scan selected miRNA sequences against the 
3’UTR sequences of PSED genes (Table 3.7; APPENDIX III); and predicted miRNA 
sites were identified. This analysis showed that most of the members of the PSED network 
could potentially be targeted by miRNAs; importantly, miR-128 and myomiR sites were 
found in the 3’UTR sequences of most of these PSED members (chapter 3).  
Gga-Eya4 was predicted to be targeted by miR-1a/206, miR-27b/128, miR-133a 
and miR-499; Gga-Eya1 by miR-27b/128 and miR-133a; Gga-Eya3 by miR-133a; Gga-
Six1 by miR-1a/206; Gga-Six4 by miR-1a/206 and miR-499. 
 
In order to validate these miRNA/target interactions, predicted by bioinformatics 
tools, in vitro (chapter 4) and in vivo (chapter 5) experiments were undertaken.  
 
 MicroRNAs and regulation of target expression: 
 
 The effect of an individual miRNA on target expression level tends to be quite 
subtle. MiRNAs can use different strategies to accomplish significant regulation (Ebert 
& Sharp 2012).  
 
For example, a miRNA can target multiple sites for a given target conferring a 
stronger repression. More often, different miRNAs can work together to co-target a given 
mRNA, leading to a combined repressive effect exceeding their individual contributions. 
Another mechanism by which a miRNA can increase its impact is by targeting a 
set of genes that are in a shared pathway or protein complex. The reduction of 
concentration of several components in a signalling cascade induced by a miRNA can 
then potentially have a significant impact in the signal output over time. 
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The predicted involvement of several miRNAs, including miR-128 and the 
myomiRs, in the regulation of the expression of members of the PSED network (1) 
suggest that a strong regulation of this network is absolutely crucial; and (2) may indicate 
that a miRNA network, composed of miRNAs, that can work individually or in 
cooperation, would be able to act at different levels of the PSED cascade, which 
eventually could have an impact on myogenesis.   
 
6.1.3. MiR-128/Gga-Eya4 interaction 
 
Gga-Eya4, candidate target of miR-128 was cloned; a fragment of its coding and 
3’UTR sequences were cloned by PCR. Fragments of coding and 3’UTR sequences were 
also cloned for Gga-Six1, Gga-Six4, Gga-Eya1, Gga-Eya3 and Gga-Dach1. 
 
The coding sequence fragment cloned was used to make a probe for Gga-Eya4 
and RNA ISH was performed. Gga-Eya4 expression pattern was characterised for the first 
time in the model chicken. It was found in the somites at HH16; as the somites 
differentiated, Gga-Eya4 was expressed in the dorsomedial lip of the dermomyotome and 
the myotome. This pattern was similar to those of miR-128 (Fig. 4.3); miR-128 and Gga-
Eya4 were both expressed in the somites. 
 
 The predicted interaction between Gga-Eya4 and miR-128 was investigated. Gga-
Eya4 3’UTR constructs, WT and mutants, generated by FastCloning technique (Li et al. 
2011), were used to perform luciferase reporter assays. These assays showed that miR-
128 can target Gga-Eya4 3’UTR and reduce its expression activity (32% decrease in 
luciferase activity); activity being rescued after mutation of miR-128 site (93% of control) 
(Fig. 4.5). Other miRNAs were tested, and amongst them miR-206 was also shown to be 
able to target Gga-Eya4 3’UTR, with slightly weaker effect than observed for miR-128 
(24% decrease in luciferase activity; rescue: 92.5% of control) (Fig. 4.5); no changes were 
observed with miR-1a, miR-133a, and miR-499. A stronger effect was observed when si-
128 and si-206 were used in combination (Fig. 4.6). 
 
 Luciferase reporter assays also showed that miR-128 and miR-133a can target 
Gga-Eya1 3’UTR (37% and 19% decrease in luciferase activity, respectively), while 
miR-27b cannot, although it has the same seed sequence as miR-128 and was predicted 
to target the same site (Fig. 4.7a, b).  
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MiR-133a was also able to target Gga-Eya3 3’UTR (22% decrease in luciferase 
activity) (Fig. 4.7d). MiR-133a and miR-499 did not seem to be able to target Gga-Six4 
3’UTR. Other experiments were performed to determine if miR-1a and miR-206 could 
target Gga-Six1, Gga-Six4 and Gga-Dach1. Although a decrease in luciferase activity 
was observed, it could not be rescued after mutation of the different miRNA sites in their 
respective 3’UTR sequences. 
This could be explained by the presence of additional cryptic/non-canonical miR-
1a/206 sites, which were not predicted by the bioinformatics tools. Further investigations 
would have to be done in order to confirm Gga-Six1, Gga-Six4 and Gga-Dach1 as targets 
of miR-1a and miR-206. 
 
 RNA probes were also generated for Gga-Six1, Gga-Six4, Gga-Eya1, Gga-Eya2, 
Gga-Eya3, and Gga-Dach1, and RNA ISH performed on chicken embryos at different 
stages of development (Fig. 4.10). Similar expression to those already published were 
observed for Gga-Six1, Gga-Six4, Gga-Eya1, Gga-Eya2, and Gga-Dach1 (Esteve & 
Bovolenta 1999; Ishihara et al. 2008; Heanue et al. 1999; Mishima & Tomarev 1998; 
Heanue et al. 2002; Kida et al. 2004).  
Gga-Eya2, expressed earlier than Gga-Eya1, and Gga-Eya4, displayed a strong 
and dynamic expression in the developing somites, the dermomyotome and the myotome; 
however, Gga-Eya1 could not be detected in the dermomyotome, and neither Gga-Eya1 
nor Gga-Eya2 were found in the limb buds. Gga-Six4 was present in the head region, the 
notochord, in somites, in the dermomyotome and the myotome. Gga-Six1 was expressed 
in the somites, in the myotome, however it was not found in the dermomyotome; and 
Gga-Dach1 was expressed in the neural tube at HH11-12, however it was not found in 
the somites or the developing limb buds as previously reported. 
Gga-Eya3, which had not been characterised in chicken before, seemed to have a 
similar expression than what was described in mouse and zebrafish; with a widespread 
expression in whole-mount, Gga-Eya3 was expressed in the neural tube and developing 
somites at HH11-12, and in the dermomyotome and myotome at HH21-22.  
 
MiR-128 and Gga-Eya4 – overlapping expression: 
 
Gga-Eya4 and miR-128 display very similar profiles, especially in the somites 
from HH16.  
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Therefore, because Gga-Eya4 and miR-128 expression patterns are not exclusive, 
miR-128 is more likely to be a regulator/modulator of Eya4 expression rather than an 
absolute repressor.  
This is consistent with the ‘miRNA buffer-like’ model described by Hornstein and 
Shomron (Hornstein & Shomron 2006), where miRNA and target are co-expressed in 
intermediate levels. This model is to oppose to the ‘anti-correlated’ model where miRNA 
and target are expressed in mutually exclusive domains; miRNA expression level being 
typically higher than the target in order to efficiently prevent target expression.  
 
This co-expression model suggests that the miRNA could play a role in buffering 
fluctuations in target expression at a post-transcriptional level. Reduction of this ‘genetic 
noise’ by the miRNA leading to the modulation of target expression level (bringing target 
gene expression back to its mean level) would be consistent with the fact that this target 
might serve different purposes from primary gene regulation (Hornstein & Shomron 
2006; Shkumatava et al. 2009; Ebert & Sharp 2012). 
 
In the case of the EYA family members, like Eya4, it has been shown that as well 
as being transcriptional cofactors, they are also protein tyrosine/threonine phosphatases 
(Rebay 2015); they belong to the phosphatase subgroup of the haloacid dehalogenase 
(HAD) superfamily. For example, Li et al. showed that EYA’s tyrosine phosphatase 
activity could be necessary in order to switch Six1-Dach1 complexes from repressive to 
activating (Li et al. 2003). This suggests a potential role for EYA as a phosphatase in the 
process of myogenesis. 
Three other protein substrates have been identified: the histone H2AX playing a 
role in the repair versus apoptosis response to DNA damage (Cook et al. 2009; Krishnan 
et al. 2009); atypical protein kinase C zeta (aPKCζ) important in the process of epithelial 
polarity and asymmetric cell division (El-Hashash et al. 2011; El-Hashash et al. 2012); 
estrogen receptor beta (ERβ) involved in Six-independent modes of transcriptional 
regulation (Yuan et al. 2014). None of these three implicate EYA phosphatase activity in 
regulating EYA-SIX-mediated transcriptional events, suggesting new roles for EYA 
(Rebay 2015).  
These elements and the overlapping expression of miR-128 and Gga-Eya4 in the 
somites observed by ISH suggest that a basal level of EYA4 expression might be 
necessary in this tissue; EYA4 being both transcription cofactor and protein phosphatase 
could also be involved in processes other than myogenesis. 
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Gga-Eya4: co-regulation by miR-128 and miR-206? 
 
Due to their short sequences, miRNAs can interact and regulate several hundred 
targets. For example, miR-128 is predicted to target 507 mRNAs. On the other hand, since 
the 3’UTR of an mRNA often displays multiple sites that can be targeted simultaneously, 
a cooperative effect of miRNA targeting can be expected (Selbach et al. 2008; Bartel 
2009; Friedman et al. 2009).  
MiRNAs can exert synergistic regulatory effects through 2 mechanisms:  (1) a 
3’UTR having target sites to multiple miRNAs; and (2) a 3’UTR with multiple target sites 
to the same miRNA. These miRNA sites have to be close to each other (around 100 
nucleotides) (Lu & Clark 2012).  
 
 During this work looking at the interaction between miR-128 and Gga-Eya4, other 
miRNAs were also identified and predicted to target Gga-Eya4; amongst them, miR-206.  
MiR-128 and miR-206 sites are 162 bp apart.  
 The luciferase reporter assays performed showed that miR-128, and miR-206, 
could target Gga-Eya4 3’UTR and reduce its expression activity; activity which was 
rescued after mutation of miR-128 and miR-206 sites, respectively (Fig. 4.5). 
Interestingly, when si-128 and si-206 were used in combination, a stronger effect was 
observed.  
 This suggests that miR-128 and miR-206, which can target Gga-Eya4 3’UTR on 
their own (39% and 24% decrease in luciferase activity, respectively (50 nM each)), might 
also be able to work in cooperation in order to have a stronger effect on the regulation of 
Gga-Eya4 expression (miR-128+miR-206: 51% decrease in luciferase activity (25 nM 
each)). Their combined effect was similar to the sum of their separate effect at the same 
final dose; although each siRNA was used at half the concentration compared to the 
experiment where they were tested on their own.  
With these results it is only possible to conclude on a potential additive effect 
between miR-128 and miR-206. More experiments, for example combining si-206 with 
siC, using miR-206 mutant or miR-128/miR-206 double mutant constructs, would have 
to be undertaken in order to determine a potential synergistic effect.  
Either additive or synergistic, this effect observed in vitro, would have to be tested 
in vivo, where potential upstream transcription factor regulation might have an effect on 
this cooperativity between miR-128 and miR-206 and the downstream miRNA target 
expression.  
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 6.1.4. MiR-128/Gga-Eya4 interaction, PSED network and myogenesis 
 
 Predicted by bioinformatics tools (chapter 3) and validated by in vitro luciferase 
reporter assays (chapter 4), the interaction between miR-128 and Gga-Eya4 in the chicken 
embryo, as well as its impact on skeletal muscle myogenesis was investigated. 
 
 MiR-128/Gga-Eya4 interaction was validated by RNA ISH and RT-qPCR after 
AM-128 injection (in vivo). After AM-128 injection, a significant increase in Gga-Eya4 
was observed (1.5-fold increase; 8 independent experiments; t-test: p<0.05). In addition, 
a significant increase in Gga-Six4 and Gga-Pax3 expression levels was observed (Gga-
Six4: 1.25-fold increase; 7 independent experiments; t-test: p<0.05; Gga-Pax3: 1.3-fold 
increase; 8 independent experiments; t-test: p<0.001), whereas Gga-MyoD1 expression 
was decreased (Fig. 5.3). 
 
 MiR-128/Gga-Eya1, miR-206/Gga-Eya4, miR-133/Gga-Eya1 and miR-133/Gga-
Eya3 interactions were also investigated by RT-qPCR.  
After AM-128 and AM-133 injections, a significant increase in Gga-Eya1 
expression level was observed (after AM-128 injection: 19%; 10 independent 
experiments; t-test: p<0.05; after AM-133 injection: 1.25-fold increase; 5 independent 
experiments; t-test: p<0.001), but not for Gga-Eya3 (Fig. 5.3). After AM-128, AM-133 
and AM-206 injections, the expression levels of Gga-Six4 and Gga-Pax3 were increased, 
and Gga-MyoD1 and Gga-Myf5 decreased (Fig. 5.4a, b). 
 
MiR-128/Gga-Eya4 interaction and myogenesis: 
  
 The functional experiments showed that disrupting the interaction between miR-
128 and Gga-Eya4, by blocking miR-128 with AM-128, not only had an impact on Gga-
Eya4 expression (de-repression), but also on the PSED members Gga-Six1/4, Gga-Pax3 
(de-repression), and on the MRF Gga-MyoD1 (downregulation). This suggest that Gga-
Eya4 might be upstream of Gga-Six1/4, Gga-Pax3 and Gga-MyoD1. 
 
 Furthermore, it has been shown that SIX and EYA can interact together to form a 
transcriptional activator complex, and one of the known targets of SIX is PAX3 (Heanue 
et al. 1999; Ohto et al. 1999; Grifone et al. 2005).  
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PAX3 downregulation is essential to initiate the myogenic programme, and 
myogenic differentiation is characterised by the activation of the MRFs (Goulding et al. 
1994; Williams & Ordahl 1994; Maroto et al. 1997; Gros et al. 2004; Bajard et al. 2006). 
 
 Taken together, it is tempting to hypothesise that in the absence of miR-128, Gga-
Eya4 would interact with Gga-Six1/4, and form an activator complex able to regulate 
Gga-Pax3. Expression of Pax3, being maintained, would prevent the MRF Gga-MyoD1 
from being activated (Fig. 5.6).  
 
 These are the potential effects that miR-128/Gga-Eya4 interaction could have in 
the context of the PSED network and Gga-Eya4 as a transcription factor during 
myogenesis. Another aspect to consider would be the fact that Gga-Eya4 is also a protein 
tyrosine/threonine phosphatase; therefore, the regulation of Gga-Eya4 by mir-128 could 
also have onward effects via alternative roles of the Eya4 protein during myogenesis (Li 
et al. 2003), or other processes (Rebay 2015). 
   
  
6.2. Future work 
 
 Despite achieving the overall aim of this project, there are a number of areas that 
can be developed further in the future, in order to consolidate the results presented and 
try to validate, or not, the proposed model. 
 
Additional luciferase reporter assays: 
 
 Other interesting interactions than the one between miR-128 and Gga-Eya4 were 
also identified during this work, constructs (WT and mutants) were generated and 
luciferase reporter assays were performed. Although these assays showed promising 
results, they were not completely successful; they did not give the complete rescue of 
luciferase activity expected after mutation of the miRNA sites. This was the case for the 
interactions between miR-128 and Gga-Eya1 (Fig. 4.7b), miR-1a/206 and Gga-Six1 (Fig. 
4.8a), miR-1a/206 and Gga-Six4 (Fig. 4.8d), and miR-1a/206 and Gga-Dach2 (Fig. 4.9a).  
 
Building on some interesting in vivo results (Fig. 5.3; Fig. 5.4a), these experiments 
will have to be repeated to make the results statistically significant.  
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For the assays involving miR-1a/206, if no improvement in the rescue experiments 
is observed, we could look for potential cryptic miRNA sites in Gga-Six1, Gga-Six4 and 
Gga-Dach2 3’UTR sequences; if such sites can be identified, they will then have to be 
mutated.  
 
 The pilot experiment looking at miRNA synergism could also be completed (Fig. 
4.6). Different combinations of constructs and siRNAs would be used.  
In order to investigate further the potential synergism identified between miR-128 
and miR-206 in the regulation of Gga-Eya4 expression, the miR-128/miR-206 double 
mutant construct will need to be generated.  
 
Additional functional experiments: 
 
To completely validate the results observed in the RNA ISH and RT-qPCR 
performed after miRNA-128 loss-of-function (Fig. 5.2; Fig. 5.3), AM-128 injection 
experiments will be repeated in order to increase the number of embryos for each 
condition. The same experiments but using a control antagomiR (AM-scr) will also be 
done, and RNA ISH will be performed for the different PSED members and MRFs.   
 
In order to investigate further miR-128/Gga-Eya4 interaction, gain-of-function 
and rescue experiments will also be done. A Gga-Eya4 expression construct has already 
been generated (pCAB(Gga-Eya4 full length-HA tag)) and will be used to perform 
overexpression experiments in order to see if it gives the same phenotype observed in the 
miR-128 loss-of-function experiments. In order to try to rescue the phenotype observed 
after AM-128 treatment it should be possible to use morpholinos directed against Gga-
Eya4.  
 
New interesting miRNA/target interactions: 
 
 In parallel to the main project focussing on miR-128 and Gga-Eya4, a group of 
miRNAs, with somitic expressions, were also characterised and bioinformatics tools 
allowed to identify potential relevant targets in skeletal muscle tissue. This analysis 
provided precious information that could be used in the future in order to investigate new 
potential miRNA/target interactions, and determine the function(s) these miRNAs could 
have in skeletal muscle tissue (see chapter 3; APPENDIX II Table 3). 
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6.3. Conclusion 
 
 Over the past decade and a half, miRNAs have emerged as key component of gene 
regulation underlying the skeletal muscle development and function. 
 
 With this project, using a combination of cell-based experiments and whole-
embryo studies, we showed that miR-128 could play an important role in the regulation 
of skeletal muscle myogenesis by targeting Gga-Eya4, a member of the PSED network.  
 The regulation of Eya4 by miR-128 could be one of the upstream regulatory steps 
contributing to the necessary downregulation of Pax3, in order to initiate the myogenic 
programme, characterised by activation of the MRFs. 
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ABBREVIATIONS 
 
 
µL  microliter 
AER  Apical ectodermal ridge 
AGO  Argonaute 
AM  AntagomiR 
AMP  Adenosine monophosphate 
ANK1  Ankyrin 1 
aPKCζ atypical protein kinase C zeta 
BBR  Boehringer Mannheim Blocking Reagent 
BCIP  5-bromo-4-chloro-3-indolyl-phosphate 
bHLH  Basic helix-loop-helix 
BLAST Basic Local Alignment Search Tool 
BMP  Bone morphogenetic protein 
BOR  Branchio-oto-renal 
bp  base pair 
CaCl2  Calcium chloride 
CaM  calmodulin 
CBP  CREB-binding protein 
cDNA  complementary DNA 
CHAPS 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate 
DACH dachshund-related homeobox 
DCM  Dilated cardiomyopathy 
DEPC  Diethylpyrocarbonate 
DIG  Digoxigenin 
DMEM Dulbecco’s modified eagle medium 
DMF  Dimethylformamide 
DNA  Deoxyribonucleic acid 
dNTP  Deoxynucleotide 
DTT  Dithiothreitol 
E  Mouse embryonic day of development 
ECM  Extracellular matrix 
ED  EYA domain 
EDTA  Ethylenediaminetetraacetic acid 
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EMT  Epithelial-to-mesenchymal transition 
ERβ  Estrogen receptor beta 
ERK  Extracellular signal-regulated kinase 
EXP5  Exportin 5 
EYA  eyes absent-related homeobox 
FGF  Fibroblast growth factor 
Fig  Figure 
FITC  Fluorescein isothiocyanate 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GFP  Green fluorescent protein 
Gga  Gallus gallus 
GO  Gene Ontology 
GTP  Guanosine-5’-triphosphate 
h  hour 
H2O  Water 
HA  Human influenza hemagglutinin 
HAD  Haloacid dehalogenase 
HCl  Hydrochloric acid 
HD  Homeodomain 
HDAC Histone deacetylase 
HF  High fidelity 
HH  Hamburger-Hamilton stage 
Hsa  Homo sapiens 
IRS1  Insulin receptor substrate 1 
ISH  in situ hybridisation 
KAc  Potassium acetate 
kb  kilo-base 
KCl  Potassium chloride 
LB  Lysogeny Broth 
Lfng  Lunatic Fringe 
LNA  Locked-nucleic acid 
Log  Logarithm 
MAB  Maleic acid buffer 
MABT Maleic acid buffer supplemented with Tween-20 
MAPK Mitogen-activated protein kinase 
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MAPKAPK2 Mitogen-activated protein kinase activated-protein kinase 2 
MCS  Multiple cloning site 
MEF2  Myocyte enhancer factor 2 
MET  Mesenchymal-to-epithelial transition 
MgCl  Magnesium chloride hexahydrate 
MHC  Myosin heavy chain 
MiR  MicroRNA 
MiRISC MiRNA/RISC 
MiRNA MicroRNA 
Mmu  Mus musculus 
MnCl2  Manganese chloride 
MO  Morpholino 
MOPS 3-(N-morpholino) propane sulfonic acid 
MPC  Myogenic progenitor cell 
MRE  MicroRNA response element 
MRF  Myogenic regulatory factor 
MRF4  Myogenic regulatory factor 4 
mRNA messenger RNA 
mTOR Mammalian target of rapamycin 
mut  mutant 
MYF5  Myogenic factor 5 
MYOD1 Myogenic differentiation 1 
MYOG Myogenin 
NaCl  Sodium chloride 
NaOH  Sodium hydroxide 
NBT  4-nitro-blue tetrazolium chloride 
ng  nanogram 
NGS  Next generation sequencing 
NMD  Nonsense-mediated decay 
nt  nucleotide 
PAX  Paired-box 
PBS  Phosphate-buffered saline 
PBT  Phosphate-buffered saline supplemented with Tween-20 
PCR  Polymerase chain reaction 
PFA  Paraformaldehyde 
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Pre-miRNA Precursor microRNA 
Pri-miRNA Primary microRNA 
PSED  PAX-SIX-EYA-DACH 
PSM  Pre-somitic mesoderm 
RA  Retinoic acid 
RbCl2  Rubidium chloride 
RISC  RNA-induced silencing complex 
RMS  Rhabdomyosarcoma 
RNAa  RNA activation 
RNasin Ribonuclease inhibitor 
rpm  revolutions per minute 
RT-qPCR Real-time quantitative PCR 
Scr  Scrambled 
SD  SIX domain 
SEM  Standard error of the mean 
SHH  Sonic hedgehog 
siC  Control small interfering RNA 
SIX  sine oculis-related homeobox 
SRF  Serum response factor 
SSC  Saline sodium citrate 
TAE  Tris base-acetic acid-EDTA 
TM  Melting temperature 
TRBP  Transactivation response cytoplasmic RNA-binding protein 
tRNA  torula RNA 
UTR  Untranslated region 
UV  Ultraviolet 
v/v  volume (of solute) per volume (of solvent) 
WMISH Whole-mount in situ hybridisation 
WT  Wild-type 
w/v  weight (of solute) per volume (of solvent) 
Xtr  Xenopus tropicalis 
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APPENDIX I 
 
 
Table 1: Primers to generate ISH probes. 
Genes Primers Sequences (5’-3’) 
Eya1 
ggaEya1(ISH)-F GCTTCGCCCATCTGGAAAAC 
ggaEya1(ISH)-R GCTGGCACCGTAGCTTAGAA 
Eya2 
ggaEya2(ISH)-F ACATTTATGCCACGGCTCCA 
ggaEya2(ISH)-R GCACAGACGTTGTTGTGTCC 
Eya3 
ggaEya3(ISH)-F CCCAGACCACCCAAACCTAC 
ggaEya3(ISH)-R ATGGTCTCATCCAGGTCCCA 
Eya4 
ggaEya4(ISH)-F CTCCGAACGCCAGGTCTATG 
ggaEya4(ISH)-R GGAGGGGCTCTGTACTGTGT 
Six1 
ggaSix1(ISH)-F ATGTCGATGCTGCCGTCGTT 
ggaSix1(ISH)-R TTAGGAGCCCAGGTCCACCA 
Six4 
ggaSix4(ISH)-F TGGAGAGCCACAACTTCGAC 
ggaSix4(ISH)-R ACACCAGATGAGCTCAAGGC 
Dach1 
ggaDach1(ISH)-F GCCTCGGGGACAAACCTATT 
ggaDach1(ISH)-R CCTGGGACAGAATGTGGCAT 
Dach2 
ggaDach2(ISH)-F CTCACCAACAGCCTCGTCAA 
ggaDach2(ISH)-R CTGCCCTGGAAAGAGGACTG 
 
 
Table 2: Primer sequences for PCR amplification of the 3’UTR region of PSED 
members. For sub-cloning purpose, restriction sites (bases underlined) were added to the 
5’ end of the primers. BglII (AGATCT), NheI (GCTAGC).  
Genes Primers Sequences (5’-3’) 
Eya1 
ggaEya1(3UTR-BglII)-F1 GC AGATCT CAGCTCAGCAGCACTTTGAA 
ggaEya1(3UTR-NheI)-R1 AT GCTAGC CTGACTCCTGGTGGAAGAGG 
ggaEya1(3UTR-BglII)-F2 AG AGATCT CAACTACCTGCAAAGCTGCG 
ggaEya1(3UTR-NheI)-R2 GC GCTAGC TCAATGTAGCAACAAAACCCAG 
Eya2 
ggaEya2(3UTR-BglII)-F AT AGATCT CAGACCCCAACATCTTAGCA 
ggaEya2(3UTR-NheI)-R AT GCTAGC TCCCACCCAAACTGAGATGG 
Eya3 
ggaEya3(3UTR-BglII)-F AT AGATCT GTAGTCTCCAGAGGGAGGGG 
ggaEya3(3UTR-NheI)-R AT GCTAGC CTGTGGCATCTGTGGTCTGA 
Eya4 
ggaEya4(3UTR-BglII)-F AG AGATCT TGTTCTAAAGTTGGCGATCCT 
ggaEya4(3UTR-NheI)-R CT GCTAGC CACTCACTGCATGGCTTTCA 
Six1 
ggaSix1(3UTR-BglII)-F AT AGATCT TAGCCAAATGCAGAGAGCGG 
ggaSix1(3UTR-NheI)-R AT GCTAGC CGGCTGTTCGGGTACAATAGA 
Six4 
ggaSix4(3UTR-BglII)-F1 AT AGATCT GGAGAAAGGAAACGCCAGGG 
ggaSix4(3UTR-NheI)-R1 AT GCTAGC AGGATGTGCTTTTCCACGCTA 
ggaSix4(3UTR-BglII)-F2 GC AGATCT ATGGGTGTCCTCTCCCTTCA 
ggaSix4(3UTR-NheI)-R2 AT GCTAGC TGTACCGTGCAACGAGTCTTTA 
ggaSix4(3UTR-BglII)-F3 AT AGATCT ACCTCCCGTTCTTTCGTGG 
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ggaSix4(3UTR-NheI)-R3 AT GCTAGC GGACCCTGCATGTCTGTTTCA 
Dach1 
ggaDach1(3UTR-BglII)-F1 AT AGATCT CCTGCTGAAGATACCTGTGCT 
ggaDach1(3UTR-NheI)-R1 GC GCTAGC TGTGTACCAGTATTGCAAGGAAG 
ggaDach1(3UTR-BglII)-F2 GC AGATCT TGCCTCATTGTTTGGCTTGG 
ggaDach1(3UTR-NheI)-R2 AT GCTAGC AACAACTGGATTACCCTCTCTG 
 
 
Table 3: Mutagenesis primers. Bases constituting miRNA sites are underlined. Mutated 
nucleotides are indicated in red. 
Genes Primers Sequences (5’-3’) 
Eya1 
ggaEya1-1 
(3UTR-m133a)-F 
TAGATAAATTTGTCAGGTACCAAAGCATGGATGT
CAAGTGTCAATATG 
ggaEya1-1 
(3UTR-m133a)-R 
CATATTGACACTTGACATCCATGCTTTGGTACCT
GACAAATTTATCTA 
ggaEya1-1 
(3UTR-m128/27(1))-F 
AGAACAGCTGTTGACTCTGGTGCGGCCGCTCCAA
CAAAAATAAGCCA 
ggaEya1-1 
(3UTR-m128/27(1))-R 
TGGCTTATTTTTGTTGGAGCGGCCGCACCAGAGT
CAACAGCTGTTCT 
ggaEya1-1 
(3UTR-m128/27(2))-F 
AGGAAATAAAGGTTCGTACCGGTACCAAAAGGAC
CTGCAAGTGCTTTG 
ggaEya1-1 
(3UTR-m128/27(2))-R 
CAAAGCACTTGCAGGTCCTTTTGGTACCGGTACG
AACCTTTATTTCCT 
Eya3 
ggaEya3 
(3UTR-m133a)-F 
CTGTTAATGAGCAGATCTTCATTAGATTCCAGCT
GTCCATGAC 
ggaEya3 
(3UTR-m133a)-R 
GTCATGGACAGCTGGAATCTAATGAAGATCTGCT
CATTAACAG 
Eya4 
ggaEya4 
(3UTR-m128/27)-F 
TTTGTGTAAATTATTGATGAAAATAACTTACCAT
GGCTTTATTAGCAGCTGATTTT 
ggaEya4 
(3UTR-m128/27)-R 
AAAATCAGCTGCTAATAAAGCCATGGTAAGTTAT
TTTCATCAATAATTTACACAAA 
ggaEya4 
(3UTR-m1a/206)-F 
CAAAGTGGTGTTCAACAAGCTTCCTCAAAATGGG
ATATATTCTCAG 
ggaEya4 
(3UTR-m1a/206)-R 
CTGAGAATATATCCCATTTTGAGGAAGCTTGTTG
AACACCACTTTG 
ggaEya4 
(3UTR-m133a)-F 
GTATGTTGGGAGGTTGATAGTGGCTAGCGCTACC
TTGAAAGCTAAAAAAGA 
ggaEya4 
(3UTR-m133a)-R 
TCTTTTTTAGCTTTCAAGGTAGCGCTAGCCACTA
TCAACCTCCCAACATAC 
ggaEya4 
(3UTR-m499)-F 
TCTGGCTTTACACATATGAATAAGCTTAAGAAGG
GAAGAAATATTTGGAATTAAAA 
ggaEya4 
(3UTR-m499)-R 
TTTTAATTCCAAATATTTCTTCCCTTCTTAAGCT
TATTCATATGTGTAAAGCCAGA 
Six1 
ggaSix1 
(3UTR-m1a/206)-F 
AGGGGAACTTTTTCGTGAGCTCTTCTTTTTTTTC
ATATTTAGCTTC 
ggaSix1 
(3UTR-m1a/206)-R 
GAAGCTAAATATGAAAAAAAAGAAGAGCTCACGA
AAAAGTTCCCCT 
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Six4 
ggaSix4-1 
(3UTR-m133a)-F 
AAGGATTGTGCCGAGCGGCCGCGTGCAGAGCAGT
GCAGAGCAGTGCAG 
ggaSix4-1 
(3UTR-m133a)-R 
CTGCACTGCTCTGCACTGCTCTGCACGCGGCCGC
TCGGCACAATCCTT 
ggaSix4-3 
(3UTR-m1a/206)-F 
GTCGTACTTAATTGGCTAGCTCAGCCACATCAGT
CGTGGACGCCTAT 
ggaSix4-3 
(3UTR-m1a/206)-R 
ATAGGCGTCCACGACTGATGTGGCTGAGCTAGCC
AATTAAGTACGAC 
ggaSix4-3 
(3UTR-m499)-F 
AGATATTTAAATAGTCCATGGACTCCTACTGTAA
ATTAAGGGTTGG 
ggaSix4-3 
(3UTR-m499)-R 
CCAACCCTTAATTTACAGTAGGAGTCCATGGACT
ATTTAAATATCT 
Dach1 
ggaDach1-2 
(3UTR-m1a/206)-F 
CTACATGATTTATTTATGTCCATGGCTCAGTTTA
TGAAGCTGTTAT 
ggaDach1-2 
(3UTR-m1a/206)-R 
ATAACAGCTTCATAAACTGAGCCATGGACATAAA
TAAATCATGTAG 
ggaDach1- 
2(3UTR-m1a-2)-F 
ACCTTTTTTTATATATTGTGAAGATCTCATGATT
CTTATTTCAGA 
ggaDach1-2 
(3UTR-m1a-2)-R 
TCTGAAATAAGAATCATGAGATCTTCACAATATA
TAAAAAAAGGT 
 
 
Table 4: Gga-Eya4 Full-length primers. For sub-cloning purpose, restriction sites 
(bases underlined) were added to the 5’ end of the primers. NotI (GCGGCCGC), EcoRI 
(GAATTC). Start and stop codons are indicated in red. The HA-tag is indicated in italic. 
Genes Primers Sequences (5’-3’) 
Eya4 
ggaEya4 
(NotI/ATG)-F 
GC GCGGCCGC ATG GAAGACTCTCAGGACCTA 
ggaEya4 
(EcoRI/stop/HA)-R 
GC GAATTC TTA 
AGCGTAATCTGGAACATCGTATGGGTA 
CAAATACTCTAGTTCCAG 
 
 
Table 5: Other primers used for sequencing and mutagenesis. 
Genes Primers Sequences (5’-3’) 
pGL3 
pGL3-F CTCATCAATGTATCTTATCATGTC 
pGL3-R CCTCATAAAGGCCAAGAA 
AmpR 
Amp_GA_1-F CAACTTTATCCGCCTCCATCCAGTCTAT 
TAATTGTTGCCGGGAAGCT 
Amp_GA_1-R GGAGCTGAATGAAGCCATACCAAACGACGAGCGT
GA 
pCAB 
pCAB-F GGCAGGAAGGAAATGGGCGGGGA 
pCAB-R GGCCCTCACATTGCCAAAAGACG 
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Table 6: AntagomiR sequences. All bases were replaced by 2’O-methyl-bases, and 
some phosphodiester bonds were replaced by thiol bonds, indicated in the sequences by 
‘m’ and ‘*’, respectively. The antagomiRs were FITC-labelled at their 5’ end (Fl), and 
included a 3’ cholesterol moiety at their 3’ end (Chl). 
AntagomiR Sequences (5’-3’) 
AntagomiR-206 
(AM-206) 
(Fl)mC(*)mC(*)mAmCmAmCmAmCmUmUmCmCmUmUmAmCmAm
UmU(*)mC(*)mC(*)mA(Chl) 
AntagomiR-133 
(AM-133) 
(Fl)mA(*)mC(*)mAmGmCmUmGmGmUmUmGmAmAmGmGmGmGm
AmC(*)mC(*)mA(*)mA(Chl) 
AntagomiR-128 
(AM-128) 
(Fl)mA(*)mA(*)mAmGmAmGmAmCmCmGmGmUmUmCmAmCmUm
G(*)mU(*)mG(*)mA(Chl) 
AntagomiR-scrambled 
(AM-scr) 
(Fl)mC(*)mA(*)mUmCmCmAmUmCmAmCmUmCmAmCmUmCmCm
AmU(*)mC(*)mA(*)mU(Chl) 
 
 
Table 7: qPCR primers. 
Genes Primers Sequences (5’-3’) 
Eya1 
gga-Eya1q-F CCGTATCCCTCGCATTACATG 
gga-Eya1q-R CTGGTATGTTGCGTTTGTGG 
Eya2 
gga-Eya2q-F CGGCTCCAGATGACATAGAAG 
gga-Eya2q-R GGATTCCTGCACTGTACTGAG 
Eya3 
gga-Eya3q-F AGAGCCACAAGATTTACCCG 
gga-Eya3q-R CAGTTGACATGGGAAGGTTTG 
Eya4 
gga-Eya4q-F GAATCAGATGTGTCAGAGCCTC 
gga-Eya4q-R TTTATCCAGTTTAGAGCTACCCG 
Six1 
gga-Six1q-F TCCTCAAGGCCAAAGCG 
gga-Six1q-R CTTCTCGGCTTCCACGTAG 
Six4 
gga-Six4q-F ATTTATCCCCACATCCGCTC 
gga-Six4q-R ACGAGGTTCCCATTCAACAG 
Dach1 
gga-Dach1q-F GATTTCGAGACCCTCTACAACG 
gga-Dach1q-R GATTCCAGGAGACATTAGGCC 
Pax3 
gga-Pax3q-F CCAACTGATGGCTTTTAACCAC 
gga-Pax3q-R CTATGGACTGTACTGCTTGGATC 
MyoD1 
gga-MyoD1q-F ACTTCCACCAACCCCAAC 
gga-MyoD1q-R TCTGACTCCCCGCTGTAG 
Myf5 
gga-Myf5q-F CAACCCCAACCAGAGACTCC 
gga-Myf5q-R GAGTCCGCCATCACATCGGA 
MyoG 
gga-MyoGq-F AGCTGGAGTTTGGCACC 
gga-MyoGq-R GAGAGCGAGTGGAGGTTG 
 
 
 
 
 
207 
 
APPENDIX II 
 
 
Table 1: MiRNA sequences used to run the miRanda algorithm. 
 
CHICKEN MiRNA 
ACCESSION 
NUMBER 
SEQUENCE (5’-3’) 
gga-miR-1306-3p MIMAT0007329 ACGUUGGCUCUGGUGGUG 
gga-let-7a-5p MIMAT0001101 UGAGGUAGUAGGUUGUAUAGUU 
gga-miR-1a-3p MIMAT0001127 UGGAAUGUAAAGAAGUAUGUA 
gga-miR-1b-3p MIMAT0001175 UGGAAUGUUAAGAAGUAUGUA 
gga-miR-10b-5p MIMAT0001148 UACCCUGUAGAUCCGAAUUUGU 
gga-miR-15a MIMAT0001117 UAGCAGCACAUAAUGGUUUGU 
gga-miR-15b-5p MIMAT0001154 UAGCAGCACAUCAUGGUUUG 
gga-miR-15c-5p MIMAT0007737 UAGCAGCACAUCAUGGUUUGUA 
gga-miR-17-5p MIMAT0001114 CAAAGUGCUUACAGUGCAGGUAGU 
gga-miR-18b-5p MIMAT0001141 UAAGGUGCAUCUAGUGCAGUUA 
gga-miR-23b-3p MIMAT0001186 AUCACAUUGCCAGGGAUUACC 
gga-miR-24-3p MIMAT0001188 UGGCUCAGUUCAGCAGGAACAG 
gga-miR-27b-3p MIMAT0001187 UUCACAGUGGCUAAGUUCUGC 
gga-miR-30a-5p MIMAT0001135 UGUAAACAUCCUCGACUGGAAG 
gga-miR-31-5p MIMAT0001189 AGGCAAGAUGUUGGCAUAGCUG 
gga-miR-128-3p MIMAT0001123 UCACAGUGAACCGGUCUCUUU 
gga-miR-130a-3p MIMAT0001167 CAGUGCAAUGUUAAAAGGGC 
gga-miR-133a-3p MIMAT0001126 UUGGUCCCCUUCAACCAGCUGU 
gga-miR-133b MIMAT0001138 UUGGUCCCCUUCAACCAGCUA 
gga-miR-133c-3p MIMAT0001176 UUGGUCCCCUUCAACCAGCUGC 
gga-miR-194 MIMAT0001133 UGUAACAGCAACUCCAUGUGGA 
gga-miR-203a MIMAT0001146 GUGAAAUGUUUAGGACCACUUG 
gga-miR-206 MIMAT0001139 UGGAAUGUAAGGAAGUGUGUGG 
gga-miR-223 MIMAT0001140 UGUCAGUUUGUCAAAUACCCC 
gga-miR-499-5p MIMAT0003367 UUAAGACUUGUAGUGAUGUUUAG 
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Table 2: Summary of miRNA expression in different tissues in chicken embryo. 
 
 
 
 
 
 
 
Table 3: Somitic miRNAs – Bioinformatics analysis. Gene ontology (GO) term and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation analysis 
performed using the Database for Annotation, Visualisation and Integrated Discovery 
tool (DAVID Bioinformatics resources). For each miRNA, the number of predicted 
targets is indicated. Genes from categories of interest (for example: Developmental 
process, signalling pathways, muscle) have been listed. Genes from the PSED network 
have been underlined. 
 
 
 
 
 
miRNA Somites Neural Tube Notochord Heart Mesonephros
gga-miR-1306-3p ✓ ✓(HH21-22; ventral) ✓ ✓ ✓
gga-let-7a-3p ✓ ✓(dorsal; ventral) ✓
gga-miR-1a ✓ ✓
gga-miR-1b ✓ ✓(early stage) ✓(early stage) ✓
gga-miR-10b ✓ ✓ ✓(early stage) ✓
gga-miR-15a ✓ ✓(early stage) ✓(early stage)
gga-miR-15b-5p ✓ ✓(HH21-22; dorsal) ✓(early stage) ✓
gga-miR-15c-5p ✓ ✓ ✓ ✓ ✓
gga-miR-17-5p ✓ ✓ ✓(early stage) ✓
gga-miR-18b ✓ ✓ ✓(early stage) ✓ ✓
gga-miR-23b ✓ ✓ ✓ ✓
gga-miR-24a ✓ ✓(early stage) ✓(early stage) ✓
gga-miR-30a-5p ✓ ✓(early stage) ✓(early stage) ✓
gga-miR-31 ✓ ✓(early stage) ✓(early stage)
gga-miR-128 ✓ ✓(early stage)
gga-miR-130a ✓ ✓(ventral) ✓(early stage)
gga-miR-133a ✓ ✓(early stage) ✓(early stage) ✓
gga-miR-133b ✓ ✓
gga-miR-133c ✓ ✓
gga-miR-194 ✓ ✓ ✓(early stage) ✓
gga-miR-203 ✓ ✓(early stage) ✓(early stage) ✓
gga-miR-206 ✓ ✓(early stage)
gga-miR-223 ✓ ✓
  
MiRNA Targets DAVID analysis 
miR-1a-3p 268 
GOTERM_BP_1 (253) 
Developmental process_list (67): 
ALX1; CD164; CITED2; E2F5; GFRA1; GLIS2; KLF4; MNT; MXD1; MEIS1; NAB1; RYBP; SH3GL1; 
SOX6; WHSC1L1; ACTB; AP3D1; ASPH; BMPR1B; BDNF; CREM; CTNND2; COL4A3BP; 
COL19A1; CCND1; CCND2; DICER1; DONSON; MECOM; EFNB2; ERBB2IP; EYA4; FGFR3; FRS2; 
FNDC3A; FOXP1; GJA1; GNAQ; HSPD1; HOXA3; KALRN; KIF2A; LEF1; MAB21L1; MEOX2; 
MAPK1; MAP3K1; MYEF2; NRCAM; NRP1; NFATC3; NR4A3; PAX6; LPPR4; PDGFA; PHLDA2; 
PDCD4; RARb; RNF111; SNAI2; SLC5A3; SPRED1; SNAP25; TCF7L2; UTRN; VEZF1; ZFP36L1 
191 Cellular process 
147 Biological regulation 
135 Metabolic process 
67 Developmental process 
GOTERM_BP_FAT (253) 
74 Regulation of transcription 
62 Transcription MAPK signalling pathway_list (10): 
RAP1B; TAOK3; ATF2; BDNF; MECOM; FGFR3; MAPK1; MAP3K1; PDGFA; PRKACB 49 Regulation of RNA metabolic process 
KEGG_PATHWAY (253) 
Wnt signalling pathway_list (8): 
RAP1B; TAOK3; ATF2; BDNF; MECOM; FGFR3; MAPK1; MAP3K1; PDGFA; PRKACB 
10 MAPK signalling pathway 
9 Neurotrophin signalling pathway 
8 Adherens function  
8 Wnt signalling pathway  
miR-10a-5p 86 
GOTERM_BP_1 (84) 
Developmental process_ list (25): 
BCL6; BCL2L11; DAZAP1; GATA6; MDGA2; RORA; SKIL; TIAM1; ACTG1; ANK3; BDNF; CREB1; 
EBF2; HOXA3; HOXD10; JARID2; MBNL3; MYT1L; NCOA6; NR2C2; NR5A2; ONECUT1; SOBP; 
SLIT2 
65 Cellular process 
49 Biological regulation 
31 Multicellular organismal process 
25 Developmental process  
GOTERM_BP_FAT (84)  
34 Regulation of transcription  
32 Transcription  
29 Regulation of RNA metabolic process  
KEGG_PATHWAY (84)  
4 Regulation of actin cytoskeleton  
2 Neurotrophin signalling pathway  
  
miR-15a 196 
GOTERM_BP_1 (182) 
Developmental process_list (57): 
FKBP1A; KLF7; NAA15; ARHGDIA; SIX5; ASPH; BHLHE41; CHD7; CCND1; DLL1; EFNB2; FOXP2; 
GHR; GNAQ; HGF; HOXA3; INSR; IRS1; JPH1; LRP6; MAP7; NAV1; NRP2; NFE2L1; NFATC3; 
OMG; PARD6B; PPAP2B; PIK3R1; PLXNA1; PBX3; PDCD4; PTPRJ; PCDHA11; PCDHAC2; 
PCDHA1; PCDHA2; PCDHA3; PCDHA5; PCDHA7; PCDHA6; RREB1; RARB; RECK; RPS6KA3; 
RUNX1; SEMA3A; SIAH1; SHOX; SCN8A; SLC5A3; SNAP25; TCF3; UBR3; WNT10B; WNT7A 
 
139 Cellular process 
97 Biological regulation 
61 Multicellular organismal process 
57 Developmental process 
16 Biological adhesion 
GOTERM_BP_FAT (182) 
 Regulation of transcription 
Insulin signalling pathway_list (8): 
PDPK1; FOXO1; INSR; IRS1; PIK3R1; PRKAR2A; SOS2; RAF1 
 Intracellular signalling cascade 
 Regulation of RNA metabolic process 
KEGG_PATHWAY (182) 
Wnt signalling pathway_list (8): 
BTRC; CCND1; LRP6; NKD1; NFATC3; SIAH1; WNT10B; WNT7A 
8 Insulin signalling pathway 
8 Wnt signalling pathway 
8 MAPK signalling pathway 
6 Neurotrophin signalling pathway 
MAPK signalling pathway_list (8): 
ELK4; RAPGEF2; TAOK1; DUSP7; PPM1A; RPS6KA3; SOS2; RAF1 
6 JAK-STAT signalling pathway 
4 mTOR signalling pathway 
miR-15b-5p 85 
GOTERM_BP_1 (77) 
Developmental process_list (25): 
DGCR2; NRARP; PAPPA; SOX6; ACVR2B; BTF3; BPTF; DLL4; DAB1; EYA1; GSK3B; LAMC1; 
MAP2K1; NF1; NLGN1; ONECUT2; PAX2; PLEKHA1; PLXNA2; RFX3; SALL4; SLIT2; TMEM189-
UBE2V1; SKI; ZNF423 
41 Biological regulation 
25 Developmental process 
20 Cellular component organisation 
GOTERM_BP_FAT (77) 
Insulin signalling pathway_list (3): 
EIF4E; GSK3B; MAP2KA 
19 Regulation of transcription 
14 Regulation of RNA metabolic process 
9 Regulation of cell death 
Skeletal muscle_list (6): 
CHD12; EEA1; GRB10; PLXNA2; SLC24A3; SLC4A4 
KEGG_PATHWAY (77) 
3 Insulin signalling pathway 
  
UP_TISSUE (77) 
 
41 Brain 
10 Kidney 
9 Fœtal brain 
6 Skeletal muscle 
miR-17-5p 111 
GOTERM_BP_1 (105) 
MAPK signalling pathway_list (7): 
MKNK2; RASA2; RASGRF2; TAOK3; HSPA8; MAP3K5; RPS6KA5 
55 Biological regulation 
GOTERM_BP_FAT (105) 
19 Intracellular signalling cascade 
12 Protein localisation 
Embryo_list (6): 
ATG2B; RASL11B; CBX8; CSRNP3; OXR1; TANC2 
11 Protein transport 
KEGG_PATHWAY (105) 
7 MAPK signalling pathway 
 
UP_TISSUE (105) 
60 Brain 
6 Stomach 
6 Embryo 
miR-23b-3p 470 
GOTERM_BP_1 (449) 
Developmental process_list (128): 
ARID3B; AGFG1; CREBBP; CELF1; DIP2A; DICER1; EGLN1; ELK3; HHIP; ISL1; LDB2; MEIS1; 
MEIS2; NKX2-1; NAA15; PRDM1; RORA; SOX11; SOX5; SOX-; TGIF1; ULK2; ADAM10; ANKRD17; 
AMBRA1; CAPZA2; CAR2; CTNND2; CDC42; CXCL12; CHD7; COL4A3BP; CBFA2T2; CUL3; 
CCND1; DACH1; DOCK7; DLL4; DST; EBF1; EBF3; ENC1; EFNA5; ESRRG; ETV1; EYA1; FOXA1; 
FOXK1; FOXP2; FMR1; GGNBP2; GABRG2; GSK3B; GREM1; GAP43; HAND2; HOXA3; HOXD10; 
HIPK2; IRS2; JAG1; JARID2; JPH1; LGR4; LRP5; KDM5A; MET; MTSS1; MITF; MACF1; MAPK8; 
MAP3K1; NLGN1; NFIB; NR6A1; OTP; PTEN; PICALM; PDE3A; PDGFA; POGZ; PBRM1; HMGB2; 
WWP1; PSEN1; PPP3CA; PTPN11; PRTG; RET; RDH10; RNF2; ROBO2; RUNX1T1; SIK1; 
SEMA3A; SEMA6D; SRPK2; STK4; SHROOM2; TRIM71; MEF2A; ZIC1; FBN2; PURA; SIX4; SIM1; 
SIRT1; SCN2A1; SPAST; SATB1; SATB2; SPRY2; SS18L1; TSHZ3; TET2; THRB; TJP1; TOP1; 
TGFB2; YWHAG; ERBB4; VANGL1; VCAN; ZEB1; ZFR; ZFHX3; ZFP423 
283 Cellular process 
226 Biological regulation 
206 Metabolic process 
139 Multicellular organismal process 
128 Developmental process 
GOTERM_BP_FAT (449) 
111 Regulation of transcription 
94 Transcription 
71 Regulation of RNA metabolic process 
  
KEGG_PATHWAY (449) MAPK signalling pathway_list (19): 
BRAF; RAP1B; RAPGEF2; ATF2; CDC42; FGF14; MAPK8; MAP3K1; MAP3K5; TAB2; MAP4K4; 
NLK; PAK2; PDGF1; RAP1A; PPP3CA; STK4; AKT3; TGFB2 
19 MAPK signalling pathway 
13 Wnt signalling pathway 
UP_TISSUE (449) Wnt signalling pathway_list (13): 
CREBBP; CSNL2A1; CSNK2A2; CCND1; GSK3B; LRP5; MAPK8; NLK; NFAT5; PSEN1; PPP2R5E; 
PPP3CA; VANGL1 
246 Brain 
111 Liver 
68 Embryo Limb_list (13): 
KDM6A; RAB39B; RBMS3; APPL1; CCNT2; DACH1; HMGN2; HOXD10; KPNA4; HMGA2; SET; 
TLK1; SPRY1 
57 Eye 
28 Heart 
16 Fœtal brain 
Skeletal muscle_list (9): 
CFL2; FOXK1; JPH1; MYH1; MYH4; NFIB; NFAT5; PDE7A; SIX4 
13 Limb 
9 Skeletal muscle 
miR-24a-3p 152 
GOTERM_BP_1 (141) 
Developmental process_list (38): 
AGPAT6; BCL2L11; DAZAP1; FREM2; HNF1B; MKL2; MEIS2; PRDM1; RASA1; B3GNT5; ANK3; 
BHLHE22; CDKN1B; DLL1; EBF3; ELL; EYA4; INSIG1; KIF2A; LMTK2; MFM1; MKX; NRP1; NRP2; 
PDE3A; PLAG1; PROX1; PTPRF; PTPRQ; SEMA6A; MEF2A; ARID5B; TSHZ1; TLL1; TOP1; 
TNFRSF19; WNT4; ZFP217 
86 Cellular process 
63 Biological regulation 
38 Developmental process 
GOTERM_BP_FAT (141) 
34 Regulation of transcription MAPK signalling pathway_list (7): 
RASA1; RAP1B; TAOK1; DUSP16; DUSP8; NLK; RAP1A 28 Transcription 
KEGG_PATHWAY (141) Embryo_list (23): 
DNAJC16; ERC2; HNF1B; MKL2; ERG; CDKN1B; DLL1; EBF3; EYA4; HDGFRP3; IGF2BP1; MKX; 
PLAG1; REEP1; SESN1; BNIP3L; RAP2C; ARID5B; TCERG1; TMEM161B; TNFRSF19; VCPIP1; 
ZFP654 
7 MAPK signalling pathway 
UP_TISSUE (141) 
71 Brain 
Limb_list (6): 
UGCG; WHSC1; CDV3; KPNA4; RAP2C; SHOC2 
23 Embryo 
6 Limb 
miR-27b-3p 596 
GOTERM_BP_1 (559)  
401 Cellular process  
  
320 Biological regulation MAPK signalling pathway_list (27): 
MKNK2; RAP1B; RAPGEF2; RASGRF1; TAOK1; ATF2; CACNA2D3; CACNB2; DUSP16; DUSP5; 
FGF14; GRB2; MAPK14; MAPK8IP3; MAP2K4; MAP3K4; TAB2; MEF2C; NLK; NF1; PDGFRA; 
PRKCB; PRKX; PPP3R1; PPP3R2; SOS1; KRAS 
 
282 Metabolic process 
184 Multicellular organismal process 
170 Developmental process 
GOTERM_BP_FAT (559) 
Insulin signalling pathway_list (19): 
PDPK1; CBLB; MKNK2; FOXO1; GRB2; INSR; IRS1; PDE3A; PDE3B; PIK3CA; PIK3R3; PRKAA2; 
PRKX; PPP1CC; RHOQ; RPS6KB1; SOS1; TSC1; KRAS 
156 Regulation of transcription 
128 Transcription 
102 Regulation of RNA metabolic process 
Wnt signalling pathway_list (12): 
APC; CAMK2D; DAAM1; FZD4; NLK; PLCB4; PRKCB; PRKX; PPP3R1; PPP3R2; TBL1Y; WNT8B 
KEGG_PATHWAY (559) 
27 MAPK signalling pathway 
19 Insulin signalling pathway 
12 Wnt signalling pathway 
Muscle_list (37): 
AKAP2; BMI1; EYA4; H3F3B; HMGXB3; INO80D; MEIS2; PALM2-AKAP2; PNISR; RORA; RASAL2; 
RYBP; TMEM189-UBE2V1; ATF3; ANKRD17; COLQ; DC1A; FOXN3; HOXA10; KPNA3; MAP1B; 
MEF2C; MYH10; MSTN; MARCKS; NCOA7; NAP1L4; OSBPL11; PALM2; PPP6R3; RFX3; 
RUNX1T1; SLC25A25; SPRY2; SDC2; TMEM189; UBE2V1 
UP_TISSUE (141) 
327 Brain 
37 Muscle 
26 Heart 
miR-30a-5p 191 
GOTERM_BP_1 (183)  
110 Cellular process  
86 Biological regulation 
Developmental process_list (46): 
BCL11B; FYN; KLF10; SMAD2; MEIS2; MSI2; NKX2-1; SKIL; ACTC1; CSNK1A1; CHD7; COL9A3; 
DLL4; DAG1; ESRRG; FOXD1; FOXF2; FOXO3; FRZB; HOXA11; HOXA3; IRS1; IRS2; IGF1R; IRF4; 
JARID2; MBNL3; MYH10; MYH11; NF1; NFIB; NR6A1; OTP; PRRX1; PGP; PRKAR1A; RPS6KA2; 
SALL4; NR2F2; LRP6; ZFAND5; SNAIL1; SATB1; SATB2; TIMP3; ZEB2 
51 Multicellular organismal process 
46 Developmental process 
GOTERM_BP_FAT (183) 
43 Regulation of transcription 
35 Transcription 
 
34 Regulation of RNA metabolic process 
UP_TISSUE (183) 
100 Brain 
  
44 Liver 
34 Thymus 
miR-31-5p 121 
GOTERM_BP_1 (112) Developmental process_list (39): 
BD11B; CLASP2; DICER1; EGLN1; ISL1; POU2F1; PTK2; RASA1; SOX11; TAF4A; ADAM10; 
ACVR1; APBB2; BMPR1A; CTNND2; DMD; EBF3; EFNA5; FOXP1; FXR1; HOMER1; ICMT; 
JARID2; MAP3K1; NUMB, PP1R9A; PCDH18; PCDH8; RET; SEMA6D; QK; SS18; SPRR2A1; 
SCN2A1; SATB2; TACC2; YWHAE; UBN1; WNT11 
82 Cellular process 
58 Biological regulation 
41 Multicellular organismal process 
39 Developmental process TGF-beta signalling pathway_list (3): 
ACVR1; BMPR1A; LTBP1 GOTERM_BP_FAT (112) 
25 Regulation of transcription Embryo_list (23): 
AHSA2; EGLN1; POU2F1; PTK2; SOX11; BICD2; BMPR1A; EBF3; FOXP1; JARID2; NUFIP2; 
NCOA2; NUMB; PPP1R9A; PPP2R2A; RERB1; QK; SPRR2A1; SGMS1; TACC2; UBN1; VAMP4; 
ZFP618 
20 Transcription 
17 Regulation of RNA metabolic process 
KEGG_PATHWAY (112) 
Skeletal muscle_list (4): 
KDELR2; DMD; NFAT5; TACC2 
3 TGF-beta signalling pathway 
UP_TISSUE (112) 
67 Brain 
 
23 Embryo 
19 Heart 
4 Skeletal muscle 
miR-130a-3p 167 
GOTERM_BP_1 (151) 
Developmental process_list (32): 
BCL2L11; FYN; HECTD1; ARHGAP24; TAF4A; UGT8A; BMPR2; COL4A3BP; DMRT3; EBF3; 
ENAH; HOXA5; HPRT; IGF1; LMTK2; MEOX2; MBNL3; NHLH2; NFIB; NCOA3; OTX2; PTEN; 
PAFAH1B1; WTAP; PTPRF; ROBO2; ARID5B; S1PR1; TGFB2; TSC1; UHRF2; MAFB 
93 Cellular process 
69 Biological regulation 
69 Metabolic process 
32 Developmental process 
Insulin signalling pathway_list (5): 
PPARGC1A; CALM1; PRKACB; PTPRF; TSC1 
GOTERM_BP_FAT (151) 
27 Regulation of transcription 
23 Transcription 
20 Regulation of RNA metabolic process 
  
KEGG_PATHWAY (151) 
Skeletal muscle_list (5): 
CFL2; IGF1; MSTN; NFIB; STIM2 
5 Insulin signalling pathway 
UP_TISSUE (151) 
83 Brain 
 
5 Skeletal muscle 
miR-133a-3p 151 
GOTERM_BP_1 (143) 
Developmental process_list (39): 
CTBP2; CELF1; EPHA7; GLI3; KLF7; MYCBP2; MEIS1; MEIS2; PRDM16; RB1CC1; AMD1; SOX11; 
SOX4; SOX8; TBPL1; BICC1; CREB1; COL8A2; CAND1; MECOM; FOXC1; FOXL2; FOXP2; GDNF; 
MLLT3; MYH9; PITPNB; ODC1; PPP2CA; PTPR21; RBPJ; RTN4RL1; RARB; RUNX1T1; SOBP; 
SP3; TGFBR1; ZBTB16; ZIC3 
95 Cellular process 
69 Biological regulation 
66 Metabolic process 
43 Multicellular organismal process 
39 Developmental process 
Notch signalling pathway_list (3): 
CTBP2; MAML3; RBPJ 
GOTERM_BP_FAT (143) 
39 Regulation of transcription 
34 Transcription 
32 Regulation of RNA metabolic process 
 KEGG_PATHWAY (143) 
3 Notch signalling pathway 
miR-194 207 
GOTERM_BP_1 (198) 
Developmental process_list (67) : 
AGPAT6; ADAM17; BRSK2; HNF1B; KLF7; LHX6; MEIS2; PRDM16; RYBP; ARHGAP24; SMURF1; 
SOX11; SOX5; SOX6; SP3; TAF4; TEAD1; ZIC1; ACVR2B; AP3D1; APP; CDH11; CDH2; CADM1; 
CHD6; COL4ABP; CLASP1; DYRK1A; DMD; EFNB2; EVX2; FLNB; FOXP2; FXR1; IGF1R; LRRC4C; 
MITF; MAP2; MEF2C; NRP1; NTRK3; NRIP1; NR2F2; ONECUT2; OPCML; OTP; PAX5; 
PPARGC1A; PAFAH1B1; PDGFA; QKI; RFX3; SALL1; SALL4; SGCE; SEMA6A; ZFAND5; SOBP; 
SHH; SRI; SPRED1; SS18; TLL1; TCF7L2; TRPS1; ERBB4; ZEB1 
144 Cellular process 
116 Biological regulation 
106 Metabolic process 
71 Multicellular organismal process 
67 Developmental process 
GOTERM_BP_FAT (198) 
63 Regulation of transcription 
50 Regulation of RNA metabolic process TGF-beta signalling pathway_list (5): 
ROCK2; SMURF1; SMURF2; ACVR2B; ZFYVE9 46 Transcription 
  
KEGG_PATHWAY (198) 
5 TGF-beta signalling pathway 
Embryo_list (9) 
PHF21A; SLTM; CADM1; ENOX1; JMJD1C; QKI; RHOQ; TRPS1; UBE2W 
UP_TISSUE (198) 
112 Brain 
23 Fœtal brain 
 
9 Embryo 
miR-203a 341 
GOTERM_BP_1 (324) 
Developmental process_list (94) : 
AGPAT6; ADAM23; AFF4; ATP5G3; BCL11B; BMI1; CTBP2; CITED2; FAT1; FAT3; FYN; GLI3; 
LMO4; LIMD1. NDRG3; RAN; RPGRIP1L; RASGRF1; SIX3; TIAM1; UGCG; ACVR1; ACVR2A; 
ACVR2B; APC; APP; BMPR2; CDH2; CDH6; CDK13; COL12A1; CNTN4; CUL1 CYR61; DICER1; 
DLX5; DYRK1A; EBF1; EBF3; EN2; EXT1; FGF10; FGF16; FOXP1; FOXP2; GPHN; GRHL3; 
HAND2; HOXA13; HIF1A; INHBA; ID4; LAMC1; MET; MAP3K1; MBNL1; MBNL3; MSH6; MEF2C; 
NRG2; NR5A2; NCL; PTCH1; PTEN; PPAP2B; PDGFRA; PROX1; PTP4A1; ROR2; RARB; ROBO2; 
RUNX1T1; RUNX2; SIK1; SGCD; SEMA3A; SEMA5A; SEMA6A; SOBP; SIM1; SNAI2; STRBP; 
SS18L1; TOP1; TCF12; TCF7L2; TGFB2; TRPS1; ULK2; MAFB; MAFK; SKI; VCAN ZMIZ1 
238 Cellular process 
189 Biological regulation 
177 Metabolic process 
104 Multicellular organismal process 
94 Developmental process 
GOTERM_BP_FAT (324) 
103 Regulation of transcription 
79 Transcription MAPK signalling pathway_list (11) : 
RAP1A; RASGRF1; FGF10; FGF16; MAPK10; MAP3K1; MEF2C; NLK; PDGFRA; PPM1A; TGFB2 71 Regulation of RNA metabolic process 
KEGG_PATHWAY (324) TGF-beta signalling pathway_list (8): 
ACVR1; ACVR2A; ACVR2B; BMPR2; CUL1; INHBA; ID4; TGBB2 11 MAPK signalling pathway 
8 TGF-beta signalling pathway Wnt signalling pathway_list (8): 
CTBP2; APC; CAMK2D; CU1; MAPK10; NLK; CACYBP; TCF7L2 8 Wnt signalling pathway 
miR-206 72 
GOTERM_BP_1 (69) 
Developmental process_list (23): 
CTBP2; RORA; RASA1; SPEG; TIMP3; BICD1; CRIM1; DLg1; FZD7; HDAC4; IGF1; JARID2; 
NR4A2; PAX3; PAX7; PLEKHA1; SEMA6D; SCML2; SRI; THBS1; TGFBR3; TRPS1; VEGFA 
53 Cellular process 
42 Biological regulation 
23 Developmental process 
GOTERM_BP_FAT (69) 
mTOR signalling pathway_list (3): 
EIF4E; IGF1; VEGFA 
19 Regulation of transcription 
16 Regulation of RNA metabolic process 
  
15 Transcription 
 
KEGG_PATHWAY (69) 
 mTOR signalling pathway 
UP_TISSUE (69) 
38 Brain 
16 Epithelium 
7 Fœtal brain 
miR-223 138 
GOTERM_BP_1 (130) 
Developmental process_list (41): 
ERC1; FAT1; LMO2; LHX8; POU2F1; POU6F2; RAB3IP; RORB; RASA1; SRPK2; SOX11; SOX6; 
SP3; ACO1; ACVF2A; CRIM1; EBF3; EGLN1; FOXO3; FOXP1; GPM6B; HLF; ITPKB; MAP1B; MSI2; 
MBNL1; MYH10; NFASC; NFIB; PAX6; RBPJ; RPS6KB1; SIAH1; SHOX2; TSH23; TOP2B; TSC1; 
TWIST1; ULK2; MAFB; ZEB1 
100 Cellular process 
84 Biological regulation 
76 Metabolic process 
43 Multicellular organismal process 
41 Developmental process 
MAPK signalling pathway_list (6): 
ELK4; RASA1; TAOK3; FGFR2; PRKACB; RRAS2 
GOTERM_BP_FAT (130) 
40 Regulation of transcription 
36 Transcription 
Insulin signalling pathway_list (4): 
CBLB; PRKACB; RPS6KB1; TSC1 
32 Regulation of RNA metabolic process 
KEGG_PATHWAY (130) 
6 MAPK signalling pathway 
mTOR signalling pathway_list (3): 
RPS6KB1; TSC1; ULK2 
4 Insulin signalling pathway 
3 mTOR signalling pathway 
 
UP_TISSUE (130) 
78 Brain 
15 Eye 
miR-499-5p 173 
GOTERM_BP_1 (166) 
 111 Cellular process 
82 Biological regulation 
  
79 Metabolic process Developmental process_list (45): 
BCL11B; FAT1; FYN; H2AFZ; KLF7; MEIS1; NHS; NOTCH1; FOXG1; SOX5; SOX6; ABI1; ATG7; 
CDH4; CTNND2; EBF1; ENAH; ESRRG; EYA4; FGF9; FNDC3A; FOXP2; FZD8; HOXD3; JPH1; 
MYH10; NTRK3; NRIP1; POGZ; WTAP; YBX1; PPP3CB; EVL; LRP6; ARID5B; SORL1; ZFAND5; 
SATB1; STRBP; SPRED2; TCF12; TAC2; ZEB2; ZIC3 
50 Multicellular organismal process 
45 Developmental process 
GOTERM_BP_FAT (166) 
46 Regulation of transcription 
Wnt signalling pathway_list (5): 
CSNK2A1; FZD8; NLK; PPP3CB; LRP6 
37 Transcription 
34 Regulation of RNA metabolic process 
MAPK signalling pathway_list (5): 
FGF9; MAP3K4; NLK; PPP3CB; SOS2 
KEGG_PATHWAY (166) 
5 Wnt signalling pathway 
5 MAPK signalling pathway  
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APPENDIX III 
 
 
List 1: Sequences of coding and 3’UTR fragments cloned and used to generate RNA 
oligonucleotides in order to perform RNA in situ hybridisation. Primer sequences 
have been underlined in the sequences cloned from coding regions. 
 
 
>Gga-Eya1-ISH [970 bp; ENSGALT00000025181.4] (from pGEMT(Eya1.2-3UTR) construct) 
CAACTACCTGCAAAGCTGCGAAGCACCAATGTAGCTGCGAAGCAACACCATTCTTTATTG 
GAGGAATCATGTTGCTGCTAGAATTAAATGTTTGTGGATTGCTTTATTACCGACAAAGAG 
GTTCTTATCCTGCCAAGACTTTCACATGTGCTTTACTTTACCCAGTATGAGTACTGGAAT 
TCACACAGTACTCACATACATACACGAAGCACATTGTGCATATCTTTTAAAACCTAGACT 
CTAGCCCTTTCTTTCTTCAAGCAAAGTAGGCAGAAATGGAGGTTGGTTGTCTTTTTTTTT 
TTCCCCATCTCTTTTCTATCTTTAGTCACTTGCAGACTGAAAAAAACAGTTTATCTGGGC 
CTTATTGTACAAAAAGCGTGTTGTGTCCACAATTGTGTACAGAATTTTTCTTCATTAATT 
TTGTTTTAAATTAATAAAATTGATTTGTGAACATATTAAGCAACTCTCTTGTATGCAAGT 
CTATGATATTTCTCCTCTCTAGGTCTGGAATGAGGAGACATCTCTCATCTTTTCACCGTC 
CTAAGACACAAGTCGTTCACCTGTTTGTGCACACCTGAGATGTTAAATAGGGTAAAAATA 
TTTGCTTCTGGTTTACAAAAGGCTAAGTTTGATGGGCAGCAGGAGGAGGAGCTAAAGGTC 
AGAAACATGTAGTAGGACTTGGACTCGGTGCATGCTGTCCTGGAAACGTGCCGAAGTGAC 
TGGCAAAAAGCAAGTGCCTAAATGTTAGGTGCTGTGTTGCCTGTGAAGGTCAGCCAGAGC 
ACACATAATGTGAGTGGATTAGCATGATCATTCAGACATTGCACTCAGGGCTATAGCAAA 
TGTCCTACCCTCTCTCTGAGGATCTACAAGCCTGAACATCTATGGGAATTCAAGAGACTT 
CAAAGGAAGCTGGTGGACAATGGTGCCCACTTTCTTGTCTACAGAGATCTGGGTTTTGTT 
GCTACATTGA 
 
>Gga-Eya2-ISH [802 bp; NM_204915.1] 
ACATTTATGCCACGGCTCCAGATGACATAGAAGGCAACAGTAAAGCAGCACCACAGTGTC 
CTCTCCATCTTTACTCAACAAATGACAGTCCAGTCTTTCCCAACAATGGCAACGTATGGA 
CAGACTCAGTACAGTGCAGGAATCCAACAGGCTGCTGCATACACTGCCTACCCTCCTCCA 
GCGCAGCCCTACGGCATACCTTCCTACAGCATCAAAACAGAGGACAGCTTGAGCCATTCC 
CCAGGACAGAGTGGGTTTCTTAGTTATGGATCCAGTTTCAGTACCCCGACTGCTGGACAA 
GCACCGTATACCTACCAGATGCATGGCACAACAGGGATTTACCAGGGAGCCAATGGCCTG 
ACAAATTCTGCTGGATTCAGTGCTGTGCATCAGGAATATTCATCATACCCAAGCTTTCCT 
CAAAGCCAGTACTCACAGTATTACAGTTCCTCCTACAACTCTCCCTACATGTCCACAAAC 
AGCATCAGCCCTTCAGCCATCCCAACCTCCACTTATTCTCTGCAGGAGTCTTCTCACAAC 
ATCACCAGTCAGAGCACAGAATCGCTGTCTGGAGAATATGGAACAACACCAGCAAAAGAT 
ATAGAAACAGACAGACATCACAGAGGGTCGGATGGCAAGGTACGAGCCCGATCAAAAAGA 
AGCAACGATCCTTCCCCCACTGCTGACAGTGAGATTGAGCGTGTATTTGTGTGGGATTTG 
GATGAGACGATAATTATTTTTCACTCCTTACTCACGGGAACCTTTGCATCCAGATATGGG 
AAGGACACAACAACGTCTGTGC 
 
>Gga-Eya3-ISH [476 bp; XM_417715.3] 
CCCAGACCACCCAAACCTACGGACTACCTCCTTTTGGCATCAACTACCAATGCCAGTCCA 
GTCTCTACATCCTCAACTGTTGTCAATATTTCCACATCAGCAGTAGCCAGCATCTCACAG 
GAATATCCTACGTACACAATCCTTGGCCAGAGTCAGTACCAGACGTGTTACCCAAGTTCT 
GGCTTTGGAGTCATAACACCAGCAGACAGCAACGCGGAGAGCACTGCATTAGCAACAGCT 
ACGTATCCATCTGAAAAACCAAACGCCATGGTGCCTACACGGACGGTGCAGAGACATTCC 
TCTGGAGATGCATCCACAAGTCCCTCATTGTCAAGAGCAACAGCAAGTAAAGAGTCAGAT 
GAACAGGCAAGAAAAAATATCCCTGGGAAGAACAGAGGGAAAAGGAAAGCAGACACCTCT 
TCTTCACAAGACAGTGAACTGGAGCGAGTGTTTCTCTGGGACCTGGATGAGACCAT 
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>Gga-Eya4-ISH [873 bp; ENSGALT00000022662.4] 
CTCCGAACGCCAGGTCTATGGAAATGCAAGATCTAGCAAGTCCTCATAATCTTGTTGGAA 
GCAGCGATGCGCCGGGTAGCTCTAAACTGGATAAGCCTAATCTCAGTAGTACATCAGTTA 
CAACAAATGGAACAGGAGTGTCTCTTCTTGCAGTCAAAACAGAGCCCATGAACAGCAATG 
AAACAACAACAACAACTGGAGATGGATCGCTTGACACTTTTACTGGTAATAACAAGTAGT 
GGCTATAGCCCAAGATCAGCGCATCAGTACTCTCCGCAGATATATCCCTCCAAGCCCTAT 
CCACACATTCTTTCTACACCAGCAGCTCAAACAATGTCTGCCTATGCCGGACAAACCCAG 
TATTCAGGAATGCAGCAACCAGCAGTCTATACAGCCTACTCACAGACAGGACAGCCATAC 
AGCCTACCTACTTACGATTTGGGTGTAATGTTGCCAGGCATCAAGACGGAAAGTGGGCTC 
TCGCAGACACAGTCACCACTGCAGAGTGGGTGCCTCAGTTACAGTCCAGGGTTTTCCACC 
CCACAGCCAGGCCAAACACCGTATTCTTATCAGATGCCAGGTTCTAGTTTTACACCATCA 
TCTACTATTTATGCAAACAATTCTGTTTCAAATTCTACGAACTTCAGTAGTTCACAACAG 
GATTATCCTTCATACACAGCTTTTGGCCAAAACCAGTATGCACAGTATTACTCGGCATCA 
ACATATGGTGCATATATGACCTCAAACAACACAGCCGATGGCACTTCATCATCATCATCA 
ACCTACCAGTTACAGGAATCTCTCCCTGGCCTGACTAGTCAACCAGGTACAGATCTACAT 
TCAGGCGAGTTTGACACAGTACAGAGCCCCTCC 
 
>Gga-Six1-ISH [597 bp; NM_001044685.1] (from pGEMT(Six1-3UTR) construct) 
CGGCTGTTCGGGTACAATAGAAAAGAAACCTGAAAGCACACGCGAGGTCGGTAACACAGA 
CTCGAGACAGACAGCTGCGGGCTCACTGCGAGGCAGAGCTGGGGGTTGGGGGAGGCAGAC 
AGAGAGAGACGCTCCTGCGGAAGGAAAGGGCCATCCGCATTTATTATCGCTGTTGTTACT 
GTCCTAAAGTGCAGCCGCATCGCTGCGTGTCCCGGCCGGGGAGCAGCACCGCCGCGTTAA 
GACAGAGGCACTCAGACTGCCGCTTCCTAATTATCTATTTTTTTTTCCCCTCTTTTTTTT 
TTTTTTTTTTAATTTTAAACTACATCGAAATCCTTCCGGTGAAGCTAAATATGAAAAAAA 
AGAAATGTAAACGAAAAAGTTCCCCTCCCTCCTCCCGCTGCCGCAAAGGGCCCCGCGCTC 
CCTCTGCCTCTGGGCCGCAACAGCCGGGATTTATGGGGCGCAATGGGATCCGGGGTTCGG 
GGTTGGGTTTTTTTTCCCCTCACCCTCTCCCCTTCTATTTCTATTTCTGCTGCTGTAATT 
CCCGCTCACTTGAACTCGAAAGGCCGAGGGCTTTCTGCCGCTCTCTGCATTTGGCTA 
 
>Gga-Six4-ISH [538 bp; XM_003641442.2] 
TGGAGAGCCACAACTTCGACTCGTCCAACCACCCGCTGCTGCAGGAGCTGTGGTACAAAG 
CTCGCTACACCGAGGCGGAGCGAGCCCGGGGCAAACCCCTGGGGGCGGTGGACAAGTACC 
GGCTGCGGAGGAAATACCCCCTGCCCCGCACCATCTGGGACGGCGAGGAGACGGTGTACT 
GCTTCAAGGAGAAGTCCCGCAACGCCCTCAAGGAGCTCTACAAGCAGAACCGCTACCCCT 
CGCCGGCCGAGAAGCGCAACCTGGCCAAGATCACCGGGCTGTCCCTCACGCAGGTCAGCA 
ACAGGTTCAAGAACCGCCGCCAGCGGGACCGCAACCCGTCCGAGACGCAGTCCAAAAGCG 
AATCAGATGGCAACCCCAGCACGGAGGATGAGTCCAGTAAGGGGCAGGAGGATTTATCCC 
CACATCCGCTCTCCAGCTCGTCCGACGGAGTCACCAGCCTCAGCCTTCCCAGCCACATGG 
AGCCCGTCTACATGCAGCAGCTTGGAAACACTAAAATAGCCTTGAGCTCATCTGGTGT 
 
>Gga-Dach1-ISH [1084 bp; ENSGALT00000027373.3] (from pGEMT(Dach1.2-
3UTR)construct) 
TGCCTCATTGTTTGGCTTGGTACATAAATGGAAATGTTAAGGTTTAAGGGGGAACCAATT 
TATAAGCTGGATGTTTAGAAAGTATCTTGCTAAAACCAGTGTAAATATTACAGACCATGA 
GATGTTAACGTAAGTTGAATTTTTTGCCCCTCTTTAGTTATACAGGTTTTGGGTTGGTAT 
TTTGTTTTTTATTTCAAATTTTGTTTTGTTTTGTTTTGTTTTCATAGATGATGAAGAAAA 
GTTGTGCTCATGTTATTGTTTATATGCTTTTGTAATCTTAAAGATATTAATGTCTAGTTG 
TTCTATATTATAACCATATTTGCGCTCTATGCAAGCCCTTGGAACAGAACATACTCATCT 
TCATGTAGGACCTATGAAAATTGTCTATTTTTATCTATATATTTAAAGTTTTCTAAAAAT 
GAAAAAAAGGTTATTACGAATTTTGTTGTACAAAATCTGTACAAAAATCTGTTTTTACAT 
CATAATGCAAGAATTGGAAATTTTTCTATGGTAGCCTAGTTATTTGAGCCTGGTTTCAAT 
GTGAGAACCACGTTTACTGTTATTGTATTTAATTTTCTTTTCTTTTCAACAATCTGCTAA 
TAAAACTGTCTGAAATCTCCCTGTGACTTCATTTACAGTTCATCTTTATTAAATTTTCTG 
AAATGTGTAACATCAGAGGAATATTTACTTTCTAATGGGAGGCATCTGAAAACAACACAA 
GTCAGCTCTTTGTAATGTGAGGAGAACAATGCTGAATGATTTTATTTAACATGCAACTGC 
TTCTATCCCTAATATGAATTACTGTGGTGAAAAACATCATAAAAGCACACTTTGTGGTTA 
TTGTTTAACAAGCAGATTTTCCATATTTTTTTTTCTTGCCAGCTAAGCAAACTGCCCCAA 
TCTACATGATTTATTTATGTACATTTCTCAGTTTATGAAGCTGTTATTTGTACCTTTTTT 
TATATATTGTGATATTCCCATGATTCTTATTTCAGAAAGCTTTGTGCTGAATAATGTAAA 
GTGGACACATTGATGGAACAAAACATATAATTCCCCTAGCTACAGAGAGGGTAATCCAGT 
TGTT 
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List 2: Sequences of 3’UTR fragments cloned in order to perform luciferase reporter 
assays. Predicted miRNA sites are indicated in bold, and the primers, containing BglII 
(grey background) and NheI (dark background) sites, have been underlined in the 
sequences. 
 
 
>Gga-Eya1.1-UTR [1291 bp; ENSGALT00000025181.4] 
AGATCTCAGCTCAGCAGCACTTTGAAACCCCAGAGCCTCCTTCTGCCCATGGACGGTACG 
CCTGTGTCTTGTGTCAGCATTGGACTACAGAACTTTGTGATTTCAACATGTTGACGTACA 
GCTGCAATTGGTCTTAACCCTTGCCCTTTCAGTAAACGGAGGAGCATGTCTTTTTCTTCA 
GAACAGCTGTTGACTCTGGTACTGCGAGTCCAACAAAAATAAGCCATGCGAATGTTTTAA     miR-27/128 site 
(1) 
CAGCTCATCTTTACTATATTTGCTACCAAAAGAAATGGAGAAGGAAGAAAAGGAAATAAA 
GGTTCGTACCTGTGAAAAAAGGACCTGCAAGTGCTTTGTAGTTTTTAAACTCTTCAATGT     miR-27/128 site 
(2) 
GACACACGCCGTTTCTTCAACACAGCAAACTTGATTGCACAATGAAGACTGAGATTTTTC 
AAAATACCAGTGGAGTAATTTTCTTCTAAAGAAGGTTTACTTTTGGTTTCTCATACCCAG 
GGTACTCTGTACATCTTTACTTATTTATGAACAGACTGTATTTTAACATCATATAACTGA 
GGATATGTGTAATAGGAATAAAGGCTATTATAAGCCTTTGCCTTACGATACAGCAACTAC 
TTTTGATTTTAGCACATTACAGAGTAGTTTAAAATATGTCTAATTTAAACTAATAGGTAC 
ATCACTGAGACAATCATGTACAGGAAGAATTTTTGTGTAAATTTGTAATAATGAATGATT 
CTTTTACATATCGTTAAGGTAAATGCTATTGAAAGATAGTAATGCCTTGTTGGTGAAGAA 
TGAGGCTACGTGTGCACAAGATGTGCAGTGCCTTGTCAACACATTGGATATAAATATGTA 
GATAATGGATTTTTTTAGATAAATTTGTCAAGACCAAAAGCATGGATGTCAAGTGTCAAT     miR-133a site 
ATGAATTGGGTTTTGTTCTTTTCAGCTATTTCTCTGCCTTTTTCCTCTCTCATCTGTTCT 
GATTATGAAAAGATTTTCTTTCCCCCCATCAAGGAAATACAGATGAAACACAACCGAAGA 
GGAGTACTTTGCTGTCTTCTGTTTGCTCTCTTAACACTTTTTTAGAGTATTGACAAATGA 
ATTAGCAGATTCCATAAAGAAATAGAGAAAACAAATATATTTTAAGACATGACTTAAACT 
GGAATCTAGGTACCGACTAGTTTATGTCTCATCCAAAAGTAAAGGAAATTATTGTGATCG 
TTATTTTTAGAAATCAGAAATGGTAATATTTTGGAGAAATTGAGCAAGATACTCGTATAC 
ATTTAAGTTTTTTTAATCCTCTTCCACCAGGAGTCAGGCTAGC 
 
>Gga-Eya1.2-UTR [970 bp; ENSGALT00000025181.4] 
AGATCTCAACTACCTGCAAAGCTGCGAAGCACCAATGTAGCTGCGAAGCAACACCATTCT 
TTATTGGAGGAATCATGTTGCTGCTAGAATTAAATGTTTGTGGATTGCTTTATTACCGAC 
AAAGAGGTTCTTATCCTGCCAAGACTTTCACATGTGCTTTACTTTACCCAGTATGAGTAC 
TGGAATTCACACAGTACTCACATACATACACGAAGCACATTGTGCATATCTTTTAAAACC 
TAGACTCTAGCCCTTTCTTTCTTCAAGCAAAGTAGGCAGAAATGGAGGTTGGTTGTCTTT 
TTTTTTTTCCCCATCTCTTTTCTATCTTTAGTCACTTGCAGACTGAAAAAAACAGTTTAT 
CTGGGCCTTATTGTACAAAAAGCGTGTTGTGTCCACAATTGTGTACAGAATTTTTCTTCA 
TTAATTTTGTTTTAAATTAATAAAATTGATTTGTGAACATATTAAGCAACTCTCTTGTAT 
GCAAGTCTATGATATTTCTCCTCTCTAGGTCTGGAATGAGGAGACATCTCTCATCTTTTC 
ACCGTCCTAAGACACAAGTCGTTCACCTGTTTGTGCACACCTGAGATGTTAAATAGGGTA 
AAAATATTTGCTTCTGGTTTACAAAAGGCTAAGTTTGATGGGCAGCAGGAGGAGGAGCTA 
AAGGTCAGAAACATGTAGTAGGACTTGGACTCGGTGCATGCTGTCCTGGAAACGTGCCGA 
AGTGACTGGCAAAAAGCAAGTGCCTAAATGTTAGGTGCTGTGTTGCCTGTGAAGGTCAGC 
CAGAGCACACATAATGTGAGTGGATTAGCATGATCATTCAGACATTGCACTCAGGGCTAT 
AGCAAATGTCCTACCCTCTCTCTGAGGATCTACAAGCCTGAACATCTATGGGAATTCAAG 
AGACTTCAAAGGAAGCTGGTGGACAATGGTGCCCACTTTCTTGTCTACAGAGATCTGGGT 
TTTGTTGCTACATTGAGCTAGC 
 
>Gga-Eya3-3UTR [487 bp; ENSGALT00000001127.4] 
AGATCTGTAGTCTCCAGAGGGAGGGGGTAACACAGCTGAGAAGGCTCTTACAGATACTTC 
TGCTTTTCTATTCAGTTTAGTTATAGAACCCAAGTAAACAGAAAACCTTATTTTTATAGA 
AAAATACTGATGGCAGAGCTGAACCTCCCTTGTTTTGCAAAGCCAAAAAGAGCTATTGTT 
TGGTTGGTTTTTTTTTCCATGGGAAATATTAATGAAAATATCAAAAATACCTCTACTGCT 
GTGAAAATGTGTCCTCTCTCCTTCTCTGGGTGTTCAAAAGCAGTTAATTTATTATGATAT 
CCTTACATTATTTCTTCAACGTGGGATTTATCCCATTCTGGGATAAGTGGTTCCTTGTAG 
AGGGAGGTGTTGCTGTTGGTTGTTCCTATTGGCTTCTAGGCAGTGCGTGTGCAATGCATG 
TGACTGAGCCCTGTTAATGAGCAGGGGATCATTAGATTCCAGCTGTCCATGACTCAGACC     miR-133 site 
ACAGATGCCACAGGCTAGC 
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>Gga-Eya4-UTR [1043 bp; ENSGALT00000022662.4] 
AGATCTTGTTCTAAAGTTGGCGATCCTTTTTTTTTATATATATATTTCAAGTACACTGAA 
TTTTTATGTGTGATTCAATGCCTCTGGCTTTACACATATGAATTGTCTTAAGAAGGGAAG     miR-499 site 
AAATATTTGGAATTAAAAATTCCAAACTGAAGAATTCAGATTGCTGAATGGAGTTAAAAC 
ATTAGTGCTACATAAGGAAGCTCTATGGTCTTATATATGCAACGTTTTTAAATGGATTAA 
AACTGTGGAGGTTGCTGGTACACACCGAATGAGCCCTGACAGGAGTGAACAAAGGACTCG 
AACTGGCAAAGCACCAACACGCGTTTTTTAACCGACAAAGTGGTGTTCAACAACATTCCT     miR-1a/206 site 
CAAAATGGGATATATTCTCAGCACTGAGGTTTGAACCAGACTTTAGCCTACCTAACCCAG 
AAAATCTGAATTGGAATGCACTCAGACTGTATAATGACAATCCTGTCTAGACCTGTAATT 
TGTGTAAATTATTGATGAAAATAACTTACTGTGACTTTATTAGCAGCTGATTTTGGAAGT     miR-27/128 site 
GGATGCAATTTTTCTTTCTTTTTGGGGGGGTGGGGGAGGGGAGAGGGTTATATAATATTA 
TCTCTTTTATAAGTTTGGCAAACAGAATGTGCATAATGATGTGTTGTGCCTTAAGGAGAA 
GACTGTGTTTGTGTGTTATAATGTAACTTTGGTTAAAAACTATGTAGATAAACAAACAAA 
AAAAGCCTTTGTGATAATTTTTGACATGACCAAATTTGAAATTCAGAGAAATCAAAGAGA 
AGGGCTGCACCAAAGCATTTAAGTTTTTGTTGCAGTAAAAAAAAAAAAATAATAATAAAG 
GAAAGTTTGTGTTTTTATTTGGATTCTCAATAATTCCACTGACTGAGGAAAGTTGAGAGT 
ATGTTGGGAGGTTGATAGTGGGGACCGCTACCTTGAAAGCTAAAAAAGAAGTGTTTAACA     miR-133 site 
CCTTCAACATCGTTTCTTGATTCTCTCATGAGAGAACTAGGAGCCATTTTCATGAATTAC 
TTAGTCCACTGAAAGCCATGCAGTGAGTGGCTAGC 
 
>Gga-Six1-UTR [594 bp; NM_001044685.1] 
AGATCTTAGCCAAATGCAGAGAGCGGCAGAAAGCCCTCGGCCTTTCGAGTTCAAGTGAGC 
GGGAATTACAGCAGCAGAAATAGAAATAGAAGGGGAGAGGGTGAGGGGAAAAAAAACCCA 
ACCCCGAACCCCGGATCCCATTGCGCCCCATAAATCCCGGCTGTTGCGGCCCAGAGGCAG 
AGGGAGCGCGGGGCCCTTTGCGGCAGCGGGAGGAGGGAGGGGAACTTTTTCGTTTACATT     miR-1a/206 site 
TCTTTTTTTTCATATTTAGCTTCACCGGAAGGATTTCGATGTAGTTTAAAATTAAAAAAA 
AAAAAAAAGAGGGGAAAAAAAAATAGATAATTAGGAAGCGGCAGTCTGAGTGCCTCTGTC 
TTAACGCGGCGGTGCTGCTCCCCGGCCGGGACACGCAGCGATGCGGCTGCACTTTAGGAC 
AGTAACAACAGCGATAATAAATGCGGATGGCCCTTTCCTTCCGCAGGAGCGTCTCTCTCT 
GTCTGCCTCCCCCAACCCCCAGCTCTGCCTCGCAGTGAGCCCGCAGCTGTCTGTCTCGAG 
TCTGTGTTACCGACCTCGCGTGTGCTTTCAGGTTTCTTTTCTATTGTACCCGAACAGCCG 
GCTAGC 
 
>Gga-Six4.1-UTR [1566 bp; XM_003641442.2] 
AGATCTGGAGAAAGGAAACGCCAGGGGAAGTACCAAGCAAATGGGTACAGGTTTGGCTAC 
TGCTACTGCGCTGATAATGTAACTAGATTCTCTGTAGTGCAACGTACTATCAACAGTAAG 
TATACACTCCTGACAGTAGATAGAAAGCAAAAATCTCGCTCTGGAAAGGTAGAAACCATG 
CAGTTGTTTTCGCTGTTTACTTCTAGTCCGTGGCATTGAAAAGTTTTTTAAGAACTCTAT 
AGACGATACCTCACAGGCTACTTTTGTGTTGTTGGAGGTTAAGAAACAAAACGAAACCCT 
AATGTTGTTACTGGTGTGTTTGCTGTTTGTTTTTTTTTCCAGCAGACTTGCCTTCATACC 
AAGAATCTCGCATCAAACATTGACAGGTTTCAAAGTGCTGCAGATAGCATTTTGTCAGTG 
CACCAGAAAAAGCATCATCTGAAACTCTAACTATGCAACTTGGAAGCTTTCTCTCCAGTA 
TGAATGTAAATATTGTTTCAGTTCTTATAAAGGAGACTTTTTTTTTTTTTTTAATTAGTA 
CGATGGATTTTATTTATGGTTTATGTTCCCTTTCACTTTAGACACAATGCATTGGAAAGG 
AAAACGTTTTCTGGCTGTTTAATTTATTTTTATTGTTTGAGCAGGAAGTAAACGTAGTTA 
TTTCTGACAAGGTTTTACTTTTTTGTAGGCTTTCAAGCAATAGACTGTAAAAGTAAAATG 
TTAATCACACTGAAACTAGAAAATGAGCTCCCAGTCTCACAAACCCAGGAGGTCCCTGTC 
TCTACCCCCTCTGTCTTTGCGTTCAGGGGTTTTCTGTTTGTTTTGTTAGTAATTTGCAAA 
TTAGTTGAACCTTTTTTCTTGGTGTATTTTTTACGGAATTCCATGTGCCTTTCTTCCTAG 
TGGNCTTATCTTTGTTACTAAAGCACAGTGGCAGGAGGAATAAAAACACTGACTTGCAAA 
TCTCCGTCCTCAGGGCTGAATCCTGATGCCTTACTTTTGCAAGTAGCCCTGCTGACCCCG 
GAGTCCCTACTTGCACGAGTAAGAAGAGTTGAGTCTTTTGGAAGAGCTGAGTCTTTTGGT 
CACGCTGGGTGACACTGAGTGGTGGTGCAGGGACCTGGAGGCAGAAGGATTGTGCCGAGG     miR-133a site 
GACCACGTGCAGAGCAGTGCAGAGCAGTGCAGGAGGGAAGATCTTGGCTCTGGCCTCGGT 
CTGATGAGTGTGGAAGGTTGGTGGGCAGGCCAGGGAAGGGAGTCCCATGTTTCCCCACAG 
CCGTTGGCCCAGCAGCCCTTGTGGGAGGGCTTCAGCTGCTGTTGAGCAAGCAGGCCCCCA 
TCCAGGAGTGCACTTAAGCATGGATTTATAAATCCTTCCAGAATAAGCAGCGCGGGGGCC 
AGTGGTGGGAACTGCAGCTGCCCAGAAGATCCATGGAGCAGCCCAGCTCCCTGCCTGCCT 
GGGGATGGGTGTCCTCTCCCTTCACCCCTCTGCTCTCCTTCAGGGACAGCATAGGTAGGC 
AGGCTGTGGGCAGGTGGAAAAGACCTTACCTTTCCTCCAGAGAAACTTTTGTAGCGTGGA 
AAAGCACATCCTGCTAGC 
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>Gga-Six4.2-UTR [1594 bp; XM_003641442.2] 
AGATCTATGGGTGTCCTCTCCCTTCACCCCTCTGCCCTCCTTCAGGGACAGCATAGGTAG 
GCAGGCTGTGGGCAGGTGGAAAAGACCTTACCTTTCCTCCAGAGAAACTTTTGTAGCGTG 
GAAAAGCACATCCTTAAGCTTTAAAATAATAATAATAATGCAGATGTATAAAAATGACAT 
GCTGTTTATCTTTGTGTTTCTGTTTTGTTTTTATTTCTTATTCTAATGTGAATATATACA 
GTAGCTAAGGCATGTATTCATCCTCGTCAGGGGCATGGGCTGAAGCCTTTGGAAGACAAT 
GGGAAATTTTTTCCTAAACTTCTGTGGGCTCCACACCAGGCCCAACCCAAAATCACTTGG 
GCAAAAAGAGTGGACAGGAAAGTGAATAGAGAGAGCACATCCCAGTCTGTTTCTGTCTTG 
GTTATTACCTGGTTCCGTGGAAAGCCTTTAAGGAATGAAGGTTTCTCCTGTATGGCACAG 
ACATCCTTGCTGTTGTTTTGCACTATATTGAATGCAGCATGTTTTGCAAGGCAGTGTGTG 
AAACCTCAGAGCTGAGCTCTGCTGGTAAATGCTGTTTACACTGCAAGCTGGAGTTCTGAA 
TGTTGCAGGGAAAAGTGCAGGGGAAGGGAAGAGCAGGCGTGCGAGGCTTGCACTTTGCAG 
CTGCAGGGAGTCCCTGGTGCTTTGCAAACAGGAGCAGCCCCTGAGCAGTTGGCTGTCCCC 
ATGTGCACCCGAACAAAAAGGGTGTTTAAGGCAAGTGCTTTAATGTGGAGATTATCGCAA 
GCAGAGCATGGAGCTATATGTTCCCTGGCACAACTTCTCTTGGCATTCGGGGGATCTCCA 
TGTGAGCAGGGAATCGGATGGTGCAGAACTCTGCTCCAGTGGTGTATCTGAGTGCCTTGC 
TGGGCTCCAGCATGAACAGTTTGTTTTCCGCCTCTCCTTCACCCTCAAAACAAAGATGAT 
GATTATGATAATAGTGTCTGTATCTGATCTGCATGAATTGCTCAACTTCTTGGAAAAAGA 
AGGATCCTGTATTGTTGTATTAATGGAGAACGTATGCACAGAGCAGGAGCTCTGTAGCTC 
TGGGGGAGTTGTTCGGGGCTTAGTGTTTGGTTTGTGAAGCTCAGACTGTTTCTAGAGGCA 
AGCTAGAGAATATTTCAGAGCCCTCCGTCAATTGTTGAACTCATCAGGTCCCATAACTGA 
AAAGACTGTGGTTTCATGCCAGTACATGTTACTTTTTTTCTCTCCTCCCTTGCATTTGTG 
GTGTTACTGAGGCTCTGAATGCCATGGCTTCGCAGCACAGTTGATGTGAAAACTGTGTAT 
GCTGTTACAGTGGTGCGTATCTCGGGGTGCCTGGTACTTCTAATAGGAGACCTCCCGTTC 
TTTCGTGGGAGCGGAGGATGTATATAAAAGCAGTGGTTTGGGACAAAGTAAGATTAATCT 
ATTCATCTTCCAGGTATCAAGTAACTTATTTCGTTATTATGTTTTACTCTTTCTTTCTCC 
CACTGAAAATAAGTGTCATTCCCTCCAGGTGATGTAGTTAGAACCTCATATGTTTTTTGC 
AGGTACATATGCACAATATAAAGACTCGTTGCACGGTACAGCTAGC 
 
>Gga-Six4.3-UTR [1448 bp; XM_003641442.2] 
AGATCTACCTCCCGTTCTTTCGTGGGAGCGGAGGATGTATATAAAAGCAGTGGTTTGGGA 
CAAAGTAAGATTAATCTATTCATCTTCCAGGTATCAAGTAACTTATTTCGTTATTATGTT 
TTACTCTTTCTTTCTCCCACTGAAAATAAGTGTCATTCCCTCCAGATGATGTAGTTAGAA 
CCTCATATGTTTTTTGCAGGTACATATGCACAATATAAAGACTCGTTGCACGGTACAGTG 
TTTCTAAAATAGATATTTAAATAGTAGTTTTACTCCTACTGTAAATTAAGGGTTGGTTTT     miR-499 site 
TATTATGTGGCCCTCAAGCGAGAAGGCTGACTGCTCTACGTAGACAGGACACAAAGCCCC 
ATCGAGCATCTGGGGCCAGATCTTCAGCTGCTGTAAATAAGGCATTGCTCCACTGTTTCC 
CAACTGAAGATTTCACATGGTGTTCAGGGGGTACGGATGCTCATCTCCCACAGATACCGA 
TGGCAGTGAGCATCTGAACCTCACGGACGGTCCTTACTCTCACGTTCTGTTGTTTCAATG 
GAAGATAAGTCTATCCAGCACAACTACTACTTCTCCCTCCCAGCTGTGGATGAGAATAAA 
GGATCATTTCAACTTCACCTATGTTTGTAACTTATAAGTCCACTGGAAATCTTACAGGAA 
ACGTTGCCAAATTCTACTGCTTTTCTGGTCCCAGACTCAGCTTTGAAAAATACGCTTAAA 
GTTTAAGCAAATTCCTATAAAGCATGAGTGCTAAAAAAACAAACAGAAAAAACTTTATTC 
TTCACTACCTTTAATTAAAGCTGCCTCTATTTCACCAGACTTTCGCAGAGAACCAGAAAT 
ATACTGAATCAAATGCTCTGTCTGGACTAATGTGCAGCATTATTCCTGTGGTCGTACTTA 
ATTGGACATTTCAGCCACATCAGTCGTGGACGCCTATCGGCCAGGTCCTTGGCTGGGATA     miR-1a/206 site 
AACGAGCACAGTTCACTGACTTTTCGTGTCATTTCACACCAGCTGAGAATGTGGTCCATT 
CATTTCACTGGAGCTGGATCGGGGATGGATTTGGCCCAGTTTGCAGTGACACTACGAACC 
GGTTCACAAGGCCGATGCTCAGACAGTTGCATTGAACGGCACCAATCTATCCATCCAAGC 
AAAATACCTCTTTCCGTTTATCTCTTCACCCTGCCTGTGGATTCAGGAAGATGAGTTTAG 
AAAGCTGTTTTCCCTAGAAGTAAGGCTGGAACCGTCTTTATTGTTGTTATCCTTATGAGA 
TCAATGACAACAATGGATGGATTCACGGAAACGATTTGCAGTTAAATGAAGCAAGGCAGA 
ATTTGGCCCCGCGTGCACAGGAACTTTTCCTGTATGTAGATTTCCAGCACCTGTGCACTT 
TTCTTAACGAGGACAGACAAACAGCCAACAGGGCACATCCCTCCAGCTCTGCATGAAACA 
GACATGCAGGGTCCGCTAGC 
 
 
 
 
 
 
 
 
 
 
224 
 
>Gga-Dach1.2-UTR [1073 bp; ENSGALT00000027373.3] 
AGATCTTGCCTCATTGTTTGGCTTGGTACATAAATGGAAATGTTAAGGTTTAAGGGGGAA 
CCAATTTATAAGCTGGATGTTTAGAAAGTATCTTGCTAAAACCAGTGTAAATATTACAGA 
CCATGAGATGTTAACGTAAGTTGAATTTTTTGCCCCTCTTTAGTTATACAGGTTTTGGGT 
TGGTATTTTGTTTTTTATTTCAAATTTTGTTTTGTTTTGTTTTGTTTTCATAGATGATGA 
AGAAAAGTTGTGCTCATGTTATTGTTTATATGCTTTTGTAATCTTAAAGATATTAATGTC 
TAGTTGTTCTATATTATAACCATATTTGCGCTCTATGCAAGCCCTTGGAACAGAACATAC 
TCATCTTCATGTAGGACCTATGAAAATTGTCTATTTTTATCTATATATTTAAAGTTTTCT 
AAAAATGAAAAAAAGGTTATTACGAATTTTGTTGTACAAAATCTGTACAAAAATCTGTTT 
TTACATCATAATGCAAGAATTGGAAATTTTTCTATGGTAGCCTAGTTATTTGAGCCTGGT 
TTCAATGTGAGAACCACGTTTACTGTTATTGTATTTAATTTTCTTTTCTTTTCAACAATC 
TGCTAATAAAACTGTCTGAAATCTCCCTGTGACTTCATTTACAGTTCATCTTTATTAAAT 
TTTCTGAAATGTGTAACATCAGAGGAATATTTACTTTCTAATGGGAGGCATCTGAAAACA 
ACACAAGTCAGCTCTTTGTAATGTGAGGAGAACAATGCTGAATGATTTTATTTAACATGC 
AACTGCTTCTATCCCTAATATGAATTACTGTGGTGAAAAACATCATAAAAGCACACTTTG 
TGGTTATTGTTTAACAAGCAGATTTTCCATATTTTTTTTTTCTTGCCAGCTAAGCAAACT 
GCCCCAATCTACATGATTTATTTATGTACATTTCTCAGTTTATGAAGCTGTTATTTGTAC     miR-1a/206 site 
CTTTTTTTATATATTGTGATATTCCCATGATTCTTATTTCAGAAAGCTTTGTGCTGAATA 
ATGTAAAGTGGACACATTGATGGAACAAAACATATAATTCCCCTAGCTACAGAGAGGGTA 
ATCCAGTTGTTGCTAGC 
 
 
 
Table 1: In vitro transcription conditions for the synthesis of the RNA 
oligonucleotides used to perform RNA in situ hybridisation. 
 
 
Genes RNA polymerase Plasmid details 
Eya1 
SP6 antisense pGEMT(Gga-Eya1.2-3UTR) 
T7 sense (3’UTR; 970 bp) 
Eya2 
SP6 antisense pGEMT(Gga-Eya2-ISH) 
T7 sense (coding region; 802 bp) 
Eya3 
SP6 antisense pGEMT(Gga-Eya3-ISH) 
T7 sense (coding region; 476 bp) 
Eya4 
T7 antisense pGEMT(Gga-Eya4-ISH) 
SP6 sense (coding region; 873 bp) 
Six1 
T7 antisense pGEMT(Gga-Six1-3UTR) 
SP6 sense (3’UTR; 597 bp) 
Six4 
SP6 antisense pGEMT(Gga-Six4-ISH) 
T7 sense (coding region; 538 bp) 
Dach1 
T7 antisense pGEMT(Gga-Dach1-3UTR) 
SP6 sense (3’UTR; 1084 bp) 
 
 
 
 
 
 
 
 
 
